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With large sample sizes, population-based cohorts and biobanks provide an exciting opportunity 
to identify genetic components of complex traits. For example, UK Biobank provides genome-
wide genotyping data of 500,000 volunteer participants, which is an invaluable resource to detect 
genetic associations and build prediction models of genetic effects. In the first two projects, we 
focus on discovery-type questions and develop robust region-based tests of genetic association. In 
the third project, we target a translation-type question and develop a multi-ethnic prediction 
method. 
In the first project, we propose SKAT/SKAT-O type region-based tests to account for unbalanced 
case-control ratios. In biobank data analysis, most binary phenotypes have unbalanced case-control 
ratios, which can cause inflation of type I error rates. Recently, a saddlepoint approximation (SPA) 
based single variant test has been developed to provide an accurate and scalable method to test for 
associations of such phenotypes. For gene- or region-based multiple variant tests, a few methods 
exist that can adjust for unbalanced case-control ratios; however, these methods are either less 
accurate when case-control ratios are extremely unbalanced or not scalable for large data analyses. 
To address these problems, we develop a robust method, where the single-variant score statistic is 
calibrated based on SPA and Efficient Resampling (ER). Through simulation studies, we show 
that the proposed method provides well-calibrated p-values. The proposed method has similar 
computation time as the unadjusted approaches and is scalable for large sample data. In our 
application, the UK Biobank whole  exome sequence data analysis of 45,596 unrelated European
xviii 
 
 samples and 791 PheCode phenotypes identified 10 rare variant associations with p-value < 10-7, 
including the associations between JAK2 and myeloproliferative disease, HOXB13 and cancer of 
prostate, and F11 and congenital coagulation defects.  
In the second project, we extend the robust method to related samples. Here we propose a scalable 
generalized mixed model region-based association test that can handle large sample sizes and 
accounts for unbalanced case-control ratios for binary traits. This method, SAIGE-GENE, utilizes 
state-of-the-art optimization strategies to reduce computational and memory cost, and hence is 
applicable to exome-wide and genome-wide region-based analysis for hundreds of thousands of 
samples. Through the analysis of the HUNT study of 69,716 Norwegian samples and the UK 
Biobank data of 408,910 White British samples, we show that SAIGE-GENE can efficiently 
analyze large sample data (N > 400,000) with type I error rates well controlled.  
In the third project, we propose a novel multi-ethnic PRS using transfer learning from machine 
learning literature. As most existing GWAS were conducted in European or East Asian individuals, 
the existing PRS models have limited transferability to minority populations such as Africans and 
South Asians. Although recent studies have developed multi-ethnic PRS models that linearly 
combine multiple PRS trained with different ancestry GWAS, they remain under-powered. Our 
approach, TL-PRS, fine-tunes the potentially biased model trained with GWAS summary statistics 
from the majority ancestry to the target dataset of the minority ancestry. Through simulation 
studies, we show that TL-PRS improved the performance of PRS with a wide range of genetic 
architectures and cross-population genetic correlations compared to the baseline methods. In the 
application of 8,168 Africans and 10,285 South Asians of UK Biobank data, TL-PRS substantially 






With large sample sizes, population-based cohorts and biobanks provide an exciting opportunity 
to identify genetic components of complex traits. For example, UK Biobank is an international 
health resource following the health and well-being of 500,000 volunteer participants, whose 
genome-wide genotyping data are all available.(Sudlow et al., 2015) In addition to the availability 
of genetics data, the wealth of information of electronic health records (EHRs) can be leveraged 
to improve our understanding of the genetic relationship with human diseases by describing a 
landscape of genetic associations across many different measures, such as disease diagnosis 
codes.(Pendergrass & Ritchie, 2015)  
With the availability of genetic data and EHRs, phenome-wide association studies (PheWASs) 
have emerged as an important tool for identifying comprehensive genetic associations between 
SNPs and a wide range of phenotypes, with successful implementation in phenotype data collected 
from EHRs. We are motivated by these abundant data resources to work on genetic association 
and prediction methods for biobank data. 
Recently, rare-variant analysis has become increasingly important. In PheWAS analysis, it was 
initially assumed that common genetic variants made a main contribution to common human 
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diseases, such as cardiovascular diseases. However, the proportion of variation explained by 
common variants seems very modest; moreover, there are very few examples of the actual variant 
being identified. Instead, additional disease risk can be explained by rare functional variants, which 
provides further challenges for genetic studies. 
 
1.2 Challenges of analyzing biobank data 
A biobank is a repository that stores human genetic and biological data. Since the late 1990s, 
biobanks have become an important resource supporting many types of contemporary research, 
such as genetic studies. However, there are several well-known challenges when analyzing 
biobank data, such as huge data size and ethical problems surrounding privacy. In this dissertation, 
we mainly focus on the following three problems.  
1.2.1 Unbalanced case-control ratios  
Because most diseases and symptoms have low prevalence in general, the binary phenotypes in 
biobanks usually have unbalanced or extremely unbalanced case-control ratios, such as 1:10 or 
1:100.  For example, in the UK Biobank data, nearly 99% of PheCode-based binary phenotypes 
have case-control ratios of less than 1:10. Substantial challenges are posed when analyzing the 
associations between rare variants and unbalanced phenotypes. For gene- or region-based multiple 
variant tests, a few methods exist that can adjust for unbalanced case-control ratios; however, these 
methods are either less accurate when case-control ratios are extremely unbalanced or not scalable 
for large data analyses. 
1.2.2 Sample relatedness 
3 
 
Sample relatedness and population stratification are major confounders in genetic association 
studies and need to be controlled in PheWAS analysis. Sample relatedness may violate the 
independence assumption required by some models, such as linear regression. Linear mixed 
models (LMM) are widely used to account for these issues in GWAS for both binary and 
quantitative traits. However, since LMM is not designed to analyze binary traits, it can have 
inflated type I error rates, especially in the presence of unbalanced case-control ratios. 
1.2.3 Translation to minor ancestry group 
Although UK Biobank reveals hundreds of thousands of European genetic data, genetic data of 
other populations are still limited for analysis, such as South Asians and Africans. Due to 
inadequate sample sizes, it is almost impossible to identify the genetic associations within these 
populations. Hence, it is an obvious idea to utilize European summary results on other populations 
to further improve the prediction accuracy of disease risks. However, due to different patterns of 
linkage disequilibrium (LD) and potentially different causal effects, the use of European data for 
polygenic risk prediction in non‐European populations reduces prediction accuracy.(Márquez‐
Luna et al., 2017; Purcell et al., 2009; Vilhjálmsson et al., 2015) For example, Vilhjálmsson et al. 
(2015) reported that Japanese and African-American populations had a relative decrease of 53–
89% in schizophrenia risk prediction accuracy when applying prediction methods using European 
data.(Vilhjálmsson et al., 2015) Although recent studies have developed multi-ethnic PRS 
models(Márquez‐Luna et al., 2017) that linearly combine multiple PRS trained with different 
ancestry GWAS, they remain under-powered. 




1.3 Summary of Objectives 
With a focus on the challenges presented above, in this dissertation, I present methodologies that 
are aimed to achieve the following analytical objectives: 
1) To develop robust region-based methods for unbalanced case-control ratios within 
independent samples to control type I error rates; 
2) To extend the robust methods to generalized linear mixed model (GLMM) to adjust for 
relatedness among samples; 
3) To build multi-ethnic polygenic risk score (PRS) models to improve the polygenic risk 
prediction in non-European individuals using summary statistics from UK Biobank 
(UKBB) and Biobank Japan (BBJ). 
The three objectives are addressed in the proposed methods in Chapter II, Chapter III, and Chapter 
IV respectively. More details on the background, pertinent literature, motivation and methodology 




UK-Biobank Whole Exome Sequence Binary Phenome 




In biobank data analysis, most binary phenotypes have unbalanced case-control ratios, which can 
cause inflation of type I error rates. Recently, a saddlepoint approximation (SPA) based single 
variant test has been developed to provide an accurate and scalable method to test for 
associations of such phenotypes. For gene- or region-based multiple variant tests, a few methods 
exist that can adjust for unbalanced case-control ratios; however, these methods are either less 
accurate when case-control ratios are extremely unbalanced or not scalable for large data 
analyses. To address these problems, we propose SKAT/SKAT-O type region-based tests, where 
the single-variant score statistic is calibrated based on SPA and Efficient Resampling (ER). 
Through simulation studies, we show that the proposed method provides well-calibrated p-
values. In contrast, when the case-control ratio is 1:99, the unadjusted approach has greatly 
inflated type I error rates (90 times of exome-wide 𝛼 =2.5×10-6). Additionally, the proposed 
method has similar computation time as the unadjusted approaches and is scalable for large 
sample data. In our application, the UK Biobank whole exome sequence data analysis of 45,596 
unrelated European samples and 791 PheCode phenotypes identified 10 rare variant associations 
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with p-value < 10-7, including the associations between JAK2 and myeloproliferative disease, 
HOXB13 and cancer of prostate, and F11 and congenital coagulation defects. All analysis 
summary results are publicly available through a web-based visual server, which can help 




With the decreased cost of sequencing, big biobanks have started to whole exome or whole genome 
sequence large number of participants to identify the role of rare variants in complex 
diseases(Clare Bycroft et al., 2018; Dewey et al., 2016; Van Hout et al., 2019). By combining rich 
phenotypic information in electronic health record (EHR)(Bush et al., 2016), these sequence data 
will illuminate the phenome-wide association patterns of rare variants. Since most diseases and 
symptoms have low prevalence, the binary phenotypes in biobanks generally have unbalanced 
case-control ratios (1:10 or 1:100, for example)(Rounak Dey et al., 2017).  For example, in the UK 
Biobank data, nearly 99% of PheCode-based binary phenotypes have case-control ratios less than 
1:10 (Zengini et al., 2018). Substantial challenges are posed when analyzing the associations 
between rare variants and unbalanced phenotypes.  
Since single-variant tests are underpowered to identify disease associated rare 
variants(Seunggeung Lee et al., 2014), gene- or region-based multiple variant tests, including the 
burden test(Li & Leal, 2008; Morgenthaler & Thilly, 2007), SKAT(Michael C Wu et al., 2011), 
and SKAT-O(Seunggeun Lee et al., 2012), are commonly used to identify rare variant associations. 
To evaluate the association signals in multiple variants, these methods aggregate single variant 
score statistics. However, as shown in our simulation studies and elsewhere(Ma et al., 2013; Wang 
et al., 2016; Zhang et al., 2019), these methods suffer from the inflation of type I error rates when 
case-control ratios are unbalanced.  For single variant tests, the recently developed saddlepoint 
approximation (SPA) based approach  provides accurate p-values under such a case-control 
imbalance(Rounak Dey et al., 2017; Wei Zhou et al., 2018). Although a few methods exist that 
adjust for unbalanced case-control ratios for gene- or region-based tests, including moment-based 
adjustment (MA)(Lee et al., 2015) and efficient resampling (ER)(Lee et al., 2015), these methods 
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are not scalable or accurate for biobank data. When the case-control ratio is extremely unbalanced, 
MA can still have inflated type I error rates. ER is computationally expensive when minor allele 
counts (MAC) are moderate or large. 
To address these problems, we propose a robust region-based test that adjusts single variant score 
statistics using SPA and ER and aggregate the adjusted statistics. The SPA and ER help to precisely 
calculate the reference distribution of the single variant score statistics, thereby properly 
controlling for type I error rates. The computation cost of the proposed approach is comparable to 
unadjusted tests, and can hence be applied to large biobank data.  Using extensive simulation 
studies, we demonstrate that our robust burden, SKAT, and SKAT-O tests have proper type I error 
rates even when the case-control ratio is 1:99 and exhibit larger power compared to the unadjusted 
burden, SKAT, and SKAT-O test. In addition, the method can be applicable not only to rare variant 
tests but also to the joint association test of common and rare variants.  
The UK Biobank resource(Clare Bycroft et al., 2018) completed the first tranche of whole exome 
sequencing (WES) data for 49,960 participants(Van Hout et al., 2019). We performed robust gene-
based rare-variant tests of 45,596 unrelated European samples on 791 phenotypes with at least 50 
cases and identified 10 rare variant associations with p-value < 10-7, including the associations 
between JAK2 (MIM: 147796) and myeloproliferative disease (MIM: 254700), HOXB13 (MIM: 
604607) and cancer of prostate (MIM: 610997), and F11 (MIM: 264900) and congenital 
coagulation defects (MIM: 134520). These results anticipate the discoveries we can make with the 
full 500,000 WES samples, which will be available in near future. In addition, the analysis results 






2.2.1 Gene/region-based rare variant tests for binary traits 
Assume 𝑛 individuals are sequenced in a region, which has 𝑚 rare variants. For the 𝑖-th individual, 
let 𝑦𝑖 denote a binary phenotype, 𝐺𝑖 = ( 𝑔𝑖1, 𝑔𝑖2, …,   𝑔𝑖𝑚)′ the hard call genotypes (𝑔𝑖𝑗 = 0,1,2) 
or dosage values of the  𝑚  genetic variants in the target gene or region, and 𝑋𝑖 = ( 𝑋𝑖1,
𝑋𝑖2, …,   𝑋𝑖𝑠)′ the covariates, including the intercept. To model a binary outcome, the following 
logistic regression model can be used: 
𝑙𝑜𝑔𝑖𝑡(𝜋𝑖) = 𝑋𝑖
′𝛼 + 𝐺𝑖′𝛽, 
where 𝜋𝑖  is the disease probability for the 𝑖 -th individual, 𝛼  is an 𝑠 × 1  vector of regression 
coefficients of covariates, and 𝛽 is an 𝑚 × 1 vector of regression coefficients of genetic variants. 
Suppose 𝑆𝑗 = ∑ 𝑔𝑖𝑗(𝑦𝑖 − 𝜋?̂?)
𝑛
𝑖=1  is the score statistic for the variant 𝑗, where 𝜋?̂? is the estimated 
disease probability under the null hypothesis of no association (i.e. 𝛽 = 0). Burden and SKAT test 
statistics can be written as 











where wj is the weight for each variant.(Michael C Wu et al., 2011) In the simulation and real data 
analysis, we used beta(1,25) weights, which upweight rarer variants(Michael C Wu et al., 2011). 
The SKAT-O method combines the burden test and SKAT with the following framework: 
𝑄𝜌 = (1 − 𝜌)𝑄𝐵 + 𝜌𝑄𝑠, 
where 𝜌 is a tuning parameter with range [0,1].  Since the optimal 𝜌 is unknown, SKAT-O applies 
the minimum p-values over a grid of 𝜌 as a test statistic. 
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Under the null hypothesis,  𝑆 = (𝑆1, … , 𝑆𝑚)
𝑇  asymptotically follows the multivariate normal 




2), where 𝐶 is the correlation matrix among m variants and 𝑉 is a 
diagonal matrix where the diagonal elements are the asymptotic variances of 𝑆. In the presence of 
a case-control imbalance, however, the distribution of score statistics is skewed, which causes the 
inflation of type I error rates. To address this problem, we will utilize SPA and ER to adjust the 
variance matrix 𝑉.  
2.2.2 Saddle Point Approximation (SPA) and Efficient Resampling (ER)  
SPA is a statistical method to calculate the distribution function using the cumulant generating 
function (CGF). Since it utilizes all the cumulants, SPA is more accurate than using normal 
approximation, which only uses the first two cumulants (mean and variance). From the work of 
Dey et al(Rounak Dey et al., 2017), suppose 𝐾𝑗(𝑡) is the CGF of the score statistic 𝑆𝑗, which can 
be derived based on the fact that  𝑌𝑖~Bernoulli(𝜋𝑖) under the null. Then, the distribution function 
of the score statistic 𝑆𝑗  can be approximated by 







where 𝑑 = 𝑠𝑔𝑛(?̂?)√2 (?̂?𝑠 − 𝐾𝑗(?̂?)), v = ?̂?√𝐾𝑗
′′(?̂?) , ?̂? is the solution to the equation 𝐾𝑗
′(?̂?) =
𝑠 , and Φ is the distribution function of the standard normal distribution(Rounak Dey et al., 
2017).  
Although SPA performs better than normal approximation, since it is still an asymptotic-based 
approach, SPA can result in inaccurate p-values when MAC is very low. To address this issue, 
we use ER for low MAC variants. ER is a resampling method that resamples the case–control 
status of individuals with a minor allele at a given variant and disease risk 𝜋𝑖 instead of 
permuting case–control status across all individuals. This is because only individuals with minor 
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alleles contribute to the score statistics S. Since ER is resampling-based, it can provide an 
accurate p-value for a very rare variant. When MAC is low (ex. MAC  10), ER can rapidly 
calculate the exact p-value by numerating all possible configurations of case-control statuses.  
The detailed derivations of ER can be found in Lee et al(Lee et al., 2015).   
2.2.3 Robust burden test, robust SKAT and robust SKAT-O 
For each variant 𝑗, when the score statistic 𝑆𝑗 lies within 2 standard deviations of the mean, the 
normal approximation generally performs well(Rounak Dey et al., 2017). Otherwise, due to the 
skewed distribution, the normal approximation causes inflated type I error rates. Hence, when 𝑆𝑗 
is beyond 2 standard deviations of the mean, we apply SPA (when MAC > 10) or ER (when 
MAC  10) to calculate the p-value 𝑝𝑗, which will be used to calibrate the variance of 𝑆𝑗. 
Let 𝑆𝑗
2/?̂?𝑗 be a square-standardized test statistic in which ?̂?𝑗 is the estimated variance of 𝑆𝑗
2. 
When 𝑆𝑗 follows the normal distribution,  𝑆𝑗
2/?̂?𝑗 follows the chi-square distribution with one 
degree of freedom. We adjust the variance so that the p-value is the same as 𝑝𝑗, in which the 
adjusted variance is  
?̃?𝑗 = 𝑆𝑗
2/𝜒𝑞𝑢𝑎𝑛𝑡𝑖𝑙𝑒
2 (1 − 𝑝𝑗), 
where 𝜒𝑞𝑢𝑎𝑛𝑡𝑖𝑙𝑒
2  is the quantile function of the chi-square distribution with one degree of 
freedom. Note that if 𝑆𝑗 lies within 2 standard deviations of the mean,  ?̃?𝑗 = ?̂?𝑗. Suppose ?̃? =
(?̃?1, ?̃?2, … , ?̃?𝑚)
𝑇 , then the p-value of the region can be calculated based on the assumption that  





These adjustments overcome the inflated type I error rates for common variants, but are 
insufficient to address the inflation issue for rare variants --4.87 times of exome-wide 
alpha=2.5×10-6 when the case-control ratio is 1:99. Details can be found in Table S2.1. We apply 
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additional adjustment by using the fact that the burden test can be presented as a single marker 
test with collapsed variants, and SPA performs very well for single marker test. From the above 





2𝑤, where 𝑤 =
(𝑤1, … , 𝑤𝑚)
𝑇 is an 𝑚 × 1 vector of the weight. Suppose 𝑔𝑖
𝑏𝑢𝑟𝑑𝑒𝑛 = ∑ 𝑤𝑗𝑔𝑖𝑗
𝑚
𝑗=1 , and then the 
burden test statistic (i.e. 𝑄𝐵) is identical to 𝑆𝑏𝑢𝑟𝑑𝑒𝑛
2 , where 𝑆𝑏𝑢𝑟𝑑𝑒𝑛 = ∑ 𝑔𝑖
𝑏𝑢𝑟𝑑𝑒𝑛(𝑦𝑖 − 𝜋?̂?)
𝑛
𝑖=1 , and 
the p-value ?̌?𝑆𝑏𝑢𝑟𝑑𝑒𝑛  of  𝑆𝑏𝑢𝑟𝑑𝑒𝑛 can be calculated from SPA. Using the similar approximation as 
above, we estimate the variance 𝑆𝑏𝑢𝑟𝑑𝑒𝑛 as ?̌?𝑠𝑢𝑚  = 𝑆𝑏𝑢𝑟𝑑𝑒𝑛
2 /𝜒𝑞𝑢𝑎𝑛𝑡𝑖𝑙𝑒
2 (1 − ?̌?𝑆𝑏𝑢𝑟𝑑𝑒𝑛). Suppose 
𝑟 = ?̃?𝑠𝑢𝑚  ?̌?𝑠𝑢𝑚⁄ . In order to control type I error inflation, we suggest utilizing a more 
conservative variance. Let ?̃? = min(1, 𝑟), then 













With this formula, Robust burden, SKAT and SKAT-O tests can be performed.  
2.2.4 Extension to the joint test of common and rare variants 




′ 𝛽1 + 𝐺2𝑖
′ 𝛽2. 
For the individual 𝑖, 𝜋𝑖 is the disease probability; 𝑋𝑖 is the vector containing all the covariates, 
including the intercept;  𝐺1𝑖 is the genotype vector of rare variants with length 𝑚𝑟; and 𝐺2𝑖 is the 
vector of common variants with length 𝑚𝑐. To test the hypothesis of no genetic effects 𝐻0: 𝛽1 =
0,  𝛽2 = 0, the test statistic 𝑄𝜙 can be written as  
𝑄𝜙 = (1 − 𝜙)𝑄𝑟𝑎𝑟𝑒 + 𝜙𝑄𝑐𝑜𝑚𝑚𝑜𝑛 




′𝑆2,    
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where 𝑆1 and 𝑆2 are the vectors of score statistics for rare and common variants respectively, 
and 𝑊1 and 𝑊2 are diagonal weight matrices for rare and common variants.  




2). Using the approach described in the previous 
section, we apply SPA and ER to calibrate variance estimates to perform a robust SKAT method.   
2.2.5 Numerical Simulations  
We conducted extensive simulation studies to evaluate the performance of the proposed methods 
for dichotomized traits. The sequence data of mimicking European ancestry over 200 kb regions 
were generated using the calibrated coalescent model(Schaffner et al., 2005). We randomly 
selected regions with lengths of 1, 2, and 3 kb and tested for associations in all simulation 
settings. On average each simulated dataset had 16.33 (SD: 4.05), 32.69 (SD: 5.65) and 49.05 
(SD: 6.71) rare variants for 1, 2, and 3 kb regions, respectively, when the sample size was 
50,000. 
We generated data sets with sample size 50,000. We included two covariates for the analysis. 
The first one followed a Bernoulli distribution with 𝑝 = 0.5 and the other followed the standard 
normal distribution, corresponding to the gender and normalized age. Four case-control ratios 
were considered, 1:1, 1:9, 1:49 and 1:99, and the binary phenotypes were simulated from 
logit(𝜋𝑖) = 𝛾0 + 𝛾1𝑋1𝑖 + 𝛾2𝑋2𝑖 + 𝛽1𝑔1𝑖 + ⋯ + 𝛽𝑚𝑔𝑚𝑖, 
where 𝛽1 = 𝛽2 = ⋯ = 𝛽𝑚 = 0; 𝛾1 and 𝛾2 were chosen to let the odds ratio (OR) of 𝑋1 and 𝑋2 
equal 1.2 and 1.5 respectively, and 𝛾0 was chosen based on disease prevalence. Seven different 
methods were applied to each of the generated datasets. For all variants in the region, we applied 
the unadjusted and robust joint test of common and rare variants. For rare variant tests 
(MAF<=0.01), we applied (1) burden test; (2) robust burden test; (3) SKAT; (4) robust SKAT;  
(5) SKAT-O; (6) robust SKAT-O; and (7) the hybrid method.  The hybrid method(Lee et al., 
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2015), developed by Lee, selects a method among ER, Quantile adjusted moment matching (QA) 
and Moment matching adjustment (MA) based on MAC, and the degree of case-control 
imbalance. A total of 107 phenotypes were generated, and type I error rates were estimated by the 
proportion of p-values smaller than the given 𝛼 level divided by given 𝛼. 
For power simulations, 30% of variants were randomly selected as causal. Two settings were 
considered: (1) 80% causal variants were risk-increasing variants and 20% were risk-decreasing 
variants; and (2) all causal variants were risk-increasing variants. For each setting, 10,000 data 
sets were generated, and the power was estimated as the proportion of p-values smaller than the 
empirical 𝛼 level, which was calculated in the type I error simulation.  
2.2.6 Analysis of whole exome sequencing (WES) data in the UK Biobank 
We analyzed the first tranche of UK Biobank WES data with 49,960 participants(Van Hout et 
al., 2019). Due to the quality issues in the Regeneron pipeline(Biobank, 2019), we analyzed 
genotype data processed from the FE pipeline(Regier et al., 2018). The details of sample 
selection and QC procedures are described elsewhere1. We excluded one individual in related 
pairs (up to second-degree relatives) to identify a set of unrelated individuals. To preserve cases, 
we first selected a maximal set of unrelated cases, then removed controls that were related to the 
unrelated cases and kept a maximal set of unrelated controls. Because of the missing values in 
the phenotypes, the individuals included in the analysis varied across phenotypes. We performed 
gene-based tests on 45,596 independent European participants in the UK Biobank, whose 
phenotype data were available. 
With a previously published scheme(Denny et al., 2013), we defined disease-specific binary 
phenotypes by combining hospital ICD-9 codes into hierarchical PheCodes, each representing a 
specific disease group. ICD-10 codes were mapped to PheCodes using a combination of 
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available maps through the Unified Medical Language System, manual review and other sources. 
Study participants were labeled a PheCode if they had one or more of the PheCode-specific ICD 
codes. Cases were defined as all study participants with the PheCode of interest and controls 
were all study participants without the PheCode of interest. Gender checks were performed, so 
PheCodes specific for one gender could not be assigned to the other gender by mistake(Wei 
Zhou et al., 2018). 
There were 791 binary phenotypes with at least 50 cases based on PheCodes, in which 551 
phenotypes had case-control ratios smaller than 1:99. Because our robust methods would cause a 
certain inflation for extremely unbalanced case-control ratios (Table S2.1), and using more 
controls than those from case-control ratio of 1:99 would not improve power (Figure S2.1), we 
did matching on these 551 traits using the first 4 genotype principal components. Specifically, 
for each case we found the closest controls in Euclidean distance to make the case-control ratio 
be 1:99. We used principal components calculated by UK-Biobank, which were calculated from 
147,551 LD-pruned SNPs with missing rate < 0.015 and  MAF > 0.01(Bycroft et al., 2017). 
We focused on the rare variants (MAF<=0.01) of the nonsynonymous and splicing variants in 
the exon and neighboring regions. Particularly we used annotation of frameshift deletion, 
frameshift insertion, nonframeshift deletion, nonframeshift insertion, nonsynonymous SNV, 
splicing, stopgain and stoploss from ANNOVAR (Version built on 2018-04-16)  with refGene 
database (hg38)(Wang et al., 2010). A total of 18,360 genes were used for the analysis. The 
number of variants in genes ranged from 2 to 7,439 with a highly skewed distribution (Figure 
S2.2). The six methods discussed in the simulation study, unadjusted and robust versions of the 
burden test, SKAT and SKAT-O methods, were applied to the data. Age, gender and the first 





2.3.1 Type I Error and Power Simulation Results 
We generated 107 datasets to compare type I error rates of the proposed approaches (robust 
burden, SKAT and SKAT-O), unadjusted approaches (burden, SKAT and SKAT-O) and a 
hybrid approach for SKAT-O(Lee et al., 2015). The hybrid approach applies several adjustment 
methods based on MAC.  Table 2.1 shows that the unadjusted approaches had substantial 
inflation of type I error rates when the case-control ratio was unbalanced and the region length 
was 1 kb. In contrast, the robust approaches controlled type I error rates much better and had 
only a slight inflation when the case-control ratio was 1:99. Interestingly, the existing hybrid 
approach showed substantially inflated type I error rates when case-control ratios were extremely 
unbalanced (case-control ratio=1:49 and 1:99). This may be due to the fact that the MAC-based 
method selection rule in the hybrid approach does not perform well under extremely unbalanced 
case-control ratios. When the case-control ratios are more extreme than 1:99, the robust SKAT 
and SKAT-O showed some inflation of type I error rates (Table S2.1). Simulation studies with 2 
and 3 kb regions show that empirical type I error rates of robust SKAT-O are generally similar 
regardless of region length (Table S2.2). Additionally, when testing both common and rare 
variants, robust SKAT can control type I error rates well compared with unadjusted SKAT 
(Table S2.3). Overall, the type I error simulation results confirmed that the proposed robust 
approaches provide substantially improved type I error rates compared to the unadjusted and 
existing hybrid approaches.  
Table 2.1. Type I error rates of unadjusted and robust versions of burden, SKAT and SKAT-O 
and hybrid method. Total 107 datasets of 1 kb regions were generated to estimate type I error 
rates. Each cell represents an empirical type I error rate divided by significance level 𝛼. The 

















10−2 1:1 1.00 1.00 0.99 0.99 1.11 1.11 1.09 
 1:9 0.99 1.00 1.01 1.01 1.13 1.13 1.09 
 1:49 1.02 0.95 1.44 1.22 1.44 1.23 1.27 
 1:99 1.07 0.91 1.92 1.41 1.82 1.33 1.53 
10−4 1:1 1.02 1.00 0.99 1.03 1.27 1.32 1.27 
 1:9 1.12 0.99 1.39 1.14 1.65 1.40 1.52 
 1:49 2.43 0.97 6.31 1.65 6.16 1.79 4.54 




1:1 1.11 1.03 1.24 1.54 1.38 1.38 1.40 
1:9 1.29 0.77 2.47 1.45 2.51 1.49 2.23 
1:49 6.88 1.06 28.27 1.91 23.70 1.98 16.69 
1:99 16.34 0.90 89.53 1.81 71.32 1.60 42.59 
 
Figure 2.1 shows the empirical powers of the hybrid, unadjusted and robust versions of SKAT-O 
methods, when 80% causal variants were risk-increasing variants and 20% were risk-decreasing 
variants. The empirical powers of unadjusted and robust versions of the burden tests and SKAT 
can be found in Figure S2.3. Since unadjusted and hybrid methods had severely inflated type I 
error rates, for the fair comparison, we used the empirical significance level estimated from type 
I error simulation studies. Assuming that the type I error rates could be properly controlled for all 
methods, robust SKAT-O had similar power as unadjusted SKAT-O in balanced and moderately 
unbalanced case-control ratios (1:1 and 1:9) and was more powerful than unadjusted SKAT-O in 
extremely unbalanced ratios (1:49 and 1:99). Robust burden tests had the same power as 
unadjusted burden tests across all four case-control ratios. Robust SKAT had similar power as 
unadjusted SKAT in balanced ratios and was more powerful than unadjusted SKAT in 
unbalanced ratios. If the number of cases was fixed, more controls (1:49 and 1:99) increased 
power greatly compared to case-control ratio 1:1 for all three robust methods (Figure S2.1). In 
addition, we found that 1:99 had slightly more power than 1:49, where we could infer that 1:99 is 
sufficient to achieve the maximum power and more controls can hardly increase the power. The 
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power simulation results with different region lengths (Figure S2.4) and power simulation results 
with all causal variants being risk-increasing variants (Figure S2.5) were quantitatively similar.  
In summary, the robust methods had similar or more power than the unadjusted methods in all 
scenarios. Among the three robust methods, robust SKAT-O generally performed better than 




Figure 2.1 Empirical power estimates for the unadjusted and robust versions of SKAT-O, and 
hybrid method. Power was calculated at the empirical 𝛼 levels estimated from Type I error 
simulations with adjusting type I error rate at 2.5×10-6. Total 10,000 datasets were generated 
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with region length 1kb. 30% of variants were causal variants with 80% causal variants being 
risk-increasing and 20% being risk-decreasing. The sample size was 50,000. The X-axis 
represents the genetic effect odds ratio and the Y-axis represents the empirical power.  
 
2.3.2 Comparison of computational times 
To compare the computation times, we generated 1,000 datasets (Figure 2.2). Since SKAT-O 
combines the burden and SKAT tests, we only considered the SKAT-O test. As the sample sizes 
increased, the computation time of ER increased and required ~16.1 CPU hours for analyzing 
one gene for 50,000 individuals. In contrast, unadjusted methods required 140x less computation 
time (~6.7 min) and the computation times barely changed by sample size (5,000-100,000 
individuals). Our robust method performed similarly as unadjusted SKAT-O (~8.5 min). Since 
the hybrid approach selects its methods based on MAC and case-control ratios, the computation 
cost of the hybrid approach is not determined by the sample size.  Overall, the hybrid approach 
was slower than the proposed method. The computation time for analyzing UK-Biobank data of 






Figure 2.2 Comparison of computation time of unadjusted, hybrid, ER and robust approaches for 
SKAT-O.  
The rare-variant region-based tests were performed on randomly selected 1 kb regions of 1,000 
resamples. The X-axis represents the sample size and the Y-axis represents the run time of 1,000 
resamples. 
 
2.3.3 Analysis of whole exome sequencing (WES) data in the UK Biobank 
We applied six methods (unadjusted and robust versions of burden, SKAT and SKAT-O) to the 
analysis of WES data in the UK Biobank. We restricted our analysis to the rare nonsynonymous 
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and splicing variants with minor allele frequencies (MAFs) < 0.01 in exon regions. A total of 
18,360 genes were analyzed based on 45,596 independent European samples across 791 binary 
phenotypes with at least 50 cases. For phenotypes with case-control ratios more extreme than 
1:99, we identified the ancestry-matched control samples to make the case-control ratios 1:99 
(See Methods).  
With the cutoff of 𝛼 =  2.5 × 10−6, unadjusted SKAT-O detected 73,723 significant 
associations, most of which would be false positives, while our robust methods detected 34 
significant associations for the burden test, 99 for SKAT and 111 for SKAT-O (Table S2.4). 
Since we were testing many phenotypes, the usual exome-based cutoff of 2.5 × 10−6 can 
produce spurious associations. Following Hout et al(Van Hout et al., 2019), we used a more 
stringent level 𝛼 =10-7 and identified that 10 gene-phenotype pairs had robust SKAT-O p-values 
smaller than 10-7 (Table 2.2). Among 10 phenotype-gene pairs, only 2 had a single SNP p-value 
< 5 × 10−8, indicating that gene/region-based approaches are more powerful than single variant 
analyses. For each gene, the top 3 smallest p-value variants were reported in Table S2.5 and 
single variant p-values are presented in Figure S2.7. QQ plots for those 10 phenotypes show that 
unadjusted SKAT-O had greatly inflated type I error rates, but our robust approach provided 
relatively well-calibrated results (Figure S2.8). 
Rare variant associations between JAK2 and myeloproliferative disease (number of 
cases=94)(Baxter et al., 2005), and HOXB13 (MIM:  604607) and prostate cancers (MIM: 
610997)  (number of cases=741)(Ewing et al., 2012) have been previously reported, which 
demonstrates that our analysis can replicate known signals, even when the number of case 
samples is very small. PheWAS plot of HOXB13 shows that there is an additional association 
signals between HOXB13 and Carditis (p-value=9.18×10-6) (Figure 2.3), and this may be due to 
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the fact that Carditis is a complication of prostate cancer biopsy and treatment(Aubry et al., 
2013).  
 
Table 2.2 Significant gene-phenotype associations in the UK Biobank WES data. Lowest P SNP 
means the lowest p-value of all single variants contained in the gene-phenotype association. 
Conditional P-value (SKAT-O) means the robust SKAT-O p-value after conditioning on the 
most significant nearby common variant (± 100 Kbp up and down stream). P-value of the most 
significant nearby variant was from SAIGE single variant analysis results(Wei Zhou et al., 2018) 





























JAK2 94:9306 73 27 442 1.36E-33 1.81E-41 1.06E-35 2.30E-17 
Unspecified 
monoarthritis (716.2) 




NFE2L3 1345:21226 171 145 1358 2.54E-08 2.72E-05 3.94E-08 2.14E-04 
Cancer of prostate (185) HOXB13 741:18940 37 18 154 3.00E-08 5.24E-08 2.50E-08 1.17E-04 
Other aneurysm (442) P3H1 164:16236 110 17 497 5.76E-08 1.71E-05 4.03E-07 1.22E-03 
Heartburn (530.9) USP45 189:18711 103 24 649 6.34E-08 5.39E-05 1.46E-09 4.08E-02 
Fracture of hand or wrist 
(804) 
GSDMC 382:37818 109 25 761 7.12E-08 8.17E-05 1.49E-07 1.84E-02 
Congenital coagulation 
defects (286.1) 
F11 76:7524 38 8 84 7.40E-08 4.52E-05 4.09E-08 6.30E-03 
Congenital anomalies of 
great vessels (747.13) 
SLC46A1 134:13266 28 11 255 9.38E-08 1.86E-08 3.87E-08 2.29E-03 
Peptic ulcer (excl. 
esophageal) (531) 
LMNB2 773:44818 171 24 508 9.89E-08 3.83E-06 9.54E-08 1.31E-03 
 
 
Among other genes, P3H1 (MIM:  610339), Prolyl 3-Hydroxylase 1, was observed to be 
associated with other aneurysm (p-value=5.76×10-8) and possibly associated with abdominal 
aortic aneurysm (p-value=5.79×10-5). P3H1 is involved in collagen metabolism and was found to 
be present in the pulmonary artery(Vranka et al., 2004). F11 (MIM:  264900), also known as 
Coagulation Factor XI, was observed as associated with congenital coagulation defects (p-
value=6.13×10-8), which is consistent with the fact that Factor XI participates in blood 
coagulation as a catalyst in the conversion of factor IX to factor IXa in the presence of calcium 
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ions(Asakai et al., 1987). SLC46A1 (MIM: 611672), which encodes a transmembrane folate 
transporter protein, is associated to congenital anomalies of great vessels (p-value=9.38×10-8), 
consistent with the role of folate in cardiovascular disease(Verhaar et al., 2002). PheWAS shows 
the close association between SLC46A1 and two other blood diseases: cardiac congenital 




Figure 2.3 PheWAS plots of 10 rare variant associations with p-value< 10-7.  
The X-axis represents 791 binary traits and the Y-axis represents the negative log10 p-values. 
The dashed line represents the cutoff of 0.05/791=6.32×10-5.
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We carried out conditional analysis to evaluate whether the rare variant association signals were 
independent of the nearby common variant association signals (± 100 Kbp up and down stream) 
(Table S2.6). To identify most significant nearby variants, we used SAIGE single variant 
analysis results of the UK-Biobank imputed datasets of 400,000 British samples(Wei Zhou et al., 
2018). All ten associations remained significant after the conditional analysis (Table 2.1).  
We have generated summary statistics for all gene-phenotype association results using our robust 
approach and made them available in a PheWEB-like visual server (See Web Resources). 
  
2.4 Discussion 
In this paper, we present a robust approach that can address case-control imbalance in region-
based rare variant tests. The proposed approach uses recently developed ER and SPA to calibrate 
the variance of single variant score statistics to accurately calculate region-based p-values. 
Computation cost of the proposed approach is similar to the unadjusted approach, which makes it 
scalable for large analysis. Simulation studies show that unadjusted methods suffer severe 
inflation of type I error rate in unbalanced case-control ratios while robust methods can 
successfully address it. The UK-Biobank exome data analysis shows that the method provides 
calibrated p-values and contribute to identifying true association signals.  
The proposed robust methods combine SPA and ER to recalibrate variances of single score 
statistics. SPA can be thought as higher order asymptotic approach with error bound 𝑂(𝑛−3/2) 
(Rounak Dey et al., 2017), where n is the sample size, which is much smaller than the error 
bound of normal approximation,  𝑂(𝑛−1/2). However, SPA is still asymptotic-based and cannot 
perform well when MAC is small. Since ER is a resampling-based approach and can calculate 
the exact p-value when MAC is small, it can complement SPA.  
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Our UK Biobank WES data analysis of 45,596 European samples and 791 binary phenotypes 
have identified 10 rare variant associations with p-value < 10-7, including the replication of two 
known signals. Currently UK-Biobank is carrying out whole exome sequencing for 500,000 
individuals. Our analysis presents an early snapshot of the discoveries that can be made with full 
UK-Biobank samples.  
All the UK-Biobank analysis summary statistics are publicly available, which can be a useful 
community resource to show detailed results of the UK-Biobank. Due to the large scale of the 
data, for labs not specialized in big data analysis, it is very challenging to analyze UK-Biobank 
exome data. The analysis results will make the data more accessible and facilitate the 
identification of the genetic basis of complex diseases. For example, researchers could utilize our 
results for meta-analysis to combine samples with different studies. They can also be used to 
validate novel signals from other studies.   
There are several limitations in the proposed method. Currently, the robust methods require that 
all individuals are unrelated. Restricting analysis to unrelated samples reduce sample size and 
case counts in many situations(Bi et al., 2019). For example, some rare phenotypes within a 
health system may be clustered in a few families. Analysis based on independent samples may 
significantly decrease the power. When there are related individuals, generalized linear mixed 
model (GLMM) based approaches(Han Chen et al., 2016; Wei Zhou et al., 2018) should be used 
to incorporate the relatedness. Recently Chen et al developed efficient mixed effect model 
approach for gene-based tests(Han Chen et al., 2019) and Zhou et al expanded scalable single-
variant GLMM to gene-based tests that can handle the full size of UK-Biobank data of 500,000 
samples(Zhou et al., 2019). Since these methods are also based on single-variant score statistics, 
the robust approach can be applied to them with modifications for GLMM. We leave it for a 
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separate work. Second, when the case-control ratios are more extreme than case: control=1:99, 
the method suffers type I error inflation. Because of this, our UK-Biobank exome analysis used 
the matching scheme in which if the case control ratios are more extreme than 1:99, we use the 
matching to reduce the number of controls. Third, novel findings are not validated from 
independent datasets, so we cannot rule out the possibility that they are false positives. Lack of 
replication can be alleviated as more sequencing studies are conducted in biobanks. 
In summary, we have proposed a robust region-based method and showed that the method can 
accurately analyze UK-Biobank exome data. With the continuous decrease of sequencing cost 
and growing effort to build large biobanks and cohorts(Collins & Varmus, 2015), rare variants 
association analysis will be increasingly applied to binary phenome. Our method will provide 
accurate results for binary phenome analysis and contribute to identifying the role of rare 







Unified medical language system, https://www.nlm.nih.gov/ research/umls 
Robust gene-based test, https://github.com/leeshawn/SKAT/tree/Sparse_Version 
SKAT (version 1.3.2.1), https://cran.r-project.org/web/packages/SKAT 
UK-Biobank, https://www.ukbiobank.ac.uk/ 
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Figure S2.1. Empirical power estimates for robust SKAT, burden, SKAT-O with the same number of cases across different case 
control ratios. 30% of variants were causal variants and all causal variants were risk-increasing. The X-axis represents the genetic 










Figure S2.3. Empirical power estimates for the unadjusted and robust version of SKAT and burden test where 30% of variants were 
causal variants and all causal variants were risk-increasing. The X-axis represents the genetic effect odds ratio and the Y-axis 





(A) Region length 2kb 
 
(B) Region length 3kb 
 
 
Figure S2.4. Empirical power estimates for the unadjusted and robust versions of SKAT-O and hybrid method where 30% of variants 
were causal variants. 80% causal variants were risk-increasing and 20% were risk-deceasing. The sample size was 50,000 and 10,000 
datasets were generated. The X-axis represents the genetic effect odds ratio and the Y-axis represents the empirical power. (A) Region 






Figure S2.5. Empirical power estimates for the unadjusted and robust versions of SKAT-O and hybrid method where 30% of variants 
were causal variants. All causal variants were risk-increasing. The sample size was 50,000 and 10,000 datasets were generated with 












Figure S2.6. Empirical power estimates for robust SKAT, burden and SKAT-O where 30% of variants were causal variants and all 
causal variants were risk-increasing. The X-axis represents the genetic effect odds ratio and the Y-axis represents the empirical power. 








Figure S2.7. P-values of single variants in 10 significant genes. The X-axis represents the position of each single variant in the gene, 






Figure S2.8. QQ Plots of SKAT-O p-values of 10 selected phenotypes. The X-axis represents the expected negative log10 p-values 
and the Y-axis represents the observed negative log10 p-values of genes.  
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2.5.2 Supplemental Tables 
Table S2.1. Type I error rate divided by 𝛼 of different methods when testing an association with dichotomous traits at stringent 𝛼 































10−2 1:1 0.99 0.99 0.99 1.00 1.00 1.00 1.11 1.11 1.11 1.09 
 1:9 1.01 1.01 1.01 0.99 0.99 1.00 1.13 1.13 1.13 1.09 
 1:49 1.44 1.24 1.22 1.02 0.95 0.95 1.44 1.24 1.23 1.27 
 1:99 1.92 1.44 1.41 1.07 0.92 0.91 1.82 1.36 1.33 1.53 
 1:199 2.74 1.76 1.71 1.19 0.91 0.88 2.47 1.56 1.52 2.00 
 1:399 3.99 2.22 2.14 1.44 0.94 0.89 3.47 1.88 1.82 2.75 
10−4 1:1 0.99 0.98 1.03 1.02 1.03 1.00 1.27 1.28 1.32 1.27 
 1:9 1.39 1.11 1.14 1.12 1.08 0.99 1.65 1.43 1.40 1.52 
 1:49 6.31 1.79 1.65 2.43 1.56 0.97 6.16 2.33 1.79 4.54 
 1:99 13.48 2.42 2.13 3.95 2.05 1.02 12.77 3.23 2.17 8.89 
 1:199 28.84 3.42 2.89 6.79 2.54 1.01 26.55 4.38 2.72 17.95 






1:1 1.24 1.03 1.54 1.11 0.94 1.03 1.38 1.19 1.38 1.40 
1:9 2.47 1.19 1.45 1.29 1.41 0.77 2.51 1.61 1.49 2.23 
1:49 28.27 1.80 1.91 6.88 2.91 1.06 23.70 3.24 1.98 16.69 
1:99 89.53 2.67 1.81 16.34 3.80 0.90 71.32 4.87 1.60 42.59 
1:199 262.60 4.62 3.16 39.57 5.99 1.17 211.90 7.93 2.80 126.26 







Table S2.2. Type I error rate divided by 𝛼 of robust SKAT-O when testing an association with dichotomous traits at stringent 𝛼 levels 
𝛼 = 10−2, 10−4 and 2.5 × 10−6 with three different region length (1) 1kb; (2) 2kb; (3) 3kb. The sample size was 50,000 and 107 















Mean:49.05        
SD: 6.71 
10−2 1:1 1.11 1.11 1.10 
 1:9 1.13 1.11 1.11 
 1:49 1.23 1.19 1.18 
 1:99 1.33 1.29 1.27 
10−4 1:1 1.32 1.15 1.14 
 1:9 1.40 1.18 1.20 
 1:49 1.79 1.73 1.67 
 1:99 2.17 2.09 1.99 
2.5 × 10−6 
  
1:1 1.38 0.96 1.04 
1:9 1.49 1.56 1.08 
1:49 1.98 2.24 1.60 






Table S2.3. Type I error rate divided by 𝛼 of different methods when testing an association between all variants, including both 
common and rare variants, and dichotomous traits at stringent 𝛼 levels 𝛼 = 10−2, 10−4 and 2.5 × 10−6. The sample size was 50,000 














10−2 1:1 1.00 0.99 0.99 
 1:9 1.00 1.01 1.01 
 1:49 1.11 1.22 1.22 
 1:99 1.26 1.42 1.41 
 1:199 1.52 1.71 1.72 
 1:399 1.97 2.15 2.15 
10−4 1:1 0.98 0.98 1.04 
 1:9 1.09 1.11 1.13 
 1:49 2.42 1.73 1.69 
 1:99 4.20 2.26 2.21 
 1:199 7.84 3.02 3.03 






1:1 0.94 1.05 1.66 
1:9 1.53 1.17 1.45 
1:49 7.48 1.57 1.94 
1:99 18.54 2.50 1.93 
1:199 50.43 3.87 3.37 








Table S2.4. Gene-phenotype associations detected by Robust SKAT-O across 791 phenotypes at α=2.5×10-6 (Number of 
associations=111) 















Myeloproliferative disease JAK2 94 9306 73 27 442 1.94E-34 4.22E-14 1.36E-33 
Unspecified monoarthritis OGG1 1728 41060 117 118 1643 1.73E-06 2.33E-07 7.73E-09 
Menopausal and postmenopausal disorders NFE2L3 1345 21226 171 145 1358 3.80E-06 9.95E-08 2.54E-08 
Cancer of prostate HOXB13 741 18940 37 18 154 6.90E-08 2.15E-05 3.00E-08 
Other aneurysm P3H1 164 16236 110 17 497 3.45E-07 1.09E-05 5.76E-08 
Heartburn USP45 189 18711 103 24 649 2.04E-05 2.06E-07 6.34E-08 
Fracture of hand or wrist GSDMC 382 37818 109 25 761 1.72E-05 6.92E-07 7.12E-08 
Congenital coagulation defects F11 76 7524 38 8 84 1.96E-06 2.00E-06 7.40E-08 
Congenital anomalies of great vessels SLC46A1 134 13266 28 11 255 9.08E-08 3.88E-05 9.38E-08 
Peptic ulcer (excl. esophageal) LMNB2 773 44818 171 24 508 5.01E-07 7.63E-06 9.89E-08 
Spondylosis and allied disorders MAP3K7CL 849 43787 59 14 155 1.99E-07 9.40E-06 1.20E-07 
Large cell lymphoma TNC 56 5544 132 14 482 9.60E-08 3.48E-04 1.30E-07 
Generalized convulsive epilepsy KRT6A 52 5148 49 16 318 1.62E-07 1.61E-05 1.43E-07 
Abnormal findings on exam of gastrointestinal tract/ 
abdominal area 
OR51T1 169 16731 45 13 204 8.77E-05 1.91E-07 1.46E-07 
Other open wound of head and face CRACR2B 304 30096 108 9 380 1.23E-07 1.70E-02 1.51E-07 
Cancer of urinary organs (incl. kidney and bladder) ATP6V1H 421 41679 70 13 656 1.12E-07 1.54E-02 1.62E-07 
Myeloproliferative disease CTAGE4;CTAGE8 94 9306 90 25 1667 5.86E-08 7.23E-02 2.17E-07 
Agorophobia, social phobia, and panic disorder GPR182 78 7722 34 6 69 6.22E-07 3.65E-05 2.98E-07 
Cervical cancer OR1J4 159 15741 33 9 136 5.31E-07 7.89E-06 3.04E-07 
Other disorders of metabolism ZNF746 84 8316 52 6 164 1.37E-07 4.99E-03 3.07E-07 
Other and unspecified disc disorder ODF2 447 43796 201 48 2294 5.72E-07 5.50E-06 4.12E-07 
Polyp of corpus uteri CD300E 1059 23305 30 14 45 2.14E-04 3.07E-07 4.32E-07 
Erythematous conditions FAM129C 267 26433 127 24 676 1.50E-04 2.15E-07 4.44E-07 
Disorders of penis RINL 360 18836 74 12 163 3.07E-07 4.42E-05 5.15E-07 
Noninflammatory female genital disorders STX17 1139 23792 36 39 335 1.32E-03 5.15E-07 5.49E-07 
Benign neoplasm of breast C8orf33 177 17523 45 15 336 4.45E-07 9.12E-06 5.70E-07 
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Spondylosis without myelopathy RASA4;RASA4B 553 43796 57 27 933 8.10E-07 8.67E-05 6.47E-07 
Asthma MCL1 4256 40751 84 63 301 1.51E-04 7.61E-07 6.50E-07 
Rheumatoid arthritis ZNF462 493 41022 435 73 4453 1.45E-07 1.40E-02 6.92E-07 
Epilepsy, recurrent seizures, convulsions MAK 497 44306 116 21 731 6.79E-07 1.74E-04 7.17E-07 
Other disorders of male genital organs ARIH1 325 18835 36 9 115 9.92E-07 1.35E-04 7.24E-07 
Open wounds of head; neck; and trunk CRACR2B 394 39006 134 9 502 3.33E-07 9.65E-02 7.41E-07 
Scar conditions and fibrosis of skin C1orf109 265 26235 54 10 242 8.86E-07 1.74E-04 7.53E-07 
Diseases of the oral soft tissues, excluding lesions 
specific for gingiva and tongue 
ECH1 533 44851 82 14 241 2.27E-05 1.24E-06 7.90E-07 
Disturbance of skin sensation CXCR5 289 28611 55 7 147 8.33E-07 4.52E-04 7.98E-07 
Redundant prepuce and phimosis/BXO RINL 296 18837 73 9 163 3.50E-07 5.58E-04 8.22E-07 
Cardiac congenital anomalies SLC46A1 207 20493 42 13 413 5.69E-07 1.90E-04 9.16E-07 
Cardiomyopathy STXBP2 116 11484 71 11 234 3.18E-06 1.61E-05 9.20E-07 
Hearing loss REEP3 372 36828 40 7 99 1.62E-06 3.12E-05 9.45E-07 
Hypertension complicating pregnancy, childbirth, 
and the puerperium 
CLDN18 173 17127 36 8 271 4.29E-07 1.21E-02 9.49E-07 
Retention of urine RNF17 722 42994 222 63 2237 4.61E-07 3.37E-04 9.59E-07 
Hyposmolality and/or hyponatremia DLX3 144 14256 26 12 179 2.39E-04 6.68E-07 1.06E-06 
Malignant neoplasm of female breast ST6GALNAC6 1307 22672 63 24 177 1.48E-06 1.64E-04 1.07E-06 
Irregular menstrual cycle GTPBP2 219 21243 39 6 44 6.44E-06 4.45E-06 1.07E-06 
Hypertensive heart and/or renal disease FKBP15 181 17919 151 13 367 1.34E-06 9.22E-05 1.08E-06 
Coagulation defects F11 125 12375 56 9 150 2.04E-06 1.90E-05 1.10E-06 
Intracerebral hemorrhage GPR108 66 6534 50 20 381 2.42E-06 2.29E-06 1.11E-06 
Nasal polyps MPO 456 43262 208 51 2313 2.39E-05 2.00E-06 1.15E-06 
Osteoarthrosis, localized, primary MRPS14 1040 42647 49 12 118 2.90E-06 2.64E-05 1.15E-06 
Primary/intrinsic cardiomyopathies STXBP2 114 11286 71 11 232 3.34E-06 1.50E-05 1.16E-06 
Regional enteritis FN3KRP 189 18711 40 19 495 1.70E-05 1.35E-06 1.19E-06 
Epistaxis or throat hemorrhage LIN7B 267 26433 37 6 103 1.25E-06 6.50E-04 1.20E-06 
Cancer, suspected or other PCDHGB6 1683 41603 165 138 2379 7.19E-07 2.25E-04 1.20E-06 
Other symptoms/disorders or the urinary system OR10G3 2126 42946 65 87 992 9.50E-06 1.48E-06 1.21E-06 
Fever of unknown origin HOXB5 455 45133 41 6 96 8.54E-07 3.40E-04 1.21E-06 
Infection/inflammation of internal prosthetic device; 
implant; and graft 
UFSP1 236 23364 40 12 209 2.50E-05 1.29E-06 1.22E-06 
Obstruction of bile duct CNST 78 7722 40 11 160 4.48E-04 4.25E-07 1.23E-06 
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Other local infections of skin and subcutaneous 
tissue 
OR4C6 144 14256 41 9 162 2.34E-06 3.70E-05 1.26E-06 
Cough IDH3A 337 33363 40 30 1043 8.38E-06 5.14E-07 1.31E-06 
Malignant neoplasm of uterus DTD1 126 12474 15 4 63 1.08E-06 1.81E-03 1.32E-06 
Type 2 diabetes with neurological manifestations SCAF8 58 5742 75 10 214 1.72E-06 1.01E-04 1.37E-06 
Polymyalgia Rheumatica RPL3 97 9603 35 6 43 1.72E-05 1.12E-06 1.37E-06 
Noninflammatory female genital disorders ACAP1 1139 23792 101 19 216 3.39E-07 2.31E-02 1.39E-06 
Cervical intraepithelial neoplasia [CIN] [Cervical 
dysplasia] 
NAGS 309 21875 78 18 334 1.17E-04 1.53E-06 1.41E-06 
Intracranial hemorrhage OAS1 172 17028 66 6 172 4.79E-07 4.15E-03 1.43E-06 
Cardiac and circulatory congenital anomalies SLC46A1 219 21681 44 13 441 9.10E-07 4.17E-04 1.44E-06 
Postmenopausal bleeding NFE2L3 1171 21228 170 125 1358 9.47E-05 9.25E-07 1.44E-06 
Gram negative septicemia SLC26A3 87 8613 63 8 100 1.52E-06 1.34E-05 1.45E-06 
Nonspecific abnormal findings in stool contents SFMBT1 184 18216 82 9 163 4.51E-06 3.13E-05 1.48E-06 
Acute pancreatitis LONRF1 190 18810 78 13 238 6.80E-04 1.03E-06 1.49E-06 
Electrolyte imbalance DLX3 345 34155 39 17 417 2.31E-03 1.39E-06 1.53E-06 
Other open wound of head and face LCTL 304 30096 98 15 927 5.72E-07 6.68E-02 1.59E-06 
Edema SFPQ 160 15840 65 6 201 1.00E-06 2.91E-02 1.59E-06 
Breast cancer ST6GALNAC6 1423 43066 106 26 376 3.88E-06 9.41E-05 1.70E-06 
Other specified benign mammary dysplasias EVPLL 82 8118 39 6 57 2.28E-06 2.61E-05 1.70E-06 
Symptoms involving digestive system ANKRD35 2001 37239 234 143 1786 1.55E-05 4.91E-06 1.71E-06 
Psoriatic arthropathy OR9Q1 72 7128 22 11 183 2.34E-05 1.07E-06 1.74E-06 
Rheumatoid arthritis and other inflammatory 
polyarthropathies 
PNOC 582 41021 35 9 108 2.01E-06 6.07E-05 1.77E-06 
Fracture of ankle and foot WNT11 227 22473 69 5 152 5.76E-07 1.59E-02 1.81E-06 
Open wounds of extremities DICER1 435 43065 227 38 1574 9.60E-05 1.15E-06 1.84E-06 
Cancer, suspected or other PCDHGC5 1683 41603 179 50 813 9.81E-07 7.36E-03 1.85E-06 
Respiratory abnormalities CBR4 72 7128 28 8 192 1.51E-06 1.56E-03 1.90E-06 
Other disorders of gallbladder OR13F1 141 13959 30 7 109 1.97E-06 8.61E-05 1.91E-06 
Hypertensive chronic kidney disease FKBP15 150 14850 137 11 304 2.92E-06 1.87E-04 1.95E-06 
Phlebitis and thrombophlebitis of lower extremities RELL1 463 41305 49 10 221 1.51E-06 3.88E-04 1.98E-06 
Convulsions TMEM5 196 19404 47 12 225 1.17E-05 3.27E-06 2.01E-06 
Other specified benign mammary dysplasias TRAIP 82 8118 39 6 94 2.16E-06 4.19E-04 2.02E-06 
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Inflammatory bowel disease and other 
gastroenteritis and colitis 
GNA15 476 37276 77 26 734 3.58E-06 7.82E-06 2.03E-06 
Vascular insufficiency of intestine COL5A3 53 5247 113 10 228 3.72E-06 1.47E-04 2.05E-06 
Benign neoplasm of colon CCDC47 2257 43090 71 40 457 2.25E-06 4.36E-03 2.09E-06 
Breast cancer [female] ST6GALNAC6 1398 22668 63 25 177 3.35E-06 1.68E-04 2.11E-06 
Viral hepatitis SLC28A1 73 7227 55 6 140 9.76E-07 2.01E-03 2.15E-06 
Hemorrhoids GLS 2564 41248 69 25 187 1.87E-06 8.14E-04 2.18E-06 
Chronic glomerulonephritis, NOS ADGRL1 75 7425 102 11 239 8.03E-06 1.56E-05 2.20E-06 
Atherosclerosis of the extremities DONSON 67 6633 42 9 199 2.37E-06 2.50E-03 2.22E-06 
Cough C20orf173 337 33363 31 5 47 2.59E-06 1.01E-04 2.22E-06 
Poisoning by anticonvulsants and anti-Parkinsonism 
drugs 
ENTPD6 60 5940 50 8 172 2.47E-06 1.79E-04 2.23E-06 
Cerebral ischemia CHTOP 341 33759 45 7 141 1.83E-06 3.86E-04 2.24E-06 
Secondary malignant neoplasm ARNTL 784 41638 65 10 112 7.98E-06 3.32E-05 2.28E-06 
Elevated blood pressure reading without diagnosis 
of hypertension 
FKBP5 167 16533 43 9 178 2.45E-06 1.02E-04 2.29E-06 
Urinary incontinence FAM98C 1012 42980 95 27 503 3.06E-06 1.13E-04 2.30E-06 
Renal colic SLC10A1 279 27621 84 11 264 5.60E-06 7.70E-05 2.30E-06 
Spondylosis without myelopathy MAP3K7CL 553 43796 58 9 155 1.91E-06 2.57E-04 2.32E-06 
Duodenal ulcer RBFOX3 322 31878 59 8 205 1.58E-06 8.63E-04 2.34E-06 
Disorders of fluid, electrolyte, and acid-base 
balance 
DDX42 675 44906 121 38 1304 1.80E-06 2.79E-04 2.35E-06 
Cholelithiasis with acute cholecystitis FAM111A 134 13266 65 16 356 8.95E-06 1.46E-05 2.39E-06 
Nontoxic uninodular goiter EIF4G1 55 5445 110 12 708 6.39E-07 5.54E-02 2.40E-06 
Fracture of radius and ulna SVOP 508 43549 61 10 176 1.40E-05 9.32E-06 2.41E-06 
Other and unspecified disorders of back PRKAG2 221 21879 73 10 149 1.32E-04 2.84E-06 2.47E-06 
Cancer of urinary organs (incl. kidney and bladder) SMYD2 421 41679 75 15 532 1.38E-06 3.25E-04 2.48E-06 





















e disease (200)  
JAK2 












































Cancer of prostate 
(185) 
HOXB13 



























Heartburn (530.9) USP45 
rs554927779 6:99468543:D:1 4.52E-03 5.39E-05 frameshift deletion LoF: High-confidence - 













Fracture of hand 
or wrist (804) 
GSDMC 




















rs140190776 4:186273178:G:A 1.97E-04 1.73E-04 splicing LoF: High-confidence - 
- 4:186267139:G:T 6.58E-05 3.85E-03 
nonsynonymous 
SNV 
probably damaging deleterious 
Congenital 
anomalies of great 
vessels (747.13) 
SLC46A1 












Peptic ulcer (excl. 
esophageal) (531) 
LMNB2 
















Table S2.6. The most significant nearby variant association signals (± 100 Kbp up and down stream) in the UK-Biobank imputed 













e MAF p-value 
Myeloproliferative disease (200) JAK2 
rs10283564 





Unspecified monoarthritis (716.2) OGG1 
rs75924392 





Menopausal and postmenopausal disorders 
(627) NFE2L3 
rs35838658 














Other aneurysm (442) P3H1 
rs14879709





Heartburn (530.9) USP45 
rs75597991 





Fracture of hand or wrist (804) GSDMC 
rs409790 chr8:12983324
























Peptic ulcer (excl. esophageal) (531) LMNB2 
rs14628306








Scalable Generalized Linear Mixed Model for Region-based 





With very large sample sizes, population-based cohorts and biobanks provide an exciting 
opportunity to identify genetic components of complex traits. To analyze rare variants, gene or 
region-based multiple variant aggregate tests are commonly used to increase association test power. 
However, due to the substantial computation cost, existing region-based rare variant tests cannot 
analyze hundreds of thousands of samples while accounting for confounders, such as population 
stratification and sample relatedness. Here we propose a scalable generalized mixed model region-
based association test that can handle large sample sizes and accounts for unbalanced case-control 
ratios for binary traits. This method, SAIGE-GENE, utilizes state-of-the-art optimization strategies 
to reduce computational and memory cost, and hence is applicable to exome-wide and genome-
wide region-based analysis for hundreds of thousands of samples. Through the analysis of the 
HUNT study of 69,716 Norwegian samples and the UK Biobank data of 408,910 White British 
samples, we show that SAIGE-GENE can efficiently analyze large sample data (N > 400,000) 




In recent years, large cohort studies and biobanks, such as Trans-Omics for Precision Medicine 
(TOPMed) study(Taliun et al., 2019) and UK Biobank(C. Bycroft et al., 2018), have sequenced or 
genotyped hundreds of thousands of samples, which are invaluable resources to identify genetic 
components of complex traits, including rare variants (minor allele frequency (MAF) < 1%). It is 
well known that single variant tests are underpowered to identify trait-associated rare variants(S. 
Lee et al., 2014). Gene- or region-based tests, such as Burden test, SKAT(M. C. Wu et al., 2011) 
and SKAT-O(S. Lee et al., 2012), can be more powerful by grouping rare variants into functional 
units, i.e. genes. To adjust for both population structure and sample relatedness, gene-based tests 
have been extended to mixed models(H. Chen et al., 2019). For example, EmmaX(Kang et al., 
2010) based SKAT(M. C. Wu et al., 2011) approaches (EmmaX-SKAT) have been implemented 
and used for many rare variant association studies including TOPMed(Natarajan et al., 2018; 
Taliun et al., 2019). The generalized linear mixed model gene-based test, SMMAT, has been 
recently developed(H. Chen et al., 2019). However, these approaches require O(𝑁3) computation 
time and O(𝑁2) memory usages, where 𝑁  is the sample size, which are not scalable to large 
datasets.  
Here, we propose a novel method called SAIGE-GENE for region-based association analysis that 
is capable of handling very large samples (> 400,000 individuals), while inferring and accounting 
for sample relatedness. SAIGE-GENE is an extension of the previously developed single variant 
association method, SAIGE(W. Zhou et al., 2018), with a modification suitable to rare variants. 
Same as SAIGE, it utilizes state-of-the-art optimization strategies to reduce computation cost for 
fitting null mixed models. To ensure computation efficiency while improving test accuracy for 
rare variants, SAIGE-GENE approximates the variance of score statistics calculated with the full 
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genetic relationship matrix (GRM) using the variance calculated with a sparse GRM and the ratios 
of these two variances estimated from a subset of genetic markers. Because the sparse GRM, which 
is constructed by thresholding small values in the full GRM, preserves close family structures, this 
approach provides a far more accurate variance estimation for very rare variants (minor allele 
count (MAC) < 20) than the original approach in SAIGE(W. Zhou et al., 2018). By combining 
single variant score statistics, SAIGE-GENE can perform Burden, SKAT and SKAT-O type gene-
based tests. We have also developed conditional analysis to perform association tests conditioning 
on a single variant or multiple variants to identify independent rare variant association signals. 
Furthermore, SAIGE-GENE can account for unbalanced case-control ratios of binary traits by 
adopting a robust adjustment based on saddlepoint approximation(Daniels, 1954; R. Dey et al., 
2017; Kuonen, 1999) (SPA) and efficient resampling(Lee et al., 2016) (ER). The robust adjustment 
was previously developed for independent samples(Zhao et al., 2019) and we have extended it for 
related samples in SAIGE-GENE.   
We have demonstrated that SAIGE-GENE controls for type I error rates in related samples for 
both quantitative and binary traits through extensive simulations as well as real data analysis, 
including the HUNT study for 69,716 Norwegian samples(Krokstad et al., 2013; Langhammer et 
al., 2012) and the UK Biobank for 408,910 White British samples(C. Bycroft et al., 2018). By 
evaluating its computation performance of SAIGE-GENE, we have shown its feasibility for large-
scale genome-wide analysis. To perform exome-wide gene-based tests on 400,000 samples with 
on average 50 markers per gene, SAIGE-GENE requires 2,238 CPU hours and less than 36 Gb 
memory, while current methods will cost more than > 10 Tb in memory. We have further applied 
SAIGE-GENE to 53 quantitative traits and 10 binary traits in the UK Biobank and identified 







3.2.1 Overview of methods 
 
SAIGE-GENE consists of two main steps: 1. Fitting the null generalized linear mixed model 
(GLMM) to estimate variance components and other model parameters. 2. Testing for association 
between each genetic variant set, such as a gene or a region, and the phenotype. Three different 
association tests: Burden, SKAT, and SKAT-O have been implemented in SAIGE-GENE. The 
workflow is shown in the Figure S3.1.  
SAIGE-GENE uses similar optimization strategies as utilized in the original SAIGE to achieve the 
scalability for fitting the null GLMM and estimating the model parameters in Step 1. In particular, 
the spectral decomposition has been replaced by the preconditioning conjugate gradient (PCG) to 
solve linear systems without calculating and inverting the 𝑁 ×  𝑁 GRM. To reduce the memory 
usage, raw genotypes are stored in a binary vector and elements of GRM are calculated when 
needed rather than being stored.  
One of the most time-consuming part in association tests is to calculate variance of single variant 
score statistic, which requires O( 𝑁2 ) computation. To reduce computation cost, existing 
approaches, such as SAIGE(W. Zhou et al., 2018), BOLT-LMM(Loh et al., 2015), and 
GRAMMA-Gamma(Svishcheva et al., 2012), approximate the variance of single variant score 
statistics with the full GRM using the variance estimate without a GRM and the ratio of these two 
variances. The ratio, which is assumed to be constant, is estimated using a subset of randomly 
selected genetic markers.  However, for very rare variants with MAC below 20, the constant ratio 
assumption is not satisfied (Figure S3.2, left panel). This is because rare variants are more 
susceptible to close family structures. Thus, to better approximate the variance, SAIGE-GENE 
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incorporates close family structures through a sparse GRM, in which GRM elements below a user-
specified relatedness coefficient are zeroed out and close family structures are preserved. The ratio 
between the variance with the full GRM and with the sparse GRM is much less variable (Figure 
S3.2, right panel). To construct a sparse GRM, a small subset of randomly selected genetic 
markers, i.e. 2,000, are firstly used to quickly estimate which sample pairs pass the user-specified 
coefficient of relatedness cutoff, e.g. ≥0.125 for up to 3rd degree relatives. Then the coefficients 
of relatedness for those related pairs are further estimated using the full set of genetic markers, 
which equal to values in the full GRM. Given that estimated values for variance ratios vary by 
MAC for the extremely rare variants (Figure S3.2, left panel), such as singletons and doubletons, 
the variance ratios need to be estimated separately for different MAC categories. By default, MAC 
categories are set to be MAC equals to 1, 2, 3, 4, 5, 6 to 10, 11 to 20, and > 20. 
In Step 2, gene-based tests are conducted using single variant score statistics and their covariance 
estimates, which are approximated as the product of the covariance with the sparse GRM and the 
pre-estimated ratio. SAIGE-GENE can carry out Burden, SKAT, and SKAT-O approaches. Since 
SKAT-O is a combined test of Burden and SKAT, and hence provides a robust power, SAIGE-
GENE performs SKAT-O by default.  
If a gene or a region is significantly associated with the phenotype of interest, it is necessary to 
test if the signal is from rare variants or just a shadow of common variants in the same locus. We 
have developed conditional analysis using linkage disequilibrium (LD) information between 
conditioning markers and the tested gene(Liu et al., 2014). Details are described in the Online 
Methods section.  
SAIGE-GENE uses the same generalized linear mixed model as in SMMAT, while SMMAT 
calculates the variances of the score statistics for all tested genes using the full GRM directly and 
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hence can be thought of as the “exact” method. When the trait is continuous, GLMM used by 
SAIGE-GENE and SMMAT is equivalent to the linear mixed model (LMM) of EmmaX-SKAT. 
We have further shown that SAIGE-GENE provides consistent association p-values to the two 
“exact” methods, EmmaX-SKAT and SMMAT (r2 of -log10 p-values > 0.99), using both simulation 
studies (Figure S3.3) and real data analysis for down-sampled UK Biobank and HUNT (Figure 
S3.4), but with much smaller computation and memory cost (Figure 3.1). We have also shown 
that SAIGE-GENE with different coefficient of relatedness cutoffs (0.125 and 0.2) produced 




Figure 3.1 Estimated and projected computation cost by sample sizes (N) for gene-based tests for 
15,342 genes, each containing 50 rare variants.  
Benchmarking was performed on randomly sub-sampled UK Biobank data with 408,144 White 
British participants for waist-to-hip ratio. The reported run times and memory are medians of five 
runs with samples randomly selected from the full sample set using different sampling seeds. The 
reported computation time and memory for EmmaX-SKAT and SMMAT is the projected 
computation time when N > 20,000. A. Log-log plots of the memory usage as a function of sample 
size (N) B. Log-log plots of the run time as a function of sample size (N). Numerical data are 











































































SAIGE−GENE, 340447 markers for GRM




For binary phenotypes with unbalanced case-control ratios (< 1:9), single variant score statistics 
do not follow the normal distribution, leading to inflated type I error rates for region-based test(Lee 
et al., 2016). To address this problem, we have recently developed a scalable robust adjustment 
for independent samples(Zhao et al., 2019). The approach uses saddlepoint approximation(Daniels, 
1954; R. Dey et al., 2017; Kuonen, 1999) (SPA) and efficient resampling(Lee et al., 2016) (ER) 
to calibrate the variance of single variant score statistics. We have extended this approach to 
GLMM for SAIGE-GENE, which provides greatly improved type I error control than the 
unadjusted approach of assuming normality (Figure S3.6). Details can be found in 
Supplementary Materials 1.3.3. 
3.2.2 Generalized linear mixed model  
In a study with sample size 𝑁, we denote the phenotype of the ith individual using 𝑦𝑖 for both 
continuous and binary traits. Let the 1 × (𝑝 + 1) vector 𝑋𝑖 represent 𝑝 covariates including the 
intercept, the 𝑁 × 𝑞 matrix 𝐺𝑖 represent the allele counts (0, 1 or 2) for 𝑞 variants in the gene to 
test. The generalized linear mixed model can be written as      
𝑔(𝜇𝑖) = 𝑋𝑖𝛼 + 𝐺𝑖𝛽 + 𝑏𝑖,  
where 𝜇𝑖 is the mean of phenotype, 𝑏𝑖 is the random effect, which is assumed to be distributed as 
𝑁(0, 𝜏 𝜓), where 𝜓 is an 𝑁 ×  𝑁 genetic relationship matrix (GRM) and 𝜏 is the additive genetic 
variance parameter. The link function 𝑔 is the identity function for continuous traits with an error 
term 𝜀~𝑁(0, 𝜙𝐼)  and logistic function for binary traits. The parameter 𝛼  is a  (𝑝 + 1)  ×
 1 coefficient vector of fixed effects and 𝛽 is a 𝑞 × 1 coefficient vector of the genetic effect. 
3.2.3 Estimate variance component and other model parameters (Step 1) 
Same as in the original SAIGE(W. Zhou et al., 2018) and GMMAT(H. Chen et al., 2016), to fit 
the null GLMM in SAIGE-GENE, penalized quasi-likelihood (PQL) method(Breslow & Clayton, 
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1993; Lee & van der Werf, 2006) and the computational efficient average information restricted 
maximum likelihood (AI-REML) algorithm(H. Chen et al., 2016; Gilmour et al., 1995) are used 
to iteratively estimate (?̂?, ?̂?, ?̂?) under the null hypothesis of 𝛽 = 0. At iteration k, let (?̂?(𝑘), ?̂?(𝑘), 
?̂?(𝑘)) be estimated (?̂?, ?̂?, ?̂?),  ?̂?𝑖
(𝑘)
 be the estimated mean of 𝑦𝑖 and Σ̂
(𝑘) = (?̂?(𝑘))−1 + ?̂?(𝑘)𝜓 be an 
𝑁 ×  𝑁  matrix of the variance of working vector ?̃?𝑖 , in which 𝜓  is the 𝑁 ×  𝑁  GRM. For 
continuous traits, ?̂?(𝑘) = ?̂?−1𝐼  and ?̃?𝑖 =  𝑋𝑖𝛼
(𝑘) + 𝑏𝑖
(𝑘)
.  For binary traits, ?̂?(𝑘) =
𝑑𝑖𝑎𝑔[?̂?𝑖
(𝑘)(1 − ?̂?𝑖
(𝑘))] and ?̃?𝑖 = 𝑋𝑖𝛼
(𝑘) + 𝑏𝑖
(𝑘)




(𝑘))}. To obtain the log 
quasi-likelihood and average information at each iteration, SAIGE and SAIGE-GENE use the 
preconditioned conjugate gradient approach (PCG) to obtain the product of inverse of Σ̂(𝑘)and any 
other vector by iteratively solving a linear system with Σ̂(𝑘) . This approach is more 
computationally efficient than using Cholesky decomposition to obtain (Σ̂(𝑘))−1.   
3.2.4 Gene-based association tests (Step 2) 
Test statistics of the Burden, SKAT and SKAT-O tests for a gene can be constructed based on 
score statistics from the marginal model for individual variants in the gene. Suppose there are 𝑞  
variants in the region or gene to test. The score statistic for variant 𝑗 (j=1,. . , 𝑞) under H0: 𝛽𝑗 = 0 
is 𝑇𝑗 = 𝑔𝑗
𝑇(𝑌 − ?̂?) where 𝑔𝑗 and Y are 𝑁 ×  1 genotype and phenotype vectors, respectively, and 
?̂? is the estimated mean of 𝑌 under the null hypothesis.  
Let 𝑢𝑗denote a threshold indicator or weight for variant 𝑗 and U = diag(𝑢1, … , 𝑢𝑞) be a diagonal 
matrix with 𝑢𝑗  as the 𝑗th element. Similar to the original SKAT and SKAT-O papers(S. Lee et al., 
2012; M. C. Wu et al., 2011),  to upweight rare variants, the default setting in SAIGE-GENE is 
𝑢𝑗 =  𝐵𝑒𝑡𝑎(𝑀𝐴𝐹𝑗 , 1, 25), which upweight rarer variants. The Burden test statistics can be written 




.  Suppose ?̃? = 𝐺 − 𝑋(𝑋𝑇?̂?𝑋)
−1
𝑋𝑇?̂?𝐺 is the covariate adjusted 
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genotype matrix, where 𝐺 = (𝑔1, … , 𝑔𝑞) is the 𝑁 × 𝑞 genotype matrix of the 𝑞 genetic variants, 
and ?̂? = ?̂?−1 − ?̂?−1𝑋(𝑋𝑇?̂?−1𝑋)
−1
𝑋𝑇?̂?−1 with ?̂? = ?̂?−1 + ?̂?𝜓. Under the null hypothesis of no 
genetic effects, 𝑄𝐵𝑢𝑟𝑑𝑒𝑛  followed 𝜆𝐵𝜒1
2 , where 𝜆𝐵 = 𝐽
𝑇U?̃?𝑇?̂??̃?U𝐽, 𝐽  is a 𝑞 × 1  vector with all 
elements being unity and 𝜒1
2is a chi-squared distribution with 1 degree of freedom(S. Lee et al., 
2014). The SKAT test(M. C. Wu et al., 2011) can be written as 𝑄𝑆𝐾𝐴𝑇 = ∑ 𝑢𝑗
2𝑇𝑗
2𝑞
𝑗=1 , which follows 
a mixture of chi-square distribution  ∑ 𝜆𝑆𝑗𝜒1
2𝑞
𝑗=1 , where 𝜆𝑆𝑗 are the eigenvalues of 𝑈?̃?
𝑇?̂??̃?𝑈. The 
SKAT-O test(S. Lee et al., 2012) uses a linear combination of the Burden and SKAT tests statistics 
𝑄𝑆𝐾𝐴𝑇𝑂 = (1 − 𝜌)𝑄𝑆𝐾𝐴𝑇 + 𝜌𝑄𝐵𝑢𝑟𝑑𝑒𝑛, 0 ≤  𝜌 ≤ 1. To conduct the test, the minimum p-value from 
grid of 𝜌 is calculated and the p-value of the minimum p-value is estimated through numerical 
integration. Following the suggestion in Lee et al(Lee et al., 2013), we use a grid of eight values 
of 𝜌 = (0, 0.12, 0.22, 0.32, 0.42, 0.52, 0.5, 1) to find the minimum p-value.  
 3.2.5 Approximate ?̃?𝑻?̂??̃? 
For each gene, given ?̂?, the calculation of ?̃?𝑇?̂??̃? requires applying PCG for each variant in the 
gene, which can be computationally very expensive. Suppose ?̃?  represents a covariate adjusted 
single variant genotype vector. To reduce computation cost, an approximation approach has been 
used in SAIGE, BOLT-LMM(Loh et al., 2015) and GRAMMAR-GAMMAR(Svishcheva et al., 
2012), in which the ratio between ?̃?𝑇?̂??̃? and ?̃?𝑇?̃? is estimated by a small subset of randomly 
selected genetic markers. The ratio has been shown to be approximately constant for all variants. 
Given the estimated ratio ?̂? = ?̃?𝑇?̂??̃? /?̃?𝑇?̃?,  ?̃?𝑇?̂??̃? for all other variants can be obtained as ?̂??̃?𝑇?̃?. 
However, the variations of the estimated ?̂? for extremely rare variants are large and including some 
closely related samples in the denominator helps reduce the variation of ?̂? as shown in Figure S3.2. 
Let 𝜓𝑆 denote a sparse GRM that preserves close family structure and 𝜓𝑓 denote a full GRM. We 
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estimate the ratio ?̂?𝑠 = ?̃?










 and ?̂?𝑠 =
 ?̂?−1 + ?̂? 𝜓𝑠.  
In 𝜓𝑠, elements below a user-specified relatedness coefficient cutoff, i.e. > 3
rd degree relatedness, 
are zeroed out with only close family structures being preserved. To construct 𝜓𝑠, a subset of 
randomly selected genetic markers, i.e. 2,000, is firstly used to quickly estimate which related 
samples pass the user-specified cutoff. Then the relatedness coefficients for those samples are 
further estimated using the full set of genetic markers, which equal to corresponding values in the 
𝜓𝑓 . In the model fitting using 𝜓𝑠 , ?̂?𝑠
−1
𝑋  and ?̂?𝑠
−1
?̃? need to be calculated. For this we use a 
sparse-LU based solve method(Davis, 2006) implemented in R. The constructed 𝜓𝑠 is also used 
for approximating the variance of score statistics with 𝜓𝑓 . For a biobank or a data set, 𝜓𝑠 only 
needs to be constructed once and can be re-used for any phenotypes in the same date set.  
SAIGE-GENE estimates variance ratios for different MAC categories. By default, MAC 
categories are set to be MAC equals to 1, 2, 3, 4, 5, 6 to 10, 11 to 20, and is greater than 20. Once 
the MAC categorical variance ratios are estimated, for each genetic marker in tested genes or 
regions,  ?̂?𝑠 can be obtained according to its MAC. Let ?̂?𝑠 be a 𝑞 ×  𝑞 diagonal matrix whose jth 
diagonal element is the ratio ?̂?𝑠 for the jth marker in the gene (i.e. ?̃?𝑗
𝑇?̂??̃?𝑗  /?̃?𝑗
𝑇?̂?𝑠?̃?𝑗). For the tested 




2 (See Supplementary Materials 
for more details).  




2 to account for unbalanced case-control 
ratios 
To account for unbalanced case-control ratios of binary traits in region- or gene-based tests, we 
recently developed a robust adjustment for independent samples(Zhao et al., 2019). The approach 
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first obtains well-calibrated p-values of single variant score statistics using SPA(Daniels, 1954; R. 
Dey et al., 2017; Kuonen, 1999) and ER(Lee et al., 2016). SPA is a method to calculate p-values 
by inverting the cumulant generating function (CGF). Since CGF completely specifies the 
distribution, SPA can be far more accurate than using the normal distribution. However, since SPA 
is still an asymptotic based approach, it does not work well when variants are very rare (ex. MAC 
≤10). For those variants, we use ER, which resamples the case-control status of only individuals 
carrying a minor allele and is extremely fast for very rare variants. To account for the fact that 
individuals can have different non-genetic risk of diseases (due to covariates), the resampling was 
done with the estimated disease risk 𝜇𝑖 . Next, variances of single variant score statistics are 
obtained by inverting those p-values, which are then used to calibrate the variances of region- or 
gene-based test statistics. We have extended the approach for related samples in SAIGE-GENE. 
For variants with MAC > 10, single-variant p-values are obtained by SAIGE, which basically 
applies SPA to GLMM. For variants with MAC ≤10, we use ER with GLMM estimated  𝜇?̂?, which 
includes the random effect to maintain the correlation structure among samples. After calculating 
p-values of 𝑇𝑗 for j=1,…,q, the variance of 𝑇𝑗 is calibrated by inverting the corresponding p-value. 




2 to compute robust p-value for the region- or 
gene-based test. The details can be found in Supplementary Materials.  
 3.2.7 Conditional analysis  
In SAIGE-GENE, we have implemented the conditional analysis to perform gene-based tests 
conditioning on a given markers using the summary statistics from the unconditional gene-based 
tests and the linkage disequilibrium 𝑟2 between testing and conditioning markers(Liu et al., 2014). 
Let 𝐺 be the genotypes for a gene to be tested for association, which contains 𝑞 markers, and 𝐺2 
be the genotypes for the conditioning markers, which contains 𝑞2 markers. Let 𝛽 denote a 𝑞 × 1 
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coefficient vector of the genetic effect for the gene to be tested and 𝛽2 be a 𝑞2 × 1 coefficient 
vector of the genetic effect for the conditioning markers. The genotype matrix with the non-genetic 
covariates projected out  ?̃? = 𝐺 − 𝑋(𝑋𝑇?̂?𝑋)−1𝑋𝑇?̂?𝐺  and ?̃?2 = 𝐺2 − 𝑋(𝑋
𝑇?̂?𝑋)−1𝑋𝑇?̂?𝐺2. In 
the unconditioned association tests, the test statistics 𝑇 = ?̃?𝑇(𝑌 − ?̂?) and 𝑇2 = ?̃?2
𝑇
(𝑌 − ?̂?). In 
conditional analysis, under the null hypothesis, E(𝑇) = E(?̃?𝑇𝑃( ?̃?2𝛽2)) = ?̃?
𝑇?̂??̃?2𝛽2  and E(𝑇2) = 
E(?̃?2
𝑇𝑃( ?̃?2𝛽2)) = ?̃?2
𝑇?̂?𝑠?̃?2𝛽2 . 𝑇 and 𝑇2 jointly follow the multivariate normal with mean (E(𝑇), 






Thus under the null hypothesis of no association of T, i.e. H0: 𝛽 = 0 , the 𝑇|𝑇2  follows the 
conditional normal distribution with E(𝑇|𝑇2) = ?̃?
𝑇?̂??̃?2 (?̃?2
𝑇?̂??̃?2)






𝑇?̂??̃? , and p-values can be calculated from the conditional distribution. 
3.2.8 Data simulation  
We carried out a series of simulations to evaluate and compare the performance of SAIGE-GENE, 
EmmaX-SKAT(Kang et al., 2010; S. Lee et al., 2012) and SMMAT(H. Chen et al., 2019). We 
used the sequence data from 10,000 European ancestry chromosomes over 1Mb regions that was 
generated using the calibrated coalescent model in the SKAT R package(S. Lee et al., 2012). We 
randomly selected 10,000 regions with 3Kb from the sequence data, followed by the gene-
dropping simulation44 using these sequences as founder haplotypes that were propagated through 
the pedigree of 10 family members shown in Figure S3.11. Only variants with MAF ≤  1% were 
used for simulation studies. Quantitative phenotypes were generated from the following linear 
mixed model 𝑦𝑖 = 𝑋1 + 𝑋2 + 𝐺𝑖𝛽 + 𝑏𝑖 + 𝜀𝑖 , where 𝐺𝑖  is the genotype value, 𝛽  is the genetic 
effect sizes, 𝑏𝑖 is the random effect simulated from 𝑁(0, τ 𝜓), and 𝜀𝑖 is the error term simulated 
from 𝑁(0, (1 − τ)𝐼).  Two covariates, X1 and X2, were simulated from Bernoulli(0.5) and N(0,1), 
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respectively. Binary phenotypes were generated from the logistic mixed model 𝑙𝑜𝑔𝑖𝑡(𝜋𝑖0) = 𝛼0 +
𝑏𝑖 +  𝑋1 + 𝑋2 + 𝐺𝑖𝛽, where 𝛽 is the genetic log odds ratio,  𝑏𝑖 is the random effect simulated from 
𝑁(0, τ 𝜓)  with τ = 1 . The intercept 𝛼0  was determined by the disease prevalence (i.e. case-
control ratios). Given τ = 1, the liability scale heritability is 0.2345. 
To evaluate the type I error rates at exome-wide α=2.5×10-6, we first simulated 10,000 regions, 
and then simulated 1000 sets of quantitative phenotypes for each simulated region with different 
random seeds under the null hypothesis with 𝛽 = 0. Gene-based association tests were performed 
using SAIGE-GENE, EmmaX-SKAT, and SMMAT therefore in total 107 tests for each of Burden, 
SKAT, and SKAT-O tests were carried out. Two different settings for τ were evaluated: 0.2 and 
0.4 and two different sample relatedness settings were used: one has 500 families and 5,000 
independent samples and other one has 1,000 families, each with 10 family members. We also 
simulated 1,000 sets of binary phenotypes for case-control ratios 1:99, 1:19, 1:9, 1:4, and 1:1 for 
500 families and 5,000 independent samples. Burden, SKAT, and SKAT-O tests were performed 
on the 10,000 genome regions using SAIGE-GENE, in total 107 tests for each method for each 
case-control ratio.  
For the power simulation, phenotypes were generated under the alternative hypothesis 𝛽 ≠ 0. Two 
different settings for proportions of causal variants are used: 10% and 40%, corresponding to |𝛽| =
|𝑙𝑜𝑔10(𝑀𝐴𝐹)| and |𝛽| = |0.3𝑙𝑜𝑔10(𝑀𝐴𝐹)|, respectively. In each setting, 80% and 100% had 
negative effect sizes. We simulated 1,000 datasets in each simulation, and power was evaluated at 
test-specific empirical α, which yields nominal α=2.5×10-6. The empirical α was estimated from 
the type I error simulations. Similarly, 1,000 sets of binary traits were generated for 10,000 samples 
(500 families and 5,000 independent samples) under the alternative hypothesis 𝛽 ≠ 0 using two 
different settings: cohort study with various disease prevalence (0.01, 0.05, 0.1, and 0.5); and case-
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control sampling with three different case-control ratios (1:19, 1:9, and 1:1) based on a disease 
prevalence 1% in the population (Supplementary Materials 2.5). 40% variants are simulated as 
causal variants, among which 80% are risk-increasing variants and 20% are risk-decreasing. The 
absolute effect sizes of causal variants are set to be |0.55log10(MAF)| and |0.35log10(MAF)| for 
cohort study and case-control sampling, respectively.  
3.2.9 HUNT and UK Biobank data analysis 
We applied SAIGE-GENE to the high-density lipoprotein (HDL) levels in 69,500 Norwegian 
samples from a population-based Nord Trøndelag Health Study (HUNT) 9. About 70,000 HUNT 
participants were genotyped using Illumina HumanCoreExome v1.0 and 1.1 and imputed using 
Minimac3(Das et al., 2016) with a merged reference panel of HRC and whole genome sequencing 
data (WGS) for 2,201 HUNT samples. Variants with imputation r2 < 0.8 were excluded from 
further analysis. Total 13,416 genes with at least two rare (MAF ≤  1%) missense and/or stop-gain 
variants with imputation r2 ≥ 0.8 were tested. Variants were annotated using Seattle Seq 
Annotations (http://snp.gs.washington.edu/SeattleSeqAnnotation138/). Age, Sex, genotyping 
batch, and first four PCs were included as covariates in the model. We used 249,749 pruned 
genotyped markers to estimate relatedness coefficients in the full GRM for Step 1 and used the 
relative coefficient cutoff  ≥ 0.125 for the sparse GRM. 
We have also analyzed 53 quantitative traits and 10 binary traits using SAIGE-GENE in the  UK 
Biobank for 408,910 participants with White British ancestry(C. Bycroft et al., 2018). Markers 
that were imputed by the Haplotype Reference Consortium (HRC)20 panel with imputation info 
score ≥ 0.8 were used in the analysis. Total 15,342 genes with at least two rare (MAF ≤  1%) 
missense and stop-gain variants that were directly genotyped or successfully imputed from HRC 
(imputation score ≥ 0.8) were tested. Sex, age when attended assessment center, and first four PCs 
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that were estimated using all samples with White British ancestry were adjusted in all tests. We 
used 340,447 pruned markers, which were pruned from the directly genotyped markers using the 
following parameters, were used to construct GRM: window size of 500 base pairs (bp), step-size 
of 50 bp, and pairwise r2 < 0.2. We used the relative coefficient cutoff  ≥ 0.125 for the sparse 
GRM. 
 
 3.3 Results 
3.3.1 Computation and Memory Cost 
To evaluate the computation performance of SAIGE-GENE, we randomly sampled subsets of the 
408,144 UK Biobank participants with the White British ancestry and non-missing measurements 
for waist hip ratio(C. Bycroft et al., 2018). We benchmarked SAIGE-GENE, EmmaX-SKAT, and 
SMMAT for exome-wide gene-based SKAT-O tests, in which 15,342 genes were tested with 
assuming that each has 50 rare variants.   
Memory usage is plotted on a log10 scale against sample sizes in Figure 3.1A. The memory cost 
of SAIGE-GENE is linear to the number of markers, M1, used for kinship estimation, but using 
too few markers may not be sufficient to account for subtle sample relatedness in the data, leading 
to inflated type I error rates in genetic association tests(Yang et al., 2014; W. Zhou et al., 2018). 
SAIGE-GENE uses 11.74 Gb with M1 = 93,511 and 35.59 Gb when M1 = 340,447 when the sample 
size N is 400,000, making it feasible for large sample data. In contrast, with N = 400,000 the 
memory usages in EmmaX-SKAT and SMMAT are projected to be nearly 10Tb, which makes 
them impossible to be used for large sample data.  
Total computation time for exome-wide gene-based tests is plotted on a log10 scale against the 
sample size as shown in Figure 3.1B. Computation time for Step 1 and Step 2 are plotted 
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separately in Figure S3.7 with numbers presented in Table S3.1. The computation time for Step 
1 in SAIGE-GENE is approximately O(M1N
1.5) and in SMMAT and EmmaX-SKAT is O(N3), 
where M1 is the number of markers used for estimating the full GRM and N is the sample size. In 
Step 2, the association test for each gene costs O(𝑞𝐾) in SAIGE-GENE, where 𝑞 is the number of 
markers in the gene and K is the number of non-zero elements in the sparse GRM. Compared to 
O(𝑞𝑁2) in Step 2 of SMMAT and EmmaX-SKAT, SAIGE-GENE decreases the computation time 
dramatically. For example, in the UK Biobank (N =408,910) with the relatedness coefficient ≥ 
0.125 (corresponding to preserving samples with 3rd degree or closer relatives in the GRM), 𝐾 = 
493,536, which is the same order of magnitude of N, and hence O(𝑞𝐾) is greatly smaller than 
𝑂(𝑞𝑁2). As the computation time in Step 2 is approximately linear to 𝑞, the number of markers 
in each variant set, the total computation time for exome-wide gene-based tests was projected by 
different 𝑞 and plotted in Figure S3.8. In addition, we plotted the projected computation time for 
genome-wide region-based tests against the sample size as shown in Figure S3.9, in which 
286,000 chunks with 50 markers per chunk were assumed to be tested, corresponding to 14.3 
million markers in HRC-imputed UK Biobank data with MAF ≤ 1% and imputation info score ≥ 
0.8.  
With M1 = 340,447, it takes SAIGE-GENE 2,238 CPU hours for exome-wide gene-based tests and 
3,919 CPU hours for genome-wide region-based tests for waist hip ratio with N = 400,000 and 
each test contains 50 markers on average. Compared to EmmaX-SKAT and SMMAT, SAIGE-
GENE is 25 times faster for exome-wide gene-based tests and 161 times faster for genome-wide 
region-based tests. More details about the computation cost are presented in Table S3.1.  
To evaluate whether the additional steps in the robust adjustment for binary traits increases 
computation cost, we have obtained computation time of SAIGE-GENE with and without the 
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adjustment when analyzing the UK Biobank data for glaucoma (PheCode:365). Samples were 
randomly selected from 4,462 glaucoma cases and 397,701 controls respectively, so the case-
control ratio remained the same in sub-sampled data sets. The results are presented in Table S3.2 
and plotted in Figure S3.10, showing that the robust adjustment only slightly increases the 
computation cost (1,269 vs 1,232 CPU hours for exome-wide analysis with M1 = 93,511) compared 
to the unadjusted approach. 
The computation time for constructing the sparse GRM is O(𝑀1
∗𝑁2 + M1𝐾). 𝑀1
∗ is the number of 
a small set of markers used for initial determination of related sample pairs based on a relationship 
coefficient cutoff, which by default is set to be 2,000. This step is only needed for each data set for 
one time to create a sparse GRM and the constructed sparse GRM will be re-used for all 
phenotypes in the same cohort or biobank. For example, for the UK Biobank with 𝑁 = 408,910, 
M1= 340,447, 𝑀1
∗ = 2000, 𝐾 = 493,536 with the relationship coefficient ≥ 0.125, corresponding to 
up to 3rd degree relatives, it took 312 CPU hours to create the sparse GRM. Parallel computation 
is allowed for this step.  
3.3.2 Gene-based association analysis of quantitative traits in HUNT and UK 
Biobank 
We applied SAIGE-GENE to analyze 13,416 genes, with at least two rare (MAF ≤ 1%) missense 
and stop-gain variants that were directly genotyped or imputed from HRC for high-density 
lipoprotein (HDL) in 69,716 Norwegian samples from a population-based Nord Trøndelag Health 
Study (HUNT)9. The HUNT study has substantial sample relatedness, in which ~55,000 samples 
have at least one up to 3rd degree relatives. The quantile-quantile (QQ) plot for the p-values of 
SKAT-O tests from SAIGE-GENE for HDL in HUNT is shown Figure 3.2A. As Table 3.1 shows, 
eight genes reached the exome-wide significant threshold (p-value ≤ 2.5x10-6) and all of them are 
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located in the previously reported GWAS loci for HDL(Willer et al., 2008; Willer et al., 2013). By 
extending 500kb up and down stream, a top significant hit from single-variant association tests has 
been identified around each gene. For genes LIPC, LIPG, NR1H3, and CKAP5, the top hits are 
common variants with MAF > 5% and the top hits in FSD1L, ABCA1 and RNF111 are less frequent 
non-coding variants that are not included in the gene-based tests. After conditioning on top hits, 
all genes, except for FSD1L, remained exome-wide significant, suggesting that SAIGE-GENE has 
identified associations of rare coding variants of those genes that are independent from the nearby 




Table 3.1 Genes that are significantly associated with automated read pulse rate and glaucoma in 
the UK Biobank and high-density lipoprotein (HDL) in the HUNT study with SKAT-O p-values 
< 2.5x10-6  from SAIGE-GENE. Conditional analysis was performed when the top hit in the locus 
(+/- 500kb of the start and end positions of the gene) is not included in the gene-based test. The p-
value of conditional analysis is NA when the top hit is a rare missense or stop gain variant included 






















TBX5 4 9.69E-35 NA 
12:114837349_C
:A 7.73E-35 0.0049 
MYH6 14 3.61E-15 2.56E-13 
14:23861811_A:
G 1.04E-168 0.3698 
TTN 368 3.18E-10 3.41E-06 
2:179721046_G:
A 8.73E-100 0.0885 
KIF1C 12 4.78E-10 NA 17:4925475_C:T 3.18E-10 0.0063 
ARHGEF
4
0 7 7.02E-08 2.57E-10 
14:21542766_A:
G 3.30E-52 0.1688 
FNIP1 8 3.58E-07 4.31E-02 
5:131107733_C:
T 1.22E-08 0.0027 
DBH 12 1.74E-06 1.74E-06 
9:136149399_G:
A 3.46E-06 0.1870 
HDL 
(HUNT) 
LCAT 3 7.34E-50 NA 
16:67974303_A:
T 1.78E-48 0.0008 
LIPC 4 1.25E-29 6.63E-31 
15:58723939_G:
A 7.50E-89 0.1889 
FSD1L 3 7.40E-15 1 
9:107793713_T:
C 1.45E-20 0.0021 
ABCA1 14 3.32E-11 1.28E-11 
9:107620797_A:
G 3.64E-48 0.0055 
LIPG 3 2.15E-10 2.41E-10 
18:47156926_C:
A 5.92E-40 0.2348 
NR1H3 2 6.53E-09 1.69E-09 
11:47246397_G:
A 3.66E-13 0.322 
CKAP5 7 1.62E-08 1.21E-09 
11:47246397_G:
A 3.66E-13 0.322 
RNF111 11 1.18E-07 1.37E-09 
15:58856899_C:















Figure 3.2 Quantile-quantile plots of exome-wide gene-based association results for A. high-
density lipoprotein (HDL) in the HUNT study (N = 69,214). SKAT-O approach in SAIGE-GENE 
was performed for 13,416 genes with stop-gain and missense variants with MAF ≤ 1%, of which 
10,600 having at least two variants are plotted. B. automated read pulse rate in the UK Biobank 
(N = 385,365). C. glaucoma in the UK Biobank (N cases = 4,462; N controls = 397,761). SKAT-
O approach in SAIGE-GENE was performed for 15,338 genes with stop-gain and missense 





We also applied SAIGE-GENE to analyze 15,342 genes for 53 quantitative traits using 408,910 
UK Biobank participants with White British ancestry(C. Bycroft et al., 2018). Heritability 
estimates based on the full GRM are presented in Table S3.3A. Table S3.4A presents all genes 
with p-values reaching the exome-wide significant threshold (p ≤ 2.5x10-6). The same MAF cutoff 
≤ 1%, for missense and stop-gain variants were applied. Figure 3.2B shows the QQ plot for 
automated read pulse rate as an exemplary quantitative phenotype in the UK Biobank. After 
conditioning on the most significant nearby variants, MYH6, ARHGEF40 and DBH remain 
significant (Table 1). Gene TBX5, MYH6, TTN, and ARHGEF40 are known genes for heart rates 
by previous GWAS studies(Arking et al., 2014; Eijgelsheim et al., 2010; Eppinga et al., 2016; 
Holm et al., 2010). To our knowledge, KIF1C and DBH have not been reported by association 
studies for heart rates, but both homozygous and heterozygous DBH mutant mice have decreased 
heart rates(Swoap et al., 2004). For the gene DBH, no single variant reaches the genome-wide 
significant threshold (the most significant variant is 9:136149399 (GRCh37) with MAF = 18.7% 
and p-value =3.46x10-6).  
 
In the analysis of all 53 quantitative traits in the UK Biobank, 199 gene-phenotype pairs were 
significant at exome-wide significant threshold (p ≤ 2.5x10-6). Among them fifteen genes for 
fourteen phenotypes were not significant by the single variant test, as the most significant single-
variant association p-value in each of these loci (500kb up and down stream around each gene) did 
not reach the genome-wide threshold (p-value < 5x10-8)(Table S3.5). For example, TBX5, which 
has been previously reported to be associated with heart rates(Holm et al., 2010), was significant 
by SAIGE-GENE for the automated read pulse rate (p-valueSKAT-O = 2.87x10
-7). However, the top 
variant in the locus was not genome-wide significant (p-value = 2.91x10-7). ARID1B has been 
previously reported to be associated with blood pressure in individuals with African ancestry(Sung 
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et al., 2018) and identified by SAIGE-GENE for automated read mean of diastolic blood pressure 
(p-valueSKAT-O = 1.08x10
-6), while the most significant single variant association p-value was 
9.01x10-7. In addition, SAIGE-GENE has identified several potentially novel gene-phenotype 
associations, including DBH for automated read pulse rate (p-valueSKAT-O =1.74x10
-6), C10orf35 
for body fat percentage (p-valueSKAT-O = 3.64x10
-7), a gene have been reported to be associated 
with type 2 diabetes(Replication et al., 2014) and blood lipids by previous GWAS(Bandesh et al., 
2019). After conditioning on the most significant nearby variants, total 64 genes for 12 traits 
remained exome-wide significant (Table S3.6A). Our results have successfully replicated several 
previous findings, such as the association between the rare coding variants of ADAMTS3 and 
height(Marouli et al., 2017), ZFAT and height(Marouli et al., 2017), and RRAS and blood 
pressure(Surendran et al., 2016). These results have demonstrated the value of gene-based tests for 
identifying genetic factors for complex traits. 
3.3.3 Gene-based association analysis of binary traits in UK Biobank 
We also applied SAIGE-GENE to ten binary phenotypes with various case-control ratios in the 
UK Biobank. The heritability estimates in a liability scale are presented in Table S3.3B. Nine 
genes for six binary phenotypes reached the exome-wide significant threshold (p-value < 2.5x10-
6)  (Table S3.4B), all of which have been identified by both SAIGE-GENE and single variant tests, 
including the gene MYOC, known for glaucoma(Turalba & Chen, 2008) (Figure 3.2C). Six genes 
for six binary phenotypes remained exome-wide significant after conditioning on top variants 
(Table S3.6B). Gene GORASP1, encoding Golgi Reassembly Stacking Protein 1 involved in the 
vesicle-mediated transport pathway, remained significant after conditioning on the top hit for 
diseases of hair and hair follicles.  
3.3.4 Simulation Studies 
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We investigated the empirical type I error rates and power of SAIGE-GENE through simulation. 
We followed the steps described in the Online Methods section to simulate genotypes and 
phenotypes for 10,000 samples in two settings. One has 500 families and 5,000 unrelated samples 
and the other one has 1,000 families, each with 10 family members based on the pedigree shown 
in Figure S3.11.  
3.3.4.1 Type I error rates 
The type I error rates of SAIGE-GENE, EmmaX-SKAT, and SMMAT have been evaluated based 
on gene-based association tests performed on 107 simulated gene-phenotype combinations, each 
with 20 genetic variants with MAF ≤  1% on average. A sparse GRM with a cutoff 0.2 for the 
coefficient of relatedness was used in SAIGE-GENE. Two different values of variance component 
parameter corresponding to the heritability ℎ2= 0.2 and 0.4 were considered for continuous traits, 
respectively. The empirical type I error rates at the  = 0.05, 10-4 and 2.5x10-6 are shown in the 
Table S3.7. Our simulation results suggest that SAIGE-GENE has relatively well controlled type 
I error rates, while the type I error rates are slightly inflated when heritability is relatively high 
(ℎ2= 0.4). Similar results have been observed on a larger sample size with 1,000 families and 
10,000 unrelated samples (Supplementary Materials 3.5.2.1 and Table S3.8). Adjusting the test 
statistics using the genomic control (GC) inflation factor lambda has addressed the inflation 
(Supplementary Materials 3.5.1.7).   
Further simulations have been conducted to evaluate type I error rates of SAIGE-GENE, EmmaX-
SKAT, and SMMAT for skewed distributed phenotypes, which are common in real data (Figure 
S3.12A). All three methods had inflated type I error rates for phenotypes having skewed 
distribution (Table S3.9). With inverse normal transformation on phenotypes (Figure S3.12B), 
the inflation has been dramatically reduced but slight inflation was still observed (Table S3.9). A 
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potential reason is that inverse normal transformation disrupts sample relatedness in raw 
phenotypes, leading to poor fitting for the null GLMM. We then conducted a three-step phenotype 
transformation procedure as described in Supplementary Materials 3.5.2.2, which maintains 
sample relatedness in raw phenotypes, and all three methods then have well controlled type I error 
rates (Table S3.10). From simulation studies using real genotype data from the UK Biobank, we 
show that SAIGE-GENE well controlled type I error rates in the presence of subtle population 
structure or non-negligible cryptic relatedness between families (Table S3.11 and S3.12). Details 
have been described in Supplementary Materials 3.5.2.3 and 3.5.2.4. 
We have also evaluated the empirical type I error rates of SAIGE-GENE for binary traits with 
various case-control ratios. Similar with continuous traits, a sparse GRM with a cutoff 0.2 for the 
coefficient of relatedness was used. The variance component parameter τ = 1 was assumed, 
corresponding to liability-scale heritability 0.23. As expected, when case-control ratios were 
balanced or moderately unbalanced (e.g. 1:1 and 1:9), type I error rates were well controlled even 
without the robust adjustment, while when the ratios were extremely unbalanced (e.g. 1:19 and 
1:99), inflation was observed (Table S3.13A and Figure S3.6). With the robust adjustment 
combining SPA and ER, type I error rates were relatively well controlled in the presence of 
unbalanced case-control ratios (Table S3.13B and Figure S3.6). However, for phenotypes with 
case-control ratio=1:99, slight inflation was still observed, although the inflation has been 
dramatically alleviated compared to the unadjusted method. Then the genomic control adjustment 
can be used to further control the type I error rates (Table S3.13B). We have also evaluated 
empirical type I error rates of SAIGE-GENE for binary traits under case-control sampling with 
case-control ratios 1:1 and 1:9 based on a disease prevalence 1% in the population 




Next, we evaluated empirical power of SAIGE-GENE and EmmaX-SKAT for quantitative traits. 
Two different settings of proportions of causal variants were used: 10% and 40%. In each setting, 
among causal variants, 80% and 100% have negative effect sizes. The absolute effect sizes for 
causal variants are set to be |0.3log10(MAF)| and |log10(MAF)|, respectively, when the proportions 
of causal variants are 0.4 and 0.1. Table S3.15 shows that the power of both methods is nearly 
identical for all simulation settings for Burden, SKAT and SKAT-O tests.  
We have also evaluated empirical power of SAIGE-GENE for binary traits using two different 
study designs: cohort study with various disease prevalence (0.01-0.5); and case-control sampling 
with different case-control ratios (1:1-1:19) based on a disease prevalence 1% in the population. 
In each setting, 40% variants are simulated as causal variants. Among them, 80% are risk-
increasing variants and 20% are risk-decreasing. The absolute effect sizes of causal variants are 
set to be |0.55log10(MAF)| and |0.35log10(MAF)| for cohort study and case-control sampling, 
respectively. Table S3.16 shows the empirical power of SKAT-O in both simulation studies. 
SAIGE-GENE had similar empirical power as unadjusted SAIGE-GENE in balanced case-control 
ratios and higher power in unbalanced scenarios. The power is small when case: control ratio is 
1:99 due to the limited number of cases (100 cases), which can be alleviated with larger sample 
size.  
 
3.4 Discussion  
In summary, we have presented a method, SAIGE-GENE, to perform gene- or region-based 
association tests in large cohorts or biobanks in the presence of sample relatedness. Similar to 
SAIGE(W. Zhou et al., 2018), which was previously developed by our group for single-variant 
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association tests, SAIGE-GENE uses generalized linear mixed models to account for sample 
relatedness, scalable computational approaches for large sample sizes, and the robust 
adjustment(Zhao et al., 2019) to account for unbalanced case-control ratios of binary traits .  
SAIGE-GENE uses several optimization strategies that are similar to those used in SAIGE to make 
fitting the null GLMM feasible for large sample sizes. For example, instead of storing the genetic 
relationship matrix (GRM) in the memory, SAIGE-GENE stores genotypes that are used for 
constructing the matrix in a binary vector and computes the elements of the matrix as needed. 
Preconditioned conjugate gradient algorithm is also used to solve linear systems instead of the 
Cholesky decomposition. However, some optimization approaches are specifically applied in the 
gene-based tests in regard of rare variants. As estimating the variances of score statistics for rare 
variants are more sensible to family structures, we use a sparse GRM to preserve close family 
structures rather than ignoring all sample relatedness. In addition, the variance ratios are estimated 
for different minor allele count (MAC) categories, especially for those extremely rare variants with 
MAC lower than or equal to 20.   
For binary phenotypes, SAIGE-GENE applies the robust adjustment combining SPA and ER, 
thereby also relatively well controls the type I error rates for both balanced and unbalanced case-
control phenotypes. However, slight inflation is still observed in extremely unbalanced phenotypes 
(≤1:99). To address this possible issue, we suggest using the genomic control to further control 
type I error.  
In numerical optimization, using good initial values can improve the model convergence. In the 
analysis of 24 quantitative traits in the UK Biobank with sample size (N) ≥ 100,000, we note that 
the models with the full GRM and the sparse GRM produced different variance component 
estimates, but they are relatively concordant (Pearson’s correlation R2 = 0.66, Figure S3.13). This 
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indicates that the parameter estimates from the sparse GRM can be used as initial values to 
facilitate the model fitting. We implemented this approach in SAIGE-GENE. 
SAIGE-GENE has some limitations. First, similar to SAIGE and other mixed-model methods, the 
time for algorithm convergence to fit the generalize linear mixed models may vary among 
phenotypes and study samples given different heritability levels and sample relatedness. Second, 
similar to SAIGE(W. Zhou et al., 2018) and SMMAT(H. Chen et al., 2019), SAIGE-GENE uses 
penalized quasi-likelihood (PQL)(Breslow & Clayton, 1993) for binary traits to estimate the 
variance component in binary phenotypes which is known to be biased. However, as shown in 
simulation studies in SAIGE(W. Zhou et al., 2018) and SMMAT(H. Chen et al., 2019), PQL-based 
approaches works well to adjust for sample relatedness.  
Overall, we have shown that SAIGE-GENE can account for sample relatedness while maintaining 
test power through extensive simulation studies. By applying SAIGE-GENE to the HUNT study9 
and the UK Biobank(C. Bycroft et al., 2018) followed by conditioning on most significant variants 
in the testing loci, we have demonstrated that SAIGE-GENE can identify potentially novel 
association signals that are independent from the nearby association signals from the single-variant 
tests. Currently, our method is the only available mixed effect model approach for gene- or region-
based rare variant tests for large sample data, while accounting for unbalanced case-control ratios 
for binary traits. By providing a scalable solution to the current largest and future even larger 
datasets, our method will contribute to identifying trait-susceptibility rare variants and genetic 
architecture of complex traits.  
 
URLs 
SAIGE (version 0.35.8.8), https://github.com/weizhouUMICH/SAIGE/.  
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SMMAT (version 1.0.2), https://github.com/hanchenphd/GMMAT.  
EmmaX-SKAT (SKAT version_1.3.2.1), https://cran.r-
project.org/web/packages/SKAT/index.html.  
UK-Biobank analysis results (Gene-based summary statistics for 53 quantitative phenotypes 
in the UK Biobank by SAIGE-GENE), https://www.leelabsg.org/resources.  
 
 
Code and data availability  
SAIGE-GENE is implemented as an open-source R package available at 
https://github.com/weizhouUMICH/SAIGE/master.  
 
The summary statistics and QQ plots for 53 quantitative phenotypes and 10 binary phenotypes in 








3.5 Supplementary Materials 
3.5.1 Algorithm details 
3.5.1.1 Step 0. Constructing the sparse GRM 
In the sparse GRM, denoted by 𝜓𝑠 , GRM elements below a user-specified relative coefficient 
cutoff are zeroed out with close family structures preserved. To improve the test accuracy for rare 
variants, SAIGE-GENE approximates the variance of score statistics calculated with the full GRM 
𝜓𝑓 using the variance calculated with the sparse GRM 𝜓𝑠  and the ratios of these two variance 
estimates estimated using a subset of genetic markers. 
To construct the sparse GRM 𝜓𝑠, a small subset of randomly select markers were used to identify 
related sample pairs whose relative coefficient pass the use-specified cutoff, which is to find out 
the indices of non-zero elements in 𝜓𝑠. Next, the values of the nonzero elements in 𝜓𝑠 are then 
estimated using the full set of genetic markers that are used in Step 1 for 𝜓𝑓. This step is only 
needed for once for each data set or biobank and parallel computation is allowed. Once the sparse 
GRM is constructed for a data set, it can be re-used in SAIGE-GENE for all phenotypes.  
3.5.1.2 Step 1. Fitting the null generalized linear mixed model  
The same model fitting framework and computation approaches used in the original SAIGE(W. 
Zhou et al., 2018) are used in SAIGE-GENE to fit the null GLMM for large sample sizes. These 
include estimating model parameters using the AI-REML approach(Gilmour et al., 1995; Lee & 
van der Werf, 2006), solving linear systems by the preconditioned conjugate gradient 
method(Kaasschieter, 1988), using Hutchinson’s randomized trace estimator(Avron & Toledo, 
2011; Hutchinson, 1990) to obtain traces of matrices, and allowing for parallel computation for 
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the vector multiplication. For AI-REML, we particularly used the approach in GMMAT(H. Chen 
et al., 2016; Gilmour et al., 1995) to calculate the average information without performing the n 
by n matrix inversion by using PCG. For details of the likelihood, parameter estimates and 
information matrices, please refer to the Supplementary Note in the SAIGE paper(W. Zhou et al., 
2018). In addition, SAIGE-GENE can estimate variance component parameters, thus heritability, 
by fitting a null GLMM using the sparse GRM. The estimated variance component parameters can 
then be used as initial values for the model fitting with the full GRM, which can be a better 
approach than using a randomly chosen initial value. By plotting the heritability estimates using 
the sparse GRM versus using the full GRM for 24 quantitative traits with sample size larger than 
or equal to 10,000 from the UK Biobank (Figure S3.13), we have shown that variance component 
estimates from the full and sparse GRMs are relatively concordant (Pearson’s correlation R2 = 
0.66). For real-data analysis, robust performance of convergence has also been observed for some 
phenotypes, such as waist hip ratio (N = 408,144) in the UK Biobank. Using initial values 0.5 for 
heritability, step 1 did not even converge after 6,300 CPU hours, while using initial values 
estimated with the sparse GRM, it took 1836 CPU hours to finish the step 1. 
3.5.1.3 Step 2. Gene-based association tests 
Test statistics of the Burden, SKAT and SKAT-O tests for a gene can be constructed based on the 
score statistics from the marginal model for individual variants in the gene. Suppose there are 𝑞  
variants in the region or gene to test. The score test statistics for variant 𝑗 (j=1,. . , 𝑞) under Ho: 
𝛽𝑗 = 0  is 𝑇𝑗 = 𝑔𝑗
𝑇(𝑌 − ?̂?)  where 𝑔𝑗  and Y are 𝑁 ×  1  genotype and phenotype vectors, 
respectively, and ?̂? is the estimated mean of 𝑌 under the null hypothesis.  
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Let 𝑢𝑗  denote a threshold indicator or weight for variant 𝑗 and U be a diagonal matrix with 𝑢𝑗  as 





?̃? = 𝐺 − 𝑋(𝑋𝑇?̂?𝑋)−1𝑋𝑇?̂?𝐺 , where 𝐺 = (𝑔1, … , 𝑔𝑞)  is the 𝑁 × 𝑞  genotype matrix of the 𝑞 
genetic variants, and ?̂? = ?̂?−1 − ?̂?−1𝑋(𝑋𝑇?̂?−1𝑋)
−1
𝑋𝑇?̂?−1 with ?̂? = ?̂?−1 + ?̂?𝜓. Under the null 
hypothesis of no genetic effects, 𝑄𝐵𝑢𝑟𝑑𝑒𝑛  followed 𝜆𝐵𝜒1
2 , where 𝜆𝐵 = 𝐽
𝑇U?̃?𝑇?̂??̃?U𝐽 and 𝐽  is a 
𝑞 × 1 vector with all elements being unity  and 𝜒1
2is a chi-squared distribution with 1 degree of 




𝑗=1 , which follows a mixture of chi-square distribution  ∑ 𝜆𝑆𝑗𝜒1
2𝑞
𝑗=1 , where 𝜆𝑆𝑗  are the 
eigenvalues of 𝑈?̃?𝑇?̂??̃?𝑈. The SKAT-O test developed by Lee et al in 2012 (S. Lee et al., 2012) 
uses a linear combination of the Burden and SKAT tests statistics 𝑄𝑆𝐾𝐴𝑇𝑂 = (1 − 𝜌)𝑄𝑆𝐾𝐴𝑇 +
𝜌𝑄𝐵𝑢𝑟𝑑𝑒𝑛, 0 ≤  𝜌 ≤ 1. To conduct the test, the minimum p-value from grid of 𝜌 is calculated and 
the p-value of the minimum p-value is estimated through numerical integration. Following the 
suggestion in Lee et al(Lee et al., 2013), we use a grid of eight values of 𝜌 =
(0, 0.12, 0.22, 0.32, 0.42, 0.52, 0.5, 1) to find the minimum p-value.  
3.5.1.4 Estimating ?̃?𝑻?̂??̃? 
For each gene, given ?̂?, calculation of ?̃?𝑇?̂??̃? can be computationally expensive Suppose ?̃? =  𝑔 −
𝑋(𝑋𝑇?̂?𝑋)
−1
𝑋𝑇?̂?𝑔 , which represents a covariate adjusted single variant genotype 𝑁 × 1 vector 
vector. To reduce computation cost, an approximation approach has been used in SAIGE(W. Zhou 
et al., 2018), BOLT-LMM(Loh et al., 2015) and GRAMMAR-GAMMAR(Svishcheva et al., 2012), 
in which the ratio between ?̃?𝑇?̂??̃? and ?̃?𝑇?̃? is estimated by a small subset of randomly selected 
genetic markers that has been shown to be approximately constant for all variants(W. Zhou et al., 
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2018). Given the ratio ?̂? = ?̃?𝑇?̂??̃? /?̃?𝑇?̃?,  ?̃?𝑇?̂??̃? for all other variants can be easily obtained as 
?̂??̃?𝑇?̃?. However, the variations of estimated ?̂? for extremely rare variants are large and including 
some closely related samples in the denominator helps reduce the variation of ?̂? as shown in 
Figure S3.2. It can also be observed from the plots in Figure S3.2 that the variance ratio for those 
extremely rare variants could be quite different from the ratio for more frequent variants, so 
SAIGE-GENE estimates variance ratios for different MAC categories. By default, MAC 
categories are set to be MAC equals to 1, 2, 3, 4, 5, 6 to 10, 11 to 20, and is greater than 20. For 
each MAC category, a ratio ?̂?𝑠 is estimated as the average of the ratios computed from 30 randomly 











 and ?̂?𝑠 =  ?̂?
−1 + τ 𝜓𝑠. 𝜓𝑆 is a sparse GRM that preserves closely 
related samples. The coefficient of variance (CV) of ?̂? is used to evaluate the numerical stability 
of the ?̂? estimation. As in SAIGE, the default value of CV threshold is 0.001. If CV of ?̂? is larger 
than the threshold, SAIGE-GENE will increase the number of markers by 10 to estimate ?̂? until 
the estimation is stable with CV below or equal to the threshold. Once the variance ratios have 
been estimated for different MAC categories. For each genetic marker in genes or regions that are 
to be tested in Step 2, a ?̂?𝑠 can be obtained according to its MAC. Let ?̂?𝑠 be a 𝑞 ×  1 vector whose 
jth element is the ratio ?̂?𝑠 for the jth marker in the tested gene. For the tested gene with 𝑞 markers, 




2 .  
Products of ?̂?𝑠
−1
and other vectors or matrices are obtained using the sparse LU decomposition 





is not sparse and ?̃? is also a dense matrix, which is converted from the sparse matrix 
𝐺, as ?̃? = 𝐺 − 𝑋(𝑋𝑇?̂?𝑋)
−1
𝑋𝑇?̂?𝐺 . It can be shown that 
?̃?𝑇?̂?𝑠?̃? = (𝐺















𝑋𝑇?̂?𝐺) =  𝐺𝑇?̂?𝑠𝐺 
Computation of 𝐺𝑇?̂?𝑠𝐺 is more computational efficient than that of ?̃?
𝑇?̂?𝑠?̃? as 𝐺 can be stored as a 
sparse matrix.  
3.5.1.5  Conditional analysis  
To test whether the association signals from a tested gene or region are independent from a given 
marker or multiple markers, the conditional analysis based on summary statistics from 
unconditional association tests with the linkage disequilibrium 𝑟2 among testing and conditioning 
markers(Liu et al., 2014) have been implemented in SAIGE-GENE. 
Let 𝐺 be the genotypes for a gene to be tested for association, which contains 𝑞 markers, and 𝐺2 
be the genotypes for the conditioning markers, which contains 𝑞2 markers. Let 𝛽 denote a 𝑞 × 1 
coefficient vector of the genetic effect for the gene to be tested and 𝛽2 be a 𝑞2  × 1 coefficient 
vector of the genetic effect for the conditioning markers. The genotype matrix with the non-genetic 
covariates projected out ?̃? = 𝐺 − 𝑋(𝑋𝑇?̂?𝑋)
−1
𝑋𝑇?̂?𝐺  and ?̃?2 = 𝐺2 − 𝑋(𝑋
𝑇?̂?𝑋)
−1
𝑋𝑇?̂?𝐺2 . In 
the unconditioned association tests, the test statistics 𝑇 = ?̃?𝑇(𝑌 − ?̂?) and 𝑇2 = ?̃?2
𝑇
(𝑌 − ?̂?). In 
conditional analysis, under the null hypothesis, E(𝑇) = E(?̃?𝑇𝑃( ?̃?2𝛽2)) = ?̃?




𝑇𝑃( ?̃?2𝛽2)) = ?̃?2
𝑇?̂?𝑠?̃?2𝛽2 . 𝑇 and 𝑇2 jointly follow the multivariate normal with mean (E(𝑇), 






Thus under the null hypothesis of 𝛽=0, the 𝑇|𝑇2 follows the conditional distribution E(𝑇|𝑇2) = 
?̃?𝑇?̂??̃?2 (?̃?2
𝑇?̂??̃?2)
−1𝑇2  and var( 𝑇|𝑇2 ) = ?̃?








𝑇?̂?𝐺 . The test statistic of the conditional analysis can be written as (T - 
E(𝑇|𝑇2))
2/ var(𝑇|𝑇2), which follows the χ
2distribtuion with one degree of freedom. Similar to the 




the corresponding variance ratio matrices.  
3.5.1.6 Robust adjustment to account for unbalanced case-control ratios in binary 
traits 
To account for unbalanced case-control ratios in binary traits, we use a recently developed robust 
adjustment approach with a simple modification(Zhao et al., 2019). Note that the robust adjustment 
was developed for independent samples. It uses saddlepoint approximation (SPA)(Daniels, 1954; 
R. Dey et al., 2017; Kuonen, 1999) and efficient resampling (ER)(Lee et al., 2016) to obtain 
accurate single variant association P-value for the 𝑗𝑡ℎ variant and then calibrates the variance of 
score statistics 𝑇𝑗 . SPA is a statistical method to calculate the distribution function using the 
cumulant generating function (CGF). Suppose 𝐾𝑗(𝑡) is the CGF of the score statistic 𝑇𝑗, which can 
be derived based on the fact that 𝑌𝑖~Bernoulli(𝜇𝑖) under the null. For independent samples, the 
estimation of 𝐾𝑗(𝑡) is  
𝐾?̂?(𝑡; ?̂?, 𝑐) = ∑ log(1 − 𝜇?̂? + 𝜇?̂?𝑒





where 𝜇?̂? is the estimation of 𝜇𝑖 from the null model, and 𝐺?̃? is the covariate adjusted genotype 
vector. To account for sample relatedness, we use the original SAIGE, which adapts the SPA to 
GLMM. Under the GLMM, we use the following CGF 
𝐾?̂?(𝑡; ?̂?, 𝑐) = ∑ log(1 − 𝜇?̂? + 𝜇?̂?𝑒
𝑐𝑡𝐺?̃?)Ni=1 − 𝑐𝑡 ∑ 𝐺?̃?𝜇?̂?
𝑁
𝑖=1 , 
where c = Var*(𝑇𝑗)
−1/2 and Var*(𝑇𝑗) = 𝐺?̃?
𝑇
𝑊𝐺?̃? is a variance estimator without accounting the 
fact that the random effect b is estimated from data. Then, the distribution function of the score 
statistic 𝑇𝑗 can be approximated by 







where 𝑤 = 𝑠𝑔𝑛(?̂?)√2 (?̂?𝑠 − 𝐾𝑗(?̂?)), 𝑣 = ?̂?√𝐾𝑗
′′(?̂?) , ?̂?  is the solution to the equation 𝐾𝑗
′(?̂?) =
𝑞 , and Φ is the distribution function of the standard normal distribution. For details, please refer 
to the SAIGE paper(W. Zhou et al., 2018).   
Since SPA is an asymptotic based approach, it can provide incorrect p-values when MAC is very 
low (ex. MAC < 10). To address this issue, we use ER(Lee et al., 2016) for variants with MAC ≤ 
10. ER is a resampling method that resamples the case–control status of individuals with a minor 
allele at a given variant given the disease risk 𝜇𝑖. ER was developed under the assumption that 
samples are independent. Here we apply ER with the disease risk 𝜇?̂? estimated by GLMM, using 
the fact that given random effects 𝑏𝑖, samples are independent. The dependency among samples 
are incorporated through the random effect estimates.        
82 
 
The remaining part is nearly identical as the robust method in independent samples(Zhao et al., 
2019). Let ?̂? = 𝑑𝑖𝑎𝑔(𝑣1, … , 𝑣𝑞)





We note that 𝑗-th diagonal element of ?̂? is the estimated variance of 𝑇𝑗. For each variant 𝑗, when 
the score statistic 𝑇𝑗 lies outside of two standard deviations of the mean (i.e. zero), we apply SPA 
(when MAC > 10) or ER (when MAC  10) to calculate the p-value 𝑝𝑗 , and calculate ?̃?𝑗 =
𝑇𝑗
2/𝜒𝑞𝑢𝑎𝑛𝑡𝑖𝑙𝑒
2 (1 − 𝑝𝑗), where 𝜒𝑞𝑢𝑎𝑛𝑡𝑖𝑙𝑒
2  is the quantile function of the chi-square distribution with 
one degree of freedom. If 𝑇𝑗 lies within the two standard deviations of the mean, we use ?̃?𝑗 = 𝑣𝑗. 









2 as the estimate of ?̃?𝑇?̂??̃? to calculate p-values and carry out conditional analysis.  
3.5.1.7 Genomic Control (GC) for the further adjustment of p-values 
To further control for type I error rates, SAIGE-GENE allows for using the genome control 
inflation factor. Let 𝜆𝐺𝐶 be the genome control inflation factor from the gene-based test, which is 
obtained by converting p-values of gene-based test to 𝜒1
2 statistics. To better capture the inflation 
in tail areas we obtain 𝜆𝐺𝐶 at p-value=0.05. And then we divide the 𝜆𝐺𝐶 in the 𝜒1
2 statistics and 
then obtain the p-values using 𝜒1
2 distribution. As shown in Table S3.7 and Table S3.13, this 
simple approach has successfully attenuated the type I error inflation. 
3.5.1.8 Novel features in SAIGE-GENE compared to SMMAT 
Same as SMMAT, SAIGE-GENE uses the logistic mixed model to conduct region- or gene-based 
association tests (Burden, SKAT and SKAT-O). Compared to SMMAT, SAIGE-GENE mainly 
has two improvements, which make it the only method so far that is feasible for large samples 
sizes, while accounting for case-control imbalance for binary phenotypes. It utilizes optimization 
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strategies as used in the original SAIGE for the scalability, including storing raw genotypes in a 
binary vector and elements of GRM are calculated when needed rather than being stored to reduce 
the memory usage, replacing the cholesky decomposition by the preconditioning conjugate 
gradient (PCG) to solve linear systems without calculating and inverting the 𝑁 ×  𝑁 GRM, and 
approximating the variance of score statistics with the full GRM using the variance with a sparse 
GRM and the ratio of the two variances. To account for unbalanced case-control ratios for binary 
phenotypes, SAIGE-GENE uses a robust adjustment approach combing SPA(Daniels, 1954; R. 
Dey et al., 2017; Kuonen, 1999) and ER(Lee et al., 2016) as described in 1.3.3.  
3.5.2 Additional simulation and real-data analysis results 
3.5.2.1 Simulation studies with a larger sample size  
Given that SAIGE-GENE has relatively well controlled type I error rates based on simulation 
studies (Table S3.7), it is noted that type I error rates are slightly higher for SAIGE-GENE than 
the other two methods. One potential reason for this could be that SAIGE-GENE uses several 
approximation approaches, to achieve feasibility for large data sets and a tradeoff exists between 
accuracy and computational efficiency for these approaches. To evaluate type I error rates with 
larger sample sizes, we conducted a simulation study containing 1,000 families and 10,000 
independent samples, which doubles the sample sizes as in the original simulation with 500 
families and 5,000 independent samples. With the heritability h2 = 0.2, the empricial type I error 
rates for the Burden test, SKAT, and SKAT-O at three different α were estimated based on 107 
tests, for which 1,000 randomly simulated phenotype sets and each was tested on 10,000 variant 
sets (Table S3.8). The type I error rates with the larger sample size (Table S3.8) are similar to 
those with a smaller sample size with 500 families and 5,000 independent samples (Table S3.7).  
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3.5.2.2 Simulation studies with skewed distributed phenotypes 
In simulation studies, the phenotype 𝑦𝑖 was generated to follow a normal distribution, but it can 
be skewed in real data. Hence, we have conducted additional simulation studies to evaluate the 
type I error rates of SAIGE-GENE in presence of skewed phenotypic distributions and compared 
to the other two methods. As described in the Data Simulation subsection of ONLINE METHODS, 
phenotypes were simulated from the following linear mixed model 𝑦𝑖 = 𝑋1 + 𝑋2 + 𝐺𝑖𝛽 + 𝑏𝑖 +  𝜀𝑖, 
where 𝐺𝑖  is the genotype value, 𝛽 is the genetic effect sizes. Two covariates, 𝑋1 and 𝑋2, were 
simulated from Bernoulli(0.5) and N(0,1), respectively. 𝑏𝑖 is the random effect simulated from 
𝑁(0, τ 𝜓) and 𝜀𝑖 is the error term simulated from chi-square distribution with degree of freedom 1 
and thereby the distribution of  𝑦 is skewed (Figure S3.12A). 500 families and 5,000 independent 
samples were simulated and the empirical type I error rates for Burden test, SKAT, and SKAT-O 
at the three different α were estimated based on 107 tests, for which 1,000 randomly simulated 
phenotype sets and each was tested on 10,000 variant sets (Table S3.9). All three methods have 
inflated type I error rates for phenotypes having skewed distribution, especially in SKAT and 
SKAT-O tests. After the phenotypes were inverse normal transformed (Figure S3.12B), type I 
error rate inflation has been substantially reduced (Table S3.9).  
Note that there is still slight inflation in all three methods after the inverse normal transformation 
on phenotypes, which can be because the inverse normal transformation may disrupt sample 
relatedness in the original phenotypes and thus impact the null model fitting. We then conducted 
a three-step phenotype transformation procedure, which is presumably able to avoid the issue 
above. Firstly, we fitted the null mixed model using raw skewed distributed phenotypes. Next, we 
conducted the inverse normal transformation on the residuals from step 1. Finally, transformed 
residuals were then used to fit another null mixed model, followed by gene- or region-based 
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association tests. As expected, using this three-step phenotype transformation procedure, the type 
I error rates are well controlled in both SAIGE-GENE and SMMAT for all Burden, SKAT, and 
SKAT-O tests (Table S3.10).  
3.5.2.3 Simulation studies in the presence of population structure 
To evaluate whether SAIGE-GENE can control type I error rates in the presence of subtle 
population stratification, we randomly selected 5,000 white British-UK samples and 5,000 non-
UK European samples from the UK-Biobank after removing up to 3rd relatives. The phenotypes 
were simulated based on real genotypes of randomly selected 𝐿= 30,000 LD-pruned (r2 < 0.2) 
markers with MAF ≥ 1%. In particular, phenotypes were simulated following the model 𝑦𝑖 =
𝑋𝑖1 + 𝑋𝑖2 + ∑ ?̂?𝑖𝑗
𝐿
𝑗=1 𝛽 +  𝜀𝑖, where ?̂?𝑖𝑗 is the standardized genotype value for the𝑗𝑡ℎ marker of 
𝑖𝑡ℎ individual, 𝛽 is the genetic effect size following 𝑁(0, 𝜏/𝐿), where 𝜏 = 0.2, and 𝜀𝑖 is the error 
term simulated from 𝑁(0, (1 − 𝜏)𝐼) . Two covariates, 𝑋𝑖1 and 𝑋𝑖2 , were simulated from 
Bernoulli(0.5) and N(0,1). We conducted ~10,000 gene-based tests for each simulated phenotype 
set, replicated the simulation for 1,000 times. Note that we include the first 4 principal components, 
which were estimated for all European participants in the UK Biobank, as well as X1 and X2 as 
covariates in the linear mixed model. We evaluated the empirical type I error rates at the α = 0.05, 
10-4 and 2.5x10-6 as shown in Table S3.11, which suggest that SAIGE can produce well calibrated 
p-values in the presence of subtle population stratification.  
3.5.2.4 Simulation studies in the presence of non-negligible cryptic relatedness 
between families 
To evaluate whether SAIGE-GENE can control type I error rates in the presence of non-negligible 
cryptic relatedness between families, we have randomly selected 10,000 samples with white 
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British ancestry from UK Biobank. In particular, 5,000 samples were selected among those who 
are up to 3rd degree relatives and 5,000 sample were selected from the rest of the unrelated pool. 
Phenotypes were simulated using the same approach in Section 2.3. We conducted ~10,000 gene-
based tests for each simulated phenotype set, replicated the simulation for 1,000 times. For each 
phenotype set, a null linear mixed model was fitted in Step 1 with covariates including the first 4 
principal components, which were estimated for all White-British participants in the UK Biobank, 
and X1 and X2. We evaluated the empirical type I error rates at the α = 0.05, 10
-4 and 2.5x10-6 as 
shown in Table S3.12. These results have indicated that SAIGE can produce well calibrated type 
I error rates in the presence of non-negligible cryptic relatedness between families. 
3.5.2.5 Simulation studies under case-control sampling  
We have conducted additional simulation studies to evaluate the performance of SAIGE-GENE 
under case-control sampling. We simulated genotypes and phenotypes with prevalence 1% for 
250,000 independent samples and 250,000 families, each with 10 family members (Figure S3.11) 
as an underlying large cohort. We then randomly selected 5,000 controls, together with the 5,000 
cases, for a phenotype with case-control ratio 1:1. In addition, for a phenotype with case-control 
ratio 1:9, we randomly selected 500 cases and 9,500 controls from the large cohort. Empirical type 
I error rates of SAIGE-GENE have been evaluated based on the 10 million tests (Table S3.14), 
indicating that the type I error rates of SAIGE-GENE were well controlled under the case-control 
sampling. We have also evaluated the empirical power of SAIGE-GENE under case-control 
sampling through simulation studies as described in the RESULTS section of main texts. Results 
are presented in Table S3.16, showing that under case-control sampling, the empirical power of 
SAIGE-GENE with and without robust adjustment is similar when the case-control ratio is 
relatively balanced (1:1). As expected, SAIGE-GENE with robust adjustment has higher power in 
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unbalanced scenarios (≤ 1: 9) than SAIGE-GENE without robust adjustment. Similar patterns 
have been observed for empirical power of SAIGE-GENE in simulations of a cohort study (Table 
S3.16). Note that the power in cohort study and case-control sampling is not directly comparable 
due to the difference effect sizes.  
3.5.2.6 Exome-wide gene-based tests for automated read pulse rate in UK Biobank 
with different relatedness cutoffs in the sparse GRM  
As a sensitivity analysis, we used another sample relatedness cutoff 0.2 for the sparse GRM to 
analyze automated read pulse rates in UK Biobank, which means all elements in the full GRM 
below 0.2 are zero’d in the sparse GRM. Scatter plots comparing p-values of the 15,342 genes 
with two different sample relatedness cutoff (0.125 and 0.2) are presented in Figure S3.5, showing 
highly concordant association p-values for all three gene-based tests: Burden, SKAT, and SKAT-
O tests.   
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3.5.3 Supplementary figures 
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Figure S3.2.  Plots of the variance ratio of the score statistics by MAC for rare variants with and without 
the full GRM for sample relatedness (left) and with the full GRM and a sparse GRM for closely related 
samples(right).  A. 500 families and 5,000 independent individuals were simulated with ℎ2= 0.2 based on 
the pedigree structure shown in Figure S3.11. The sparse GRM was constructed using a coefficient of 
relatedness cutoff 0.2. B. 20,000 samples with White British ancestry were randomly selected from the UK 
Biobank and the null model was fitted for the automated read pulse rate. The sparse GRM was constructed 
using a coefficient of relatedness cutoff 0.125. C. 20,000 samples were randomly selected form the HUNT 
study and the null model was fitted for HDL. The sparse GRM was constructed using a coefficient of 
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C. HUNT: HDL, randomly selected 20,000 individuals  
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Figure S3.3. Scatter plots of association p-values from SAIGE-GENE versus SMMAT(Chen et al., 2018) 
and EmmaX-SKAT for the Burden, SKAT, and SKAT-O tests based on simulation data on the -log10 scale. 
1,000,000 genes were tested with 1000 families, each having 10 members, as shown in the Figure S3.11. 
The Pearson’s correlation coefficients r2 > 0.99 for -log10(P-values) between SAIGE and SMMAT and 
between SAIGE and EmmaX-SKAT.  A. ℎ2= 0.2, B. ℎ2= 0.4 
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Figure S3.4. Scatter plots of association p-values from SAIGE-GENE versus SMMAT and EmmaX-SKAT 
for the Burden, SKAT, and SKAT-O tests based on real data analysis on the -log10 scale. 12,000 genes 
were tested for A. automated read pulse rate using 20,000 randomly selected white British samples in the 
HRC-imputed UK Biobank; B. HDL using 20,000 randomly selected samples in HUNT.  Missense and 
stop-gain variants with MAF ≤ 1% were included.  The Pearson’s correlation coefficients r2 > 0.99 for -
log10(P-values) between SAIGE and SMMAT and between SAIGE and EmmaX-SKAT.    
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Figure S3.5. Scatter plots of association p-values on the -log10 scale from SAIGE-GENE with two sample 
relatedness cutoffs for the sparse GRM, 0.125 and 0.2. 15,338 genes were tested for automated read pulse 
rate in white British samples in the HRC-imputed UK Biobank. Missense and stop-gain variants with MAF 
≤ 1% were included. A. Burden. B. SKAT, C. SKAT-O 
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Figure S3.6. Quantile-quantile plots of association p-values for 10 million variant sets from the 
simulation study for phenotypes with various case-control ratios.  
 
 
          A. Case: Control = 1:9          B. Case: Control = 1:19           C. Case: Control = 1:99 













Figure S3.7. Empirical computation time for A. step 1 for fitting a null mixed model and B. step 2 for 
association tests, respectively by sample sizes (N) for gene-based tests for 15,342 genes, each containing 
50 rare variants. Benchmarking was performed on randomly sub-sampled UK Biobank data with 408,144 
White British participants for waist-to-hip ratio. The reported run times and memory are medians of five 
runs with samples randomly selected from the full sample set using different sampling seeds. The reported 
computation time and memory for EmmaX-SKAT and SMMAT is the projected computation time when 
N > 20,000. As the number of tested markers varies by sample sizes, the computation time is projected for 
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Figure S3.8. Log-log plot of the estimated run time as a function of number of markers per gene. 
Benchmarking was performed on randomly sub-sampled 400,000 UK Biobank data with 408,144 white 
British participants for waist-to-hip ratio on 15,342 genes. Run times are medians of five runs with samples 
randomly selected from the full sample set using different sampling seeds. The computation time for other 






Figure S3.9. Log-log plots of the estimated A. run time and B. memory usage as a function of sample size 
(N) for genome-wide tests for 286,000 chunks, each containing 50 variants on average, given that there are 
14.3 million markers in the HRC-imputed UK Biobank with MAF ≤ 1% and imputation info score ≥ 0.8. 
Numerical data are provided in Table S3.1. Benchmarking was performed on randomly sub-sampled UK 
Biobank data with 408,144 white British participants for waist-to-hip ratio. run times are medians of five 
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Figure S3.10. Log-log plots of the estimated run time for as a function of sample size (N) for SAIGE-
GENE with and without using the robust adjustment.  A. Exome-wide gene-based tests for 15,871 genes 
and B. Genome-wide tests for 286,000 chunks. Each gene or chunk contains 50 variants on average.  
Benchmarking was performed on randomly sub-sampled UK Biobank data with 402,163 white British 
participants tested for glaucoma (PheCode: 365, 4,462 cases and 397,701 controls). The case-control ratio 
remained the same in subsampled data sets. The reported run times and memory are medians of five runs 
with samples randomly selected from the full sample set using different sampling seeds. As the number of 
tested markers varies by sample sizes, the computation time is projected for 50 markers per gene for plotting. 
Numerical data are provided in Table S3.2.  
 












Figure S3.12. Histogram of simulated phenotypes. A. with skewed distribution. B. after inverse normal 
transformation as described in the subsection 2.2 of the section “Additional simulation and real-data 
analysis results”  
 




Figure S3.13. Comparing heritability estimates using the sparse GRM to heritability estimates using the 
full GRM for 24 quantitative traits in the UK Biobank with sample size (N) ≥ 100,000. The sparse GRM 







3.5.4 Supplementary tables 
 
Table S3.1. The estimated run time (A) and memory use (B) across different sample sizes. Benchmarking 
was performed on randomly sub-sampled UK Biobank data with 408,144 white British participants and 
15,342 genes were tested for waist hip ratio. For simplicity, the number of markers in the gene was 50 
regardless of sample sizes. The run times and memory are medians of five runs with samples randomly 
selected from the full sample set using different sampling seeds. The computation cost for genome-wide 
region-based tests were projected from the exome-wide gene-based tests results given that there are 14.3 
million markers in the HRC-imputed UK Biobank with MAF ≤ 1% and imputation info score ≥ 0.8. Total 














5,000 0.43 10.94 11.37 0.44 SAIGE-GENE; 93,511 markers for GRM 
10,000 0.98 11.29 12.26 0.50 SAIGE-GENE; 93,511 markers for GRM 
20,000 2.28 12.34 14.61 0.78 SAIGE-GENE; 93,511 markers for GRM 
50,000 9.29 14.57 23.87 1.62 SAIGE-GENE; 93,511 markers for GRM 
100,000 17.58 63.51 81.09 3.04 SAIGE-GENE; 93,511 markers for GRM 
200,000 101.85 79.87 181.71 6.39 SAIGE-GENE; 93,511 markers for GRM 
400,000 958.98 116.65 1075.63 11.74 SAIGE-GENE; 93,511 markers for GRM 
5,000 1.26 10.94 12.20 0.98 SAIGE-GENE; 340,447 markers for GRM 
10,000 3.85 11.29 15.14 1.77 SAIGE-GENE; 340,447 markers for GRM 
20,000 7.95 12.34 20.28 1.93 SAIGE-GENE; 340,447 markers for GRM 
50,000 32.88 14.57 47.45 4.51 SAIGE-GENE; 340,447 markers for GRM 
100,000 102.71 63.51 166.22 8.87 SAIGE-GENE; 340,447 markers for GRM 
200,000 672.29 79.87 752.16 17.82 SAIGE-GENE; 340,447 markers for GRM 
400,000 2120.89 116.65 2237.54 35.59 SAIGE-GENE; 340,447 markers for GRM 
5,000 0.02 16.42 16.45 1.85 EmmaX-SKAT 
10,000 0.15 28.72 28.87 6.57 EmmaX-SKAT 
20,000 1.32 100.32 101.64 25.82 EmmaX-SKAT 
50,000 20.62 626.98 647.60 161.37 EmmaX-SKAT 
100,000 164.93 2507.93 2672.86 645.50 EmmaX-SKAT 
200,000 1319.44 10031.73 11351.17 2581.99 EmmaX-SKAT 
400,000 10555.55 40126.91 50682.46 10327.96 EmmaX-SKAT 
5,000 0.03 8.07 8.11 2.50 SMMAT 
10,000 0.21 23.68 23.90 8.34 SMMAT 
20,000 1.57 99.44 101.01 32.03 SMMAT 
50,000 24.57 621.47 646.04 200.22 SMMAT 
100,000 196.56 2485.89 2682.46 800.87 SMMAT 
200,000 1572.50 9943.57 11516.07 3203.49 SMMAT 






5,000 0.43 203.89 204.33 0.44 SAIGE-GENE; 93,511 markers for GRM 
10,000 0.98 210.42 211.40 0.50 SAIGE-GENE; 93,511 markers for GRM 
20,000 2.28 229.96 232.24 0.78 SAIGE-GENE; 93,511 markers for GRM 
50,000 9.29 271.67 280.97 1.62 SAIGE-GENE; 93,511 markers for GRM 
100,000 17.58 1183.98 1201.56 3.04 SAIGE-GENE; 93,511 markers for GRM 
200,000 101.85 1488.86 1590.70 6.39 SAIGE-GENE; 93,511 markers for GRM 
400,000 958.98 2174.55 3133.53 11.74 SAIGE-GENE; 93,511 markers for GRM 
5,000 1.26 203.89 205.15 0.98 SAIGE-GENE; 340,447 markers for GRM 
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10,000 3.85 210.42 214.27 1.77 SAIGE-GENE; 340,447 markers for GRM 
20,000 7.95 229.96 237.90 1.93 SAIGE-GENE; 340,447 markers for GRM 
50,000 32.88 271.67 304.55 4.51 SAIGE-GENE; 340,447 markers for GRM 
100,000 102.71 1183.98 1286.69 8.87 SAIGE-GENE; 340,447 markers for GRM 
200,000 672.29 1488.86 2161.15 17.82 SAIGE-GENE; 340,447 markers for GRM 
400,000 2120.89 2174.55 4295.44 35.59 SAIGE-GENE; 340,447 markers for GRM 
5,000 0.02 306.15 306.17 1.85 EmmaX-SKAT 
10,000 0.15 535.40 535.55 6.57 EmmaX-SKAT 
20,000 1.32 1870.08 1871.40 25.82 EmmaX-SKAT 
50,000 20.62 11687.99 11708.61 161.37 EmmaX-SKAT 
100,000 164.93 46751.96 46916.89 645.50 EmmaX-SKAT 
200,000 1319.44 187007.85 188327.29 2581.99 EmmaX-SKAT 
400,000 10555.55 748031.39 758586.94 10327.96 EmmaX-SKAT 
5,000 0.03 150.51 150.55 2.50 SMMAT 
10,000 0.21 441.50 441.71 8.34 SMMAT 
20,000 1.57 1853.64 1855.22 32.03 SMMAT 
50,000 24.57 11585.28 11609.85 200.22 SMMAT 
100,000 196.56 46341.12 46537.68 800.87 SMMAT 
200,000 1572.50 185364.46 186936.96 3203.49 SMMAT 




Table S3.2. The estimated run time (A) and memory use (B) across different sample sizes for binary traits with and without the robust adjustment. 
Benchmarking was performed on randomly sub-sampled UK Biobank data with 402,163 white British participants and 15,871 genes were tested for 
glaucoma (PheCode: 365). Samples were randomly selected from 4,462 glaucoma cases and 397,701 controls respectively, so the case-control ratio 
remained the same in sub-sampled data sets. For simplicity, the number of markers in the gene was 50 regardless of sample sizes. The run times and 
memory are medians of five runs with samples randomly selected from the full sample set using different sampling seeds. The computation cost for 
genome-wide region-based tests were projected from the exome-wide gene-based tests results given that there are 14.3 million markers in the HRC-

















5,000 0.09 15.47 15.56 0.35 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
10,000 0.16 22.14 22.30 0.47 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
20,000 0.84 26.37 27.21 0.73 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
50,000 2.18 34.69 36.87 2.68 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
100,000 6.11 141.10 147.21 2.97 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
200,000 20.05 188.79 208.84 6.39 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
400,000 151.22 360.24 511.46 12.76 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
5,000 0.09 16.55 16.64 0.35 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
10,000 0.16 22.68 22.84 0.47 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
20,000 0.84 29.55 30.39 0.73 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
50,000 2.18 36.94 39.12 2.68 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
100,000 6.11 141.58 147.69 2.97 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
200,000 20.05 202.43 222.48 6.39 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
400,000 151.22 396.94 548.16 12.76 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
5,000 0.26 15.47 15.73 0.98 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
10,000 0.49 22.14 22.63 1.06 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
20,000 2.24 26.37 28.61 3.39 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
50,000 7.93 34.69 42.62 4.44 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
100,000 24.68 141.10 165.79 8.94 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
200,000 94.84 188.79 283.63 17.51 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
400,000 872.30 360.24 1232.54 35.38 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
5,000 0.26 16.55 16.81 0.98 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
10,000 0.49 22.68 23.18 1.06 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
20,000 2.24 29.55 31.79 3.39 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
50,000 7.93 36.94 44.87 4.44 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
100,000 24.68 141.58 166.27 8.94 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
200,000 94.84 202.43 297.26 17.51 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 






5,000 0.09 278.79 278.88 0.35 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
10,000 0.16 398.98 399.14 0.47 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
20,000 0.84 475.16 476.00 0.73 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
50,000 2.18 625.10 627.28 2.68 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
100,000 6.11 2542.81 2548.91 2.97 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
200,000 20.05 3402.16 3422.22 6.39 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
400,000 151.22 6491.80 6643.02 12.76 SAIGE-GENE without robust adjustment; 93,511 markers for GRM 
5,000 0.09 298.30 298.39 0.35 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
10,000 0.16 408.80 408.96 0.47 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
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20,000 0.84 532.50 533.34 0.73 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
50,000 2.18 665.67 667.85 2.68 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
100,000 6.11 2551.42 2557.53 2.97 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
200,000 20.05 3647.87 3667.92 6.39 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
400,000 151.22 7153.23 7304.45 12.76 SAIGE-GENE with robust adjustment; 93,511 markers for GRM 
5,000 0.26 278.79 279.05 0.98 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
10,000 0.49 398.98 399.47 1.06 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
20,000 2.24 475.16 477.40 3.39 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
50,000 7.93 625.10 633.03 4.44 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
100,000 24.68 2542.81 2567.49 8.94 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
200,000 94.84 3402.16 3497.00 17.51 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
400,000 872.30 6491.80 7364.11 35.38 SAIGE-GENE without robust adjustment; 340,447 markers for GRM 
5,000 0.26 298.30 298.56 0.98 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
10,000 0.49 408.80 409.29 1.06 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
20,000 2.24 532.50 534.75 3.39 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
50,000 7.93 665.67 673.60 4.44 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
100,000 24.68 2551.42 2576.10 8.94 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 
200,000 94.84 3647.87 3742.70 17.51 SAIGE-GENE with robust adjustment; 340,447 markers for GRM 




Table S3.3.  Heritability estimated based on the full GRM by step 1 in SAIGE-GENE A. for 53 quantitative 
traits and B. for 10 binary traits in the UK Biobank. For quantitative traits, ℎ̂2 =  ?̂?/(?̂? + ?̂?), where ?̂? is the 
additive genetic variance parameter estimate and ?̂? is the variance parameter estimate for the error term 
(see ONLINE METHODS) from step 1 in SAIGE-GENE. For binary traits, heritability estimates in a 
liability scale, ℎ̂𝑙𝑎𝑡𝑒𝑛𝑡
2 , is reported here. The ℎ̂𝑙𝑎𝑡𝑒𝑛𝑡
2  was obtained using the fact that the logistic regression 





, where ?̂? is the additive genetic variance parameter estimate from step 1 in 
SAIGE-GENE. Since GRM was constructed using variants with MAF ≥ 0.01, the estimated heritability is 




Phenotype Sample Size ?̂?𝟐 
Townsend_deprivation_index 408422 0.061 
Waist_circumference 408227 0.214 
Hip_circumference 408182 0.233 
Waist_hip_ratio 408144 0.185 
Height_standing 408034 0.477 
Body_mass_index 407605 0.254 
Days_per_week_walked_10min 402016 0.050 
Weight 401786 0.276 
Whole_body_water_mass 401782 0.315 
Basal_metabolic_rate 401771 0.309 
Whole_body_fat_free_mass 401747 0.316 
Body_fat_percentage 401556 0.238 
Days_week_vigorous_phys_activity_10min 389393 0.050 
Days_per_week_moderate_phys_activity_10min 389204 0.052 
Blood_pressure_diastolic_automated_mean 385365 0.160 
Pulse_rate_automated_mean 385365 0.171 
Blood_pressure_systolic_automated_mean 385362 0.172 
Duration_moderate_activity 303663 0.045 
Duration_of_vigorous_activity 221867 0.035 
Duration_of_light_DIY 203191 0.038 
Duration_of_other_exercises 194610 0.025 
Duration_of_heavy_DIY 165319 0.043 
Smoking_packyear 124011 0.264 
Age_high_blood_pressure 99296 0.106 
Duration_of_strenuous_sports 41133 0.032 
Blood_pressure_diastolic_manual_mean 35283 0.149 
Blood_pressure_systolic_manual_mean 35283 0.156 
Age_diabetes 18552 0.187 
Age_at_death 11928 0.000 
Heart_rate 8421 0.208 
P_wave_duration 8421 0.296 
QRS_duration 8421 0.337 
Average_heart_rate_MRI 3875 0.231 
Body_surface_area_MRI 3875 0.521 
Cardiac_index 3875 0.083 
Cardiac_output 3875 0.154 
LV_ejection_fraction 3875 0.504 
LV_end_diastolic_volume 3875 0.650 
LV_end_systolic_volume 3875 0.522 
LV_stroke_volume 3875 0.681 
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Maximum_carotid_IMT_150 2221 0.135 
Mean_carotid_IMT_150 2221 0.379 
Minimum_carotid_IMT_150 2221 0.590 
Maximum_carotid_IMT_210 2209 0.830 
Mean_carotid_IMT_210 2209 0.790 
Minimum_carotid_IMT_210 2209 0.678 
Maximum_carotid_IMT_120 2204 0.000 
Mean_carotid_IMT_120 2204 0.000 
Minimum_carotid_IMT_120 2204 0.000 
Maximum_carotid_IMT_240 2183 0.178 
Mean_carotid_IMT_240 2183 0.300 
Minimum_carotid_IMT_240 2183 0.000 
 

















Hematuria 593 16409 379936 0.074 
Cholelithiasis and cholecystitis 574 16225 391307 0.121 
Prostate cancer 185 6743 169185 0.082 
Diseases of hair and hair follicles 704 5344 402357 0.156 
Colorectal cancer 153 4562 382756 0.135 
Glaucoma 365 4462 397761 0.133 
Pulmonary heart disease 415 4257 402375 0.111 
Melanomas of skin, dx or hx 172.1 2691 395071 0.161 
Ankylosing spondylitis 715.2 620 365085 0.000 
Thyroid cancer 193 358 407399 0.000 
107 
 
Table S3.4. Exome-wide significant genes with p-values ≤ 2.5x10-6 identified by SAIGE-GENE in the 
UK Biobank a. for 53 quantitative traits, b for 10 binary traits with various case-control ratios. 
 
A.  






Waist circumference GPR151 2.15E-10 6 408227 
Waist circumference C16orf70 1.94E-06 2 408227 
Hip circumference SYPL2 2.91E-08 4 408182 
Hip circumference TRAPPC4 5.83E-07 2 408182 
Hip circumference ANO1 5.98E-07 4 408182 
Hip circumference GPR151 6.08E-07 6 408182 
Hip circumference C16orf70 1.14E-06 2 408182 
Waist hip ratio TAS2R46 1.36E-08 2 408144 
Waist hip ratio GPR151 3.00E-08 6 408144 
Waist hip ratio SLC5A3 1.33E-07 4 408144 
Height standing SCMH1 3.41E-39 8 408034 
Height standing ACAN 1.39E-36 33 408034 
Height standing FBN2 3.15E-32 16 408034 
Height standing ZFAT 3.61E-32 13 408034 
Height standing HTRA1 1.66E-29 4 408034 
Height standing NPR3 3.60E-25 3 408034 
Height standing STC2 1.10E-24 4 408034 
Height standing SPSB3 1.10E-22 4 408034 
Height standing NUBP2 2.01E-22 9 408034 
Height standing ATAD2 8.07E-21 6 408034 
Height standing ADAMTS6 1.83E-17 6 408034 
Height standing GRAMD2A 3.41E-16 4 408034 
Height standing GRM4 7.23E-16 2 408034 
Height standing MTMR11 1.94E-15 3 408034 
Height standing CRISPLD2 2.04E-14 11 408034 
Height standing CERCAM 7.05E-14 10 408034 
Height standing PDE3B 1.88E-13 8 408034 
Height standing FNDC3B 1.39E-12 8 408034 
Height standing PKD1 6.40E-12 43 408034 
Height standing FER 6.68E-12 5 408034 
Height standing C16orf70 7.45E-12 2 408034 
Height standing HAPLN3 1.25E-11 6 408034 
Height standing ST3GAL4 5.37E-11 5 408034 
Height standing SHANK1 8.09E-11 5 408034 
Height standing TRAPPC13 1.04E-10 2 408034 
Height standing S1PR5 1.44E-10 5 408034 
Height standing PTCH1 2.65E-10 15 408034 
Height standing COL8A1 3.25E-10 2 408034 
Height standing EXD1 3.84E-10 3 408034 
Height standing ATAD5 4.74E-10 8 408034 
Height standing ESR1 7.28E-10 9 408034 
Height standing CLEC3A 9.08E-10 3 408034 
Height standing PTH1R 1.40E-09 3 408034 
Height standing FGFR3 3.50E-09 4 408034 
Height standing NOX4 4.09E-09 4 408034 
Height standing CYR61 4.40E-09 2 408034 
Height standing TBX3 4.59E-09 2 408034 
Height standing SAMD4A 4.77E-09 7 408034 
Height standing ZCCHC6 1.42E-08 7 408034 
Height standing CTU2 2.09E-08 12 408034 
Height standing LPP 2.11E-08 8 408034 
Height standing LRRC8A 2.87E-08 2 408034 
Height standing DGKH 3.08E-08 9 408034 
Height standing ABCB6 4.74E-08 11 408034 
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Height standing PIEZO1 6.63E-08 55 408034 
Height standing ELN 6.67E-08 8 408034 
Height standing ATG10 1.35E-07 4 408034 
Height standing CADM1 1.35E-07 2 408034 
Height standing CPPED1 1.40E-07 7 408034 
Height standing PFDN2 1.41E-07 2 408034 
Height standing PROP1 1.63E-07 4 408034 
Height standing PRSS56 1.68E-07 3 408034 
Height standing GYG1 1.78E-07 5 408034 
Height standing CHGA 2.20E-07 9 408034 
Height standing SERPINE2 2.80E-07 3 408034 
Height standing SPATA5 2.83E-07 5 408034 
Height standing AMOTL1 2.85E-07 6 408034 
Height standing TMEM150B 2.88E-07 3 408034 
Height standing COL11A1 2.91E-07 8 408034 
Height standing PTK7 2.95E-07 6 408034 
Height standing PHC3 3.24E-07 7 408034 
Height standing TARS2 4.22E-07 3 408034 
Height standing VASN 5.25E-07 7 408034 
Height standing TXLNA 5.66E-07 3 408034 
Height standing FAM76A 5.70E-07 3 408034 
Height standing C11orf57 5.71E-07 2 408034 
Height standing FBLN2 6.61E-07 13 408034 
Height standing MC3R 6.92E-07 2 408034 
Height standing GTF2E2 7.05E-07 3 408034 
Height standing FIBIN 1.09E-06 2 408034 
Height standing PREB 1.12E-06 5 408034 
Height standing SIX6 1.16E-06 3 408034 
Height standing DOT1L 1.20E-06 5 408034 
Height standing SETD2 1.30E-06 19 408034 
Height standing USP37 1.40E-06 8 408034 
Height standing BCKDHA 1.91E-06 2 408034 
Height standing HR 1.92E-06 21 408034 
Height standing PAM 1.98E-06 5 408034 
Height standing PLG 2.04E-06 11 408034 
Height standing LLGL1 2.30E-06 9 408034 
Height standing ZNF205 2.42E-06 4 408034 
Body mass index GPR151 1.74E-09 6 407605 
Body mass index SYPL2 6.43E-09 4 407605 
Body mass index TRAPPC4 2.87E-07 2 407605 
Body mass index IQSEC1 7.02E-07 12 407605 
Body mass index HCRTR2 1.50E-06 4 407605 
Body mass index FRMD5 1.92E-06 4 407605 
Weight ZFAT 1.80E-11 13 401786 
Weight C16orf70 7.28E-11 2 401786 
Weight STC2 1.69E-09 4 401786 
Weight GPR151 1.73E-09 6 401786 
Weight ANO1 3.10E-08 4 401786 
Weight SYPL2 6.22E-08 4 401786 
Weight FRMD5 6.24E-08 4 401786 
Weight NUBP2 1.70E-07 9 401786 
Weight SCMH1 1.87E-07 8 401786 
Weight TRAPPC4 1.16E-06 2 401786 
Weight HTRA1 2.00E-06 4 401786 
Weight SPSB3 2.32E-06 4 401786 
Whole body water mass STC2 8.55E-24 4 401782 
Whole body water mass NUBP2 1.52E-19 9 401782 
Whole body water mass ZFAT 1.83E-18 13 401782 
Whole body water mass SCMH1 8.44E-18 8 401782 
Whole body water mass SPSB3 2.40E-17 4 401782 
Whole body water mass HTRA1 2.11E-12 4 401782 
Whole body water mass ANO1 4.31E-12 4 401782 
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Whole body water mass PHC3 1.32E-11 7 401782 
Whole body water mass C16orf70 3.33E-11 2 401782 
Whole body water mass ATAD2 2.82E-09 6 401782 
Whole body water mass GRM4 6.47E-09 2 401782 
Whole body water mass ESR1 1.15E-07 9 401782 
Whole body water mass ZMYM6 1.75E-07 11 401782 
Whole body water mass TMEM150B 2.96E-07 3 401782 
Whole body water mass FRMD5 2.98E-07 4 401782 
Whole body water mass LCOR 3.88E-07 11 401782 
Whole body water mass PLEKHJ1 9.18E-07 5 401782 
Whole body water mass GLI3 1.09E-06 8 401782 
Whole body water mass ACAN 2.12E-06 33 401782 
Basal metabolic rate STC2 1.50E-20 4 401771 
Basal metabolic rate ZFAT 2.39E-17 13 401771 
Basal metabolic rate NUBP2 4.62E-17 9 401771 
Basal metabolic rate SCMH1 3.15E-15 8 401771 
Basal metabolic rate SPSB3 5.37E-15 4 401771 
Basal metabolic rate C16orf70 9.08E-12 2 401771 
Basal metabolic rate HTRA1 4.87E-11 4 401771 
Basal metabolic rate ANO1 5.53E-11 4 401771 
Basal metabolic rate PHC3 2.11E-10 7 401771 
Basal metabolic rate GRM4 9.53E-10 2 401771 
Basal metabolic rate FRMD5 1.35E-07 4 401771 
Basal metabolic rate ATAD2 2.27E-07 6 401771 
Basal metabolic rate LCOR 7.41E-07 11 401771 
Basal metabolic rate ZMYM6 8.04E-07 11 401771 
Basal metabolic rate TMEM150B 1.10E-06 3 401771 
Basal metabolic rate ESR1 1.14E-06 9 401771 
Basal metabolic rate GPR151 1.97E-06 6 401771 
Whole body fat free mass STC2 5.52E-24 4 401747 
Whole body fat free mass NUBP2 1.70E-19 9 401747 
Whole body fat free mass ZFAT 5.30E-19 13 401747 
Whole body fat free mass SCMH1 2.90E-18 8 401747 
Whole body fat free mass SPSB3 2.51E-17 4 401747 
Whole body fat free mass HTRA1 1.32E-12 4 401747 
Whole body fat free mass ANO1 6.36E-12 4 401747 
Whole body fat free mass PHC3 7.42E-12 7 401747 
Whole body fat free mass C16orf70 1.18E-10 2 401747 
Whole body fat free mass GRM4 6.51E-09 2 401747 
Whole body fat free mass ATAD2 6.80E-09 6 401747 
Whole body fat free mass ESR1 7.69E-08 9 401747 
Whole body fat free mass ZMYM6 2.27E-07 11 401747 
Whole body fat free mass TMEM150B 5.78E-07 3 401747 
Whole body fat free mass FRMD5 5.88E-07 4 401747 
Whole body fat free mass LCOR 1.06E-06 11 401747 
Whole body fat free mass ACAN 1.31E-06 33 401747 
Whole body fat free mass PLEKHJ1 1.72E-06 5 401747 
Whole body fat free mass GLI3 1.94E-06 8 401747 
Whole body fat free mass PAM 2.01E-06 5 401747 
Impedance of whole body CYR61 3.81E-18 2 401746 
Impedance of whole body POR 2.90E-12 7 401746 
Impedance of whole body ADAMTS3 7.23E-12 8 401746 
Impedance of whole body ANO1 4.91E-11 4 401746 
Impedance of whole body STC2 1.61E-09 4 401746 
Impedance of whole body ECM2 1.95E-08 10 401746 
Impedance of whole body ZNF469 3.93E-08 53 401746 
Impedance of whole body NUBP2 3.02E-07 9 401746 
Impedance of whole body FBN2 3.59E-07 16 401746 
Impedance of whole body FAM198A 1.08E-06 7 401746 
Impedance of whole body ZMYM6 1.18E-06 11 401746 
Impedance of whole body SNED1 1.99E-06 9 401746 
Body fat percentage CYR61 4.99E-12 2 401556 
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Body fat percentage GPR151 2.85E-10 6 401556 
Body fat percentage SYPL2 2.81E-07 4 401556 
Body fat percentage C10orf35 3.64E-07 2 401556 
Days per week moderate phys activity 10min RAD51AP1 3.87E-07 7 389204 
Blood pressure diastolic automated mean DBH 3.08E-14 12 385365 
Blood pressure diastolic automated mean SLC9A3R2 2.90E-11 5 385365 
Blood pressure diastolic automated mean ARID1B 1.08E-06 7 385365 
Pulse rate automated mean TBX5 9.69E-35 4 385365 
Pulse rate automated mean MYH6 3.61E-15 14 385365 
Pulse rate automated mean TTN 3.18E-10 368 385365 
Pulse rate automated mean KIF1C 4.78E-10 12 385365 
Pulse rate automated mean ARHGEF40 7.02E-08 7 385365 
Pulse rate automated mean FNIP1 3.58E-07 8 385365 
Pulse rate automated mean DBH 1.74E-06 12 385365 
Blood pressure systolic automated mean SLC9A3R2 2.36E-12 5 385362 
Blood pressure systolic automated mean ZFAT 7.06E-12 13 385362 
Blood pressure systolic automated mean DBH 2.85E-10 12 385362 
Blood pressure systolic automated mean RRAS 1.33E-07 2 385362 
Blood pressure systolic automated mean NOX4 1.91E-07 4 385362 
Blood pressure systolic automated mean TBX5 2.87E-07 4 385362 












cholecystitis 574 ABCG5 2.31E-13 13 16225 391307 
Cholelithiasis and 
cholecystitis 574 ABCG8 4.47E-10 12 16225 391307 
Cholelithiasis and 
cholecystitis 574 ABCB4 6.86E-07 9 16225 391307 
Sebaceous cyst 706.2 GORASP1 1.26E-18 8 8876 399255 
Diseases of hair and hair 
follicles 704 GORASP1 4.36E-16 8 5344 402357 
Glaucoma 365 MYOC 1.24E-06 6 4462 397761 
Pulmonary heart disease 415 CREB3L1 9.59E-10 6 4257 402375 
Ankylosing spondylitis 715.2 SLC44A4 1.23E-15 8 620 365085 
Ankylosing spondylitis 715.2 PSMB9 5.83E-10 3 620 365085 





Table S3.5. Exome-wide significant genes with p-values ≤ 2.5x10-6 identified by SAIGE-GENE but not identified by SAIGE in the UK Biobank 




     
Most significant variant 


























) function Gene 






6 0.07 0.01 
5.57E
-07 0 intronic CES3 




G 3.14E-05 1.64 0.34 
1.12E
-06 0 intronic PPP2R2B 






5 0.07 0.02 
7.05E
-07 0 intronic CES3 

















9 -0.05 0.01 
8.08E
-08 1 stopgain GPR151 















2 -0.03 0.01 
1.09E
-06 0 intronic FRMD5 









Body_mass_index HCRTR2 4 407605 
1.50E-
06 6:54854851:A:C 0.0145852 0.05 0.01 
4.09E
-07 0 intergenic 
FAM83B(dist=44954), 
HCRTR2(dist=116407) 






6 0.07 0.01 
1.65E
-07 0 intronic WDR76 






1 0.01 0.00 
1.16E
-07 0 intergenic 
PLEKHA1(dist=1310), 
ARMS2(dist=20998) 






5 -0.63 0.12 
1.60E
-07 0 intergenic 
TREH(dist=51861), 
DDX6(dist=16231) 
Whole_body_water_mass ZMYM6 11 401782 
1.75E-
07 1:35298496:C:T 5.12E-05 1.18 0.23 
1.59E
-07 0 intergenic 
GJA4(dist=37148), 
SMIM12(dist=17467) 




G 0.025069 -0.03 0.01 
6.33E
-08 0 intergenic 
FRMD5(dist=77200), 
CASC4(dist=16217) 




6 -0.21 0.04 
1.22E








G 3.13E-05 1.09 0.23 
1.74E
-06 0 intronic PPP2R2B 
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Basal_metabolic_rate ZMYM6 11 401771 
8.04E-
07 1:35298496:C:T 5.12E-05 1.20 0.24 
3.81E
-07 0 intergenic 
GJA4(dist=37148), 
SMIM12(dist=17467) 
Whole_body_fat_free_mass ZMYM6 11 401747 
2.27E-
07 1:35298496:C:T 5.12E-05 1.19 0.23 
1.42E
-07 0 intergenic 
GJA4(dist=37148), 
SMIM12(dist=17467) 






2 -0.03 0.01 
7.16E
-08 0 intergenic 
FRMD5(dist=77200), 
CASC4(dist=16217) 




9 -0.21 0.04 
1.34E














































4 -0.02 0.00 
3.46E
-06 0 intronic ABO 
Blood_pressure_systolic_ 













Table S3.6. Exome-wide significant genes with p-values ≤ 2.5x10-6 identified by SAIGE-GENE and remained significant after conditioning on 
the most significant variant, given that the most significant variant is a common variant with MAF > 1% or a less frequent non-coding variant that 
is not included in the gene-based tests for A. 53 quantitative traits B. 6 binary traits. 
 
A. 
      
Most significant variant 


























value function Gene 




G 3.14E-05 1.636 0.336 
1.12E
-06 intronic PPP2R2B 


























-10 intronic DIXDC1 










Height_standing PTH1R 3 408,034 
1.40E-




-18 intronic PTH1R 
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C 0.257 0.016 0.002 
1.75E
-14 UTR3 TBX3 




A 0.796 0.015 0.002 
9.65E
-11 intronic NOX4 








-29 UTR3 SLC44A2 













C 0.004 0.224 0.016 
5.68E
-47 intronic CUL3 




:T 0.582 0.015 0.002 
1.81E
-14 intergenic DDX25 








-76 intronic NHEJ1 
Height_standing 
TMEM150



















-31 intronic ZFAT 
Height_standing ELN 8 408,034 
6.67E-









G 3.18E-03 0.099 0.017 
3.21E
-09 intronic AMOTL1 








-24 intronic COL11A1 
Height_standing PTCH1 15 408,034 
2.65E-







Height_standing GRM4 2 408,034 
7.23E-















-69 intronic ACAN 
Height_standing VASN 7 408,034 
5.25E-
07 5.16E-07 16:4019350:C:T 0.821 0.021 0.002 
2.35E
-18 intronic ADCY9 




G 0.916 0.048 0.003 
1.64E
-45 intronic DIS3L2 
Height_standing TXLNA 3 408,034 
5.66E-













-24 intronic SEC62 













C 0.661 0.020 0.002 
5.95E
-24 intronic ESR1 




T 0.321 0.016 0.002 
3.64E
-16 intronic SAMD4A 















A 1.01E-03 0.211 0.035 
1.82E
-09 intronic SNX29 
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A 0.083 0.044 0.003 
2.40E
-38 synonymous FER 




A 0.071 0.036 0.004 
1.48E
-23 synonymous BCL6 
Height_standing 
TRAPPC1
3 2 408,034 
1.04E-

































A 0.296 0.013 0.002 
8.92E
-10 intronic FAM193B 




























-09 intronic HPS3 
Height_standing NUBP2 9 408,034 
2.01E-




-34 synonymous PKD1 
Height_standing SPSB3 4 408,034 
1.10E-




-34 synonymous PKD1 
Height_standing PKD1 43 408,034 
6.40E-




-34 synonymous PKD1 








-19 intronic KCTD19 








-87 intronic ATAD5 
Height_standing CYR61 2 408,034 
4.40E-
09 7.38E-09 1:85997286:G:C 0.168 0.019 0.003 
6.28E
-13 intronic DDAH1 











Height_standing PTK7 6 408,034 
2.95E-







Height_standing ZCCHC6 7 408,034 
1.42E-





Height_standing NPR3 3 408,034 
3.60E-




-61 UTR5 NPR3 











Weight SCMH1 8 401,786 
1.87E-




-15 intronic SCMH1 
Weight NUBP2 9 401,786 
1.70E-




-19 synonymous PKD1 








-15 synonymous ZFAT 
Whole_body_ 
water_mass ZMYM6 11 401,782 
1.75E-
















































A 0.455 0.014 0.002 
2.55E
-17 intronic ESR1 
Whole_body_ 
water_mass SCMH1 8 401,782 
8.44E-




-29 intronic SCMH1 
Whole_body_ 
water_mass NUBP2 9 401,782 
1.52E-




-29 synonymous PKD1 
Whole_body_ 
water_mass SPSB3 4 401,782 
2.40E-




-29 synonymous PKD1 
Whole_body_ 








-22 synonymous ZFAT 
Basal_metabolic_rate ZMYM6 11 401,771 
8.04E-


























-08 downstream CATSPER2P1(dist=99) 
Basal_metabolic_rate GRM4 2 401,771 
9.53E-
10 5.94E-07 6:34620153:T:A 0.139 0.035 0.002 
1.86E
-45 intronic C6orf106 
Basal_metabolic_rate SCMH1 8 401,771 
3.15E-




-27 intronic SCMH1 
Basal_metabolic_rate SPSB3 4 401,771 
5.37E-




-27 synonymous PKD1 
Basal_metabolic_rate NUBP2 9 401,771 
4.62E-




-27 synonymous PKD1 








-21 synonymous ZFAT 
Whole_body_fat_ 
free_mass ZMYM6 11 401,747 
2.27E-
























A 0.455 0.014 0.002 
8.43E
-17 intronic ESR1 
Whole_body_fat_ 
free_mass SCMH1 8 401,747 
2.90E-




-29 intronic SCMH1 
Whole_body_fat_ 
free_mass SPSB3 4 401,747 
2.51E-




-29 synonymous PKD1 
Whole_body_fat_ 
free_mass NUBP2 9 401,747 
1.70E-




-29 synonymous PKD1 
Whole_body_fat_ 












3 8 401,746 
7.23E-










G 0.329 0.014 0.002 
1.29E
-11 intronic PASK 
Impedance_of_ 
whole_body NUBP2 9 401,746 
3.02E-
07 1.59E-07 16:2163962:A:G 0.098 0.025 0.003 
1.92E











































































2 5 385,362 
2.36E-




-14 UTR3 SLC9A3R2 
Blood_pressure_systoli
c_ 














        
Most significant variant 









































-18 upstream ABCB4(dist=776) 
Cholelithiasi
s and 






A 0.065 0.767 0.025 
4.16E
-201 intronic ABCG8 
Cholelithiasi
s and 






A 0.065 0.767 0.025 
4.16E
-201 intronic ABCG8 
Diseases of 
hair and hair 
follicles 704 
GORASP






C 0.113 0.408 0.033 
1.50E
-35 intronic SCN5A 
Ankylosing 

































Table S3.7. Empirical type I error rates for SAIGE-GENE, SAIGE-GENE-GCadj (GC adjusted SAIGE-GENE), EmmaX-SKAT(Kang et al., 
2010; M. C. Wu et al., 2011) and SMMAT(Chen et al., 2018). ℎ2: heritability.   
 
    500 families and 5000 independent samples 1000 families and no independent samples 
    𝒉𝟐=0.2 𝒉𝟐=0.4 𝒉𝟐=0.2 𝒉𝟐=0.4 
  alpha  burden skat skato burden skat skato burden skat skato burden skat skato 
SAIGE-GENE 
0.05 5.25E-02 5.62E-02 5.79E-02 5.49E-02 6.26E-02 6.32E-02 5.26E-02 5.62E-02 5.79E-02 5.48E-02 6.24E-02 6.30E-02 
0.0001 1.10E-04 1.30E-04 1.30E-04 1.40E-04 1.70E-04 1.80E-04 1.20E-04 1.30E-04 1.40E-04 1.40E-04 1.70E-04 1.80E-04 
2.50E-06 2.80E-06 4.20E-06 2.80E-06 3.50E-06 5.20E-06 3.30E-06 3.71E-06 5.22E-06 5.82E-06 3.81E-06 6.51E-06 5.61E-06 
SAIGE-GENE 
-Gcadj 
0.05 5.00E-02 5.00E-02 5.45E-02 5.01E-02 5.01E-02 5.10E-02 4.99E-02 4.99E-02 5.47E-02 4.99E-02 4.99E-02 5.10E-02 
0.0001 9.00E-05 9.00E-05 1.10E-04 1.00E-04 1.00E-04 8.00E-05 1.00E-04 1.00E-04 1.20E-04 1.00E-04 1.00E-04 8.00E-05 
2.50E-06 2.20E-06 2.20E-06 2.20E-06 1.90E-06 1.80E-06 1.30E-06 2.91E-06 2.91E-06 4.41E-06 2.51E-06 2.61E-06 2.51E-06 
EmmaX-SKAT 
0.05 5.16E-02 5.36E-02 5.58E-02 5.33E-02 5.75E-02 5.91E-02 5.18E-02 5.39E-02 5.60E-02 5.32E-02 5.76E-02 5.91E-02 
0.0001 1.10E-04 1.10E-04 1.20E-04 1.20E-04 1.30E-04 1.50E-04 1.10E-04 1.20E-04 1.30E-04 1.30E-04 1.40E-04 1.50E-04 
2.50E-06 2.36E-06 3.37E-06 2.13E-06 2.58E-06 3.03E-06 2.25E-06 3.71E-06 4.61E-06 5.40E-06 3.49E-06 5.06E-06 4.95E-06 
SMMAT 
0.05 5.17E-02 5.36E-02 5.41E-02 5.33E-02 5.74E-02 5.73E-02 5.18E-02 5.39E-02 5.43E-02 5.32E-02 5.76E-02 5.74E-02 
0.0001 1.10E-04 1.10E-04 1.40E-04 1.20E-04 1.30E-04 1.70E-04 1.10E-04 1.20E-04 1.50E-04 1.30E-04 1.40E-04 1.70E-04 
2.50E-06 2.50E-06 3.80E-06 2.90E-06 2.80E-06 3.40E-06 3.30E-06 3.47E-06 4.42E-06 6.00E-06 3.26E-06 4.63E-06 5.47E-06 
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Table S3.8. Empirical type I error rates for SAIGE-GENE with the larger sample size of 1,000 families 
and 10,000 independent samples (total sample size N = 20,000). The heritability ℎ2 = 0.2. 
 
  alpha  Burden SKAT SKAT-O 
SAIGE-GENE 
0.05 5.28E-02 5.68E-02 5.84E-02 
0.0001 1.00E-04 1.00E-04 1.00E-04 
2.50E-06 3.44E-06 4.33E-06 3.00E-06 
 
 
Table S3.9.  Empirical type I error rates for SAIGE-GENE, EmmaX-SKAT(Kang et al., 2010; M. C. Wu 
et al., 2011) and SMMAT(Chen et al., 2018) for skewed distributed phenotypes with and without inverse 
normal transformation for 500 families and 5,000 independent samples (total sample size N = 10,000). The 
heritability ℎ2 = 0.2.  
 
    with inverse normal transformation without inverse normal transformation 
  alpha  Burden SKAT SKAT-O Burden SKAT SKAT-O 
SAIGE-
GENE 
0.05 5.19E-02 5.61E-02 5.75E-02 5.13E-02 5.85E-02 5.87E-02 
0.0001 1.25E-04 1.75E-04 1.81E-04 1.52E-04 3.50E-04 3.27E-04 
2.50E-
06 
4.44E-06 8.27E-06 6.65E-06 5.68E-06 2.86E-05 2.19E-05 
EmmaX-
SKAT 
0.05 5.10E-02 5.37E-02 5.55E-02 5.09E-02 5.75E-02 5.79E-02 
0.0001 1.18E-04 1.55E-04 1.61E-04 1.45E-04 3.48E-04 3.30E-04 
2.50E-
06 
4.82E-06 6.55E-06 6.55E-06 6.92E-06 2.42E-05 2.29E-05 
SMMAT 0.05 5.14E-02 5.41E-02 5.45E-02 5.09E-02 5.72E-02 5.59E-02 
0.0001 1.19E-04 1.62E-04 1.83E-04 1.42E-04 3.40E-04 3.40E-04 
2.50E-
06 
5.42E-06 8.34E-06 9.17E-06 6.79E-06 2.59E-05 2.59E-05 
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Table S3.10.  Empirical type I error rates for SAIGE-GENE and SMMAT(Chen et al., 2018) for skewed 
distributed phenotypes with the three-step phenotype transformation procedure for 500 families and 5,000 
independent samples (total sample size N = 10,000).  The heritability ℎ2 = 0.2.  
 
  alpha  Burden SKAT SKAT-O 
SAIGE-GENE 0.05 4.71E-02 4.42E-02 4.77E-02 
0.0001 8.53E-05 7.94E-05 9.32E-05 
2.50E-06 1.79E-06 2.53E-06 2.74E-06 
SMMAT 0.05 5.03E-02 5.06E-02 5.16E-02 
0.0001 1.03E-04 1.05E-04 1.29E-04 




Table S3.11. Empirical type I error rates for SAIGE-GENE in the presence of population stratification. 
Phenotypes were simulated based on real genotypes from the UK Biobank for randomly selected 5,000 
samples with white British ancestry and 5,000 samples with European ancestry but not white British. The 
heritability ℎ2 = 0.2. 
 
alpha  Burden SKAT SKAT-O 
0.05 5.05E-02 5.09E-02 5.33E-02 
0.0001 1.02E-04 1.06E-04 1.33E-04 




Table S3.12. Empirical type I error rates for SAIGE-GENE in the presence of non-negligible cryptic 
relatedness. Phenotypes were simulated based on real genotypes from the UK Biobank for randomly 
selected 10,000 sample with White British ancestry (5,000 are related with up to 3rd degree and 5,000 are 
unrelated). The heritability ℎ2 = 0.2. 
 






















Table S3.13. Empirical Type I error rates of SAIGE-GENE for binary traits with five different prevalence. 
Phenotypes were simulated for 500 families and 5,000 independent samples (total sample size N = 10,000). 
The liability scale heritability ℎ𝑙𝑎𝑡𝑒𝑛𝑡
2 =0.23. A. Unadjusted SAIGE-GENE; B. SAIGE-GENE with the 
robust adjustment to account for unbalanced case-control ratios. SKAT-O-GCadj and SKAT-GCadj are 
GC-adjusted SKAT-O and SKAT.  
 




Prev=0.05 Prev=0.1  Prev=0.2  Prev=0.5  
SKAT-O 
0.05 7.27E-02 5.55E-02 5.38E-02 5.31E-02 5.32E-02 
0.0001 2.77E-03 4.57E-04 2.32E-04 1.43E-04 1.04E-04 
2.50E-06 5.38E-04 4.04E-05 1.49E-05 5.76E-06 1.70E-06 
SKAT 
0.05 8.67E-02 5.59E-02 5.21E-02 5.05E-02 5.03E-02 
0.0001 3.10E-03 4.74E-04 2.33E-04 1.30E-04 8.96E-05 
2.50E-06 6.34E-04 4.64E-05 1.58E-05 6.69E-06 1.70E-06 
Burden 
0.05 4.57E-02 4.94E-02 4.99E-02 5.03E-02 5.06E-02 
0.0001 5.69E-04 1.85E-04 1.27E-04 1.08E-04 1.01E-04 
2.50E-06 7.09E-05 1.16E-05 4.80E-06 3.60E-06 2.90E-06 
 
 




Prev=0.05 Prev=0.1  Prev=0.2  Prev=0.5  
SKAT-O 
0.05 5.52E-02 5.06E-02 4.77E-02 4.39E-02 4.12E-02 
0.0001 3.14E-04 1.58E-04 1.16E-04 8.10E-05 5.51E-05 
2.50E-06 7.30E-06 4.51E-06 3.80E-06 1.54E-06 1.10E-06 
SKAT-O-
GCadj 
0.05 5.00E-02 5.00E-02 4.77E-02 4.39E-02 4.12E-02 
0.0001 2.08E-04 1.51E-04 1.16E-04 8.10E-05 5.51E-05 
2.50E-06 3.90E-06 4.51E-06 3.80E-06 1.54E-06 1.10E-06 
SKAT 
0.05 6.59E-02 5.01E-02 4.49E-02 3.97E-02 3.63E-02 
0.0001 3.40E-04 1.53E-04 1.13E-04 6.76E-05 3.94E-05 
2.50E-06 8.20E-06 4.11E-06 2.90E-06 1.65E-06 5.01E-07 
SKAT-GCadj 
0.05 5.00E-02 5.00E-02 4.49E-02 3.97E-02 3.63E-02 
0.0001 1.01E-04 1.53E-04 1.13E-04 6.76E-05 3.94E-05 
2.50E-06 9.00E-07 4.11E-06 2.90E-06 1.65E-06 5.01E-07 
Burden 
0.05 3.95E-02 4.67E-02 4.66E-02 4.54E-02 4.42E-02 
0.0001 7.82E-05 8.58E-05 7.65E-05 7.19E-05 6.41E-05 








Table S3.14. Empirical type I error rates for SAIGE-GENE in the simulation study with case-control 
sampling from an underlying large cohort. The liability scale heritability ℎ𝑙𝑎𝑡𝑒𝑛𝑡
2 =0.23. 
 
    Case:Control=1:1 
 
Case:Control=1:9 
  alpha  Burden SKAT SKAT-O Burden SKAT SKAT-O 
SAIGE-GENE 
0.05 4.97E-02 4.86E-02 5.17E-02 4.87E-02 4.96E-02 5.16E-02 
0.0001 9.21E-05 9.05E-05 1.01E-04 9.07E-05 1.18E-04 1.27E-04 
2.50E-06 2.68E-06 1.56E-06 2.23E-06 2.37E-06 3.85E-06 2.07E-06 
 
 
Table S3.15. Empirical power for SAIGE-GENE and EmmaX-SKAT with two different percentages of 
causal variants (top vs bottom panels) and two different ratios of positive and negative effect directions (left 
vs right). 𝛽: effect size. ℎ2: heritability. 
 
Table S3.16. Empirical power for the SKAT-O test in SAIGE-GENE for binary phenotypes in cohort 
studies and case-control sampling studies. 40% of variants were simulated to be causal. 80% of causal 
variants were risk-increasing variants, while 20% were risk-decreasing variants. The liability scale 
heritability ℎ𝑙𝑎𝑡𝑒𝑛𝑡
2 =0.23. Note that the effect sizes in cohort study and case-control sampling were 
different, so the power in these two designs is not directly comparable.  
 








Robust     
SKAT-O 
1:1 56.00% 58.00% 60.00% 61.00% 
1:9 44.00% 56.00% 21.00% 23.00% 
1:19 27.00% 37.00% 8.00% 9.00% 
1:99 5.00% 8.00%   
 
𝒉𝟐=0.4 Proportion of causal variants= 0.4 
  𝜷 −/+=0.8/0.2 𝜷 −/+=1/0 
  Burden SKAT SKAT-O Burden SKAT SKAT-O 
EmmaX-
SKAT 54.80% 80.20% 84.20% 89.10% 82.1% 92.00% 
SAIGE-
GENE 54.60% 81.30% 84.00% 89.00% 83.20% 91.70% 
  Proportion of causal variants= 0.1 
  𝜷 −/+=0.8/0.2 𝜷 −/+=1/0 
  Burden SKAT SKAT-O Burden SKAT SKAT-O 
EmmaX-
SKAT 35.3% 66.30% 66.60% 51.70% 65.6% 66.10% 
SAIGE-




The Construction of Multi-ethnic Polygenic Risk Score 




Methods for constructing polygenic risk scores (PRS), including pruning and thresholding (PT), 
lassosum (lsum) and PRS-CS, have been extensively investigated in recent years. As most existing 
GWAS were conducted in European or East Asian individuals, the existing PRS models have 
limited transferability to minority populations such as Africans and South Asians. Although recent 
studies have developed multi-ethnic PRS models that linearly combine multiple PRS trained with 
different ancestry GWAS, they remain under-powered.  
Here we propose a novel multi-ethnic PRS using transfer learning techniques, borrowed from the 
machine learning literature. Our approach, TL-PRS, fine-tunes the potentially biased model trained 
with GWAS summary statistics from the majority/source ancestry to the target dataset of the 
minority ancestry. TL-PRS can use any existing PRS methods (such as lsum and PRS-CS) as a 
baseline method for fine-tuning. Using the potentially biased baseline parameter estimates as initial 
values, TL-PRS iterates the gradient descent algorithm to adapt the parameters for the target 
ancestry group. In the presence of multiple GWAS summary sources from different ancestries, 
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TL-PRS combines fine-tuned PRS using linear combination. 
Through simulation studies, we show that TL-PRS improved the performance of PRS across a 
wide range of genetic architectures and cross-population genetic correlations. TL-PRS was most 
effective when genetic correlations between populations and samples used for calculating 
summary statistics were small and the genetic architecture was less polygenic. For example, when 
genetic correlation was 0.4, TL-PRS-lsum attained on average a 228% and 36% relative 
improvement in prediction accuracy compared to lsum when the causal variants were 0.1% and 1% 
respectively while TL-PRS-CS attained on average a 26% and 20% relative improvement 
compared to PRS-CS. 
In our application using 8,168 African samples from the UK Biobank data, TL-PRS substantially 
improved the prediction accuracy of the six quantitative and two dichotomous traits. Compared to 
lsum, TL-PRS-lsum attained a 21% and 26% average relative improvement in prediction accuracy 
when using Biobank Japan and UK Biobank white British GWAS summary statistics, respectively; 
the average relative improvement of TL-PRS-CS over PRS-CS was 40% and 9%, respectively. 
When combining summary statistics from Biobank Japan and UK Biobank, TL-PRS-lsum, and 
TL-PRS-CS outperformed the linear combination of PT and PRS-CSx. By improving the 
polygenic risk prediction in non-European individuals, our approach will increase the usefulness 





Genetic risk prediction is one of the important and widely investigated topics in genetic 
epidemiology because it can help us better understand the genetic architecture of complex traits 
and potentially aid the clinical decision-making(Lewis & Vassos, 2020; Sugrue & Desikan, 2019; 
Torkamani et al., 2018). Many polygenic risk prediction methods have been developed and applied 
to complex traits, such as pruning and thresholding (PT)(Vilhjálmsson et al., 2015), lassosum 
(lsum)(Mak et al., 2017), PRS-CS(Ge et al., 2019) and LDpred(Vilhjálmsson et al., 2015).  
In the prediction of polygenic risk in European-ancestry populations, these methods perform well 
and help to identify high risk groups because of the large sample size of Europeans in the training 
data (Duncan et al., 2019; Martin et al., 2019; Torkamani et al., 2018; Vilhjálmsson et al., 2015). 
However, due to insufficient non-European training data, these methods are inadequate for the 
polygenic risk prediction in non-European populations (Ge et al., 2019; Mak et al., 2017). Directly 
using PRS models trained by European samples for the prediction of non-European groups may 
reduce the prediction accuracy for genetic differences across ancestry groups (Duncan et al., 2019; 
Vilhjálmsson et al., 2015). 
To tackle this issue, Márquez‐Luna et al. proposed a multi-ethnic polygenic risk scores (PRS) 
model by linearly combining the PRS of two training populations(Márquez‐Luna et al., 2017). 
They attained more than 70% relative improvement in prediction accuracy for type 2 diabetes in 
both Latino and South Asian cohorts compared to prediction methods using training data from a 
single population. However, this method implicitly assumes that the effect sizes from two 
populations are linearly combined with a constant weight for all SNPs and this linear assumption 
may not hold in all situations.  
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To address this problem, we propose a novel multi-ethnic PRS using transfer learning techniques, 
borrowed from the machine learning literature. Transfer learning is a tool in machine learning that 
focuses on storing knowledge gained while solving one problem and applying it to a different but 
related problem.(West et al., 2007) The procedure of transfer learning is an optimization that 
allows rapid progress or improved performance when modeling the second task.(Pan & Yang, 
2009; Torrey & Shavlik, 2010) From the practical viewpoint, reusing or transferring information 
from previously learned tasks for the learning of new tasks has the potential to significantly 
improve the prediction performance as well as model efficiency(West et al., 2007). 
Our approach, Transfer Learning PRS or TL-PRS, fine-tunes the potentially biased model trained 
with GWAS summary statistics from majority ancestry to the target dataset of minority ancestry. 
TL-PRS can use any existing PRS methods (such as lsum and PRS-CS) as a baseline method for 
fine-tuning. Using the potentially biased baseline parameter estimates as initial values, TL-PRS 
iterates the gradient descent algorithm to adapt the parameters for the target ancestry group. In 
addition, in the presence of multiple GWAS summary statistics from different ancestries, TL-PRS 
combines fine-tuned PRS using linear combination. The implementation is also scalable for large 
data analysis.  
In the simulations, TL-PRS outperformed the existing PRS models in a wide range of genetic 
architectures and cross-population genetic correlations. In the application, we use 10,285 South 
Asian samples and 8,168 African samples from the UK Biobank data. The prediction accuracy of 
many traits was improved by TL-PRS. By improving the polygenic risk prediction in non-
European individuals, our approach will improve the performance of PRS and help reduce 




4.2.1 Polygenic risk score using GWAS summary statistics from a single ancestry 
Assuming that summary statistics (i.e. the estimated effect size ?̂?𝑗 ) are available, PRS is 
constructed as the summation of the estimated effects across all single-nucleotide polymorphisms 
(SNPs) on a given phenotype. Given a typical individual 𝑖, PRS can be defined as  




Although 𝑃𝑅𝑆𝑖  aggregate the effects of all genetic variants to phenotypes, it has two major 
limitations: (1) The LD correlation among SNPs is ignored and this formula implicitly assumes 
that all SNPs are independent. (2) Some SNPs may not contribute to the phenotype; therefore, 
including them in the model reduces the prediction accuracy. 
There are several well-known methods to overcome the limitations, such as pruning and 
thresholding (PT), lassosum (lsum), and PRS-CS. PT computes the PRS on a subset of SNPs based 
on LD-pruning and P-value thresholding. It has two tuning parameters: a pairwise threshold 𝑅𝐿𝐷
2   
and a p-value threshold 𝑃𝑇. Lsum re-estimates the effect sizes using elastic net on GWAS summary 
statistics. The hyperparameters include the coefficients of L1 and L2 penalty. PRS-CS is a 
Bayesian polygenic prediction approach that uses a continuous shrinkage prior to derive posterior 
SNP effect sizes from summary statistics. The global shrinkage parameter in PRS-CS is a hyper-
parameter that models the overall sparseness of the genetic architecture. Overall, PT and lsum are 
computationally efficient while PRS-CS requires more computational time due to the Bayesian 
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framework. In terms of prediction accuracy, lsum and PRS-CS generally outperform than PT in 
most circumstances.  
4.2.2 Transfer learning (TL-PRS) using GWAS summary statistics from a single 
ancestry 
Suppose that we have trained a PRS model using summary statistics from source population A, 
this model could be considered as prior knowledge to predict the genetic effects in the target 
population B. However, due to different LD patterns and possible effect size heterogeneity across 
ancestries, effect size estimation from population A can be viewed as biased estimators of effect 
sizes in population B. In order to reduce the bias and achieve better prediction performance, we 
borrow the idea of transfer learning and attempt to utilize a small fraction of the target sample to 
combine information from the biased model and the target sample data.    
Specifically, for the target population, we have the following model:   
𝑌 = ∑ 𝐺𝑗𝛽𝑗 + 𝐶𝛾 + 𝜀 = ∑ 𝐺𝑗(𝛽𝑗
𝑢 + 𝜏𝑗) + 𝐶𝛾 + 𝜀, 
where 𝛽𝑗 is the true effect size of the target population, assumed to be unknown;  𝛽𝑗
𝑢 is given by 
the trained model, assumed to be biased; 𝜏𝑗 is the bias term between 𝛽𝑗
𝑢 and 𝛽𝑗; 𝐶 is the covariate 
matrix including the intercept; and 𝛾 is a vector of covariate coefficients. Since this problem can 
be converted into a convex optimization, we can perform gradient descent algorithms on 𝛽𝑗 with 
the initial value 𝛽𝑗


















where 𝐺𝑗𝑌 and 𝐺𝑗
𝑇𝐺 can be pre-calculated using the training data and 𝛼 is the learning rate. In 
addition, early stopping of iteration is required to avoid overfitting.  
Both the learning rate 𝛼 and the number of iterations 𝑛𝑠𝑡𝑜𝑝 can be tuned based on the validation 
dataset in terms of the best prediction accuracy. In order to reduce computation cost, we suggest 




Additionally, any PRS method can be used for initial value 𝛽𝑗
𝑢 for transfer learning. In this paper, 
we used lsum and PRS-CS trained models as the baseline methods, which are referred as TL-PRS-
lsum and TL-PRS-CS, respectively. TL-PRS method can also be applied to other training models, 
such as LDpred(Vilhjálmsson et al., 2015).  
4.2.3 Combining multiple GWAS summary statistics from different ancestries 
Suppose we have constructed the PRS from two different GWAS summary statistics 𝑃𝑅𝑆1 and 
𝑃𝑅𝑆2, then the multi-ethnic PRS can be built as  
𝑃𝑅𝑆 = 𝜋𝑃𝑅𝑆1 + (1 − 𝜋)𝑃𝑅𝑆2, 
where 𝜋 is a tuning parameter with range [0,1] and can be decided using the cross-validation 
method.(Márquez‐Luna et al., 2017) This idea was first proposed by Márquez-Luna et al in 2017 
using PT to construct a single-ancestry PRS, which was referred as PT-multi. We can extend this 
approach to other PRS construction methods, such as lsum and PRS-CS, which are lsum-multi, 
PRS-CSx(Huang et al., 2021). Similarly, the linear combination can also be applied to TL-PRS 
models. For example, if we have TL-PRS-lsum models from two populations, we might linearly 
combine them and refer to this method as MTL-PRS-lsum. MTL-PRS-CS can also be constructed 
in the same way. 
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Beyond the combination of two populations, we can further extend this idea to three or more 
different ancestries. Suppose that we have PRS from three different populations 𝑃𝑅𝑆1, 𝑃𝑅𝑆2 and 
𝑃𝑅𝑆3, then the multi-ethnic PRS can be built as  
𝑃𝑅𝑆 = 𝜋1𝑃𝑅𝑆1 + 𝜋2𝑃𝑅𝑆2 + (1 − 𝜋1 − 𝜋2)𝑃𝑅𝑆3, where 𝜋1, 𝜋2 ≥ 0 and 𝜋1 + 𝜋2 ≤ 1. 
4.2.4 Simulations using South Asian samples in UK Biobank 
We simulated quantitative phenotypes using real genotypes from the South Asian samples in the 
UK Biobank. The proportion of causal markers was fixed as 1% and 0.1%, the SNP-heritability 
ℎ𝑔
2
 was fixed at 0.5. The normalized effect sizes 𝑏𝑖 were sampled from a normal distribution with 
mean 0 and variance equal to ℎ𝑔
2
 divided by the number of causal markers. The per-allele effect 
sizes could be calculated by 𝛽𝑖 =
𝑏𝑖  
√2𝑝𝑖(1−𝑝𝑖)
, where 𝑝𝑖 is the minor allele frequency of i-th SNP. 
We simulated phenotypes as  
𝑌𝑗 = ∑ 𝛽𝑖𝑔𝑖𝑗 + 𝜖𝑗
𝑀
𝑖=1 , where 𝜖𝑗~𝑁(0,1 − ℎ𝑔
2). 
𝑀 is the number of SNPs and only HapMap3 variants (Consortium, 2010) are included in the 
simulation.  
The GWAS summary statistics based on 10,000 South Asians and 100,000 Europeans were 
generated respectively based on the formula ?̂?𝑖~𝑁(?̂?𝛽𝑖, ?̂?/𝑛), where n is the sample size and ?̂? is 
the estimated correlation matrix of the LD block region using South Asians and Europeans in 1000 
Genomes Project. We assumed that causal variants could be shared across all populations 
(Europeans and South Asians), but varying effect sizes were allowed and sampled from a 
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multivariate normal distribution with a genetic correlation of 0.4, 0.7, or 1.0. The simulation of the 
phenotype was repeated 20 times. 
The target South Asian data set was randomly split into training, validation and testing datasets. 
In the training and validation dataset, we applied single-source prediction methods (PT, lsum, 
PRS-CS) as well as TL-PRS methods (TL-PRS-lsum, TL-PRS-CS) to GWAS summary statistics 
generated by 10K South Asians and 100K Europeans samples and evaluated their predictive 
performance measured by 𝑅2 between the simulated and predicted phenotypes in the testing set. 
The multi-source prediction methods (PT-mutli, lsum-multi, MTL-PRS-lsum, PRS-CSx, MTL-
PRS-CS) were then utilized to compare the cross-population polygenic prediction. 
4.2.5 Analysis of South Asian, African, and non-British White samples in UK 
Biobank 
We constructed PRSs for following target samples in UK Biobank: South Asian (SAS), African 
(AFR) and Non-British White (NBW). In each target sample, we used the software KING to 
exclude one individual in each related pair (up to second-degree relatives). We then built the 
polygenic prediction models on the following eight traits: high-density lipoproteins (HDL), low-
density lipoproteins (LDL), body mass index (BMI), triglycerides (TG), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), coronary artery disease (CAD), and Type II diabetes (T2D). 
The first six traits were quantitative and the last two traits were dichotomous. 
Summary statistics of GWAS analyses on White British in UK Biobank (UKBB) and Japanese in 
Biobank Japan (BBJ) were downloaded from UKBB (https://pheweb.org/UKB-Neale/) and BBJ 
PheWeb (http://jenger.riken.jp/en/result). We restricted our analysis to common variants 
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(MAF>=0.01) presented in summary data and target genotype files after removing A/T and C/G 
SNPs to eliminate potential strand ambiguity (Márquez‐Luna et al., 2017).  
We applied single-source prediction methods (PT, lsum, TL-PRS-lsum, PRS-CS, TL-PRS-CS) to 
UKBB and BBJ summary statistics, and used multi-source prediction methods (PT-multi, lsum-
multi, MTL-PRS-lsum, PRS-CSx, MTL-PRS-CS) to combine UKBB and BBJ GWAS results. The 
prediction accuracy was assessed in the testing dataset of each target population separately, 
adjusting for age, sex and the top four principal components (PCs). We used 𝑅2 as the prediction 
accuracy metric for quantitative traits and Nagelkerke 𝑅2  for dichotomous traits. For each 
population, the target samples were randomly split into a training dataset (for model fitting), a 
validation dataset (for hyper-parameter tuning) and a testing dataset (for the evaluation of 
predictive performance).  
4.3 Results 
4.3.1 Overview of TL-PRS 
We first build PRS models using existing methods, such as lsum and PRS-CS. These models 
provide biased effect sizes of causal SNPs, which are used as the initial values of TL-PRS. The 
hyperparameters in TL-PRS include the learning rate and the number of iterations. Given TL-PRS 
models from different GWAS summary sources, we can integrate them by learning an optimal 




Figure 4.1: Overview of transfer learning on PRS methods. LD ref: LD reference panel. 
(A) The general procedure how to construct PRS using transfer learning;  
(B) The procedure how to combine multiple PRS into the final PRS; 
(C) The detailed procedure of transfer learning. 
 
Figure 4.2 shows the relative accuracy (𝑅𝑇𝐿
2 /𝑅𝐵𝑎𝑠𝑒
2 ) of TL-PRS as a function of iterations. The 
relative accuracy in the training dataset kept increasing with respect to the iterations, which caused 
the overfitting. However, the fifth iteration reached the maximum relative accuracy in the 
validation sets of both simulation and real data analysis, which suggested that the fifth iteration 
was the optimal point to stop in these two examples. A similar strategy can be applied to choose 





Figure 4.2. Relative accuracy of transfer learning method as a function of iterations. 
(A) The simulation setting where the causal markers were 0.1%, genetic correlation was 0.4 
and European summary statistics were used. 
(B) The real data analysis of HDL in a South Asian cohort from UK Biobank, where UKBB 
summary statistics were used.  
 
4.3.2 Simulations using South Asian samples in UK Biobank 
In the simulation, different scenarios were considered by randomly selecting 0.1% or 1% variants 
across the genome as causal variants, which explained 50% of the phenotypic variance in total. 
Additionally, causal variants were assumed to be the same across populations, but different effect 
sizes were simulated from a multivariate normal distribution using the cross-population genetic 
correlation 0.4, 0.7 and 1. We generated 20 datasets in each scenario to evaluate the predictive 





Figure 4.3. Prediction accuracy of single-source and multi-source polygenic prediction methods 
in simulations. Different genetic designs (0.1% and 1% causal variants) were simulated as well 
as cross-population genetic correlations (0.4, 0.7 and 1.0). Heritability was fixed at 50%. 
Prediction accuracy was measured by the squared correlation (R2) between the simulated and 
predicted phenotypes in the testing dataset, averaged across 20 simulation replicates. Error bar 
indicates the standard deviation of R2 across simulation replicates. 
 
The prediction accuracy of single-source and multi-source polygenic prediction methods in the 
simulations can be found in Figure 4.3. For a fixed heritability 0.5, the predictive performance of 
all ten PRS methods increased when the genetic architecture became less polygenic (1.0% vs 0.1% 
causal). Although the causal variants were identical between populations, all ten PRS methods 
decreased prediction accuracy when the genetic effects were less correlated among populations. 
This is also the situation where TL-PRS could further improve the prediction accuracy. For 
example, when genetic correlation was 0.4, TL-PRS-lsum improved a 228% and 36% average 
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prediction accuracy compared to lsum when the causal variants were 0.1% and 1%, respectively 
(Figure 4.4). The relative improvement of TL-PRS-CS over PRS-CS was 26% and 20% on average. 
However, when genetic correlation was 1.0, lsum and PRS-CS are sufficient for prediction in target 
population due to the unbiased effect sizes. TL-PRS-lsum and TL-PRS-CS could attain limited 
relative improvement of the prediction accuracy in this situation. In general, TL-PRS worked better 
when the genetic correlation was smaller and the causal variants were sparser. 
We further assessed whether multi-source prediction methods (PT-multi, lsum-multi, MTL-PRS-
lsum, PRS-CSx, MTL-PRS-CS) could improve cross-population polygenic prediction. 
Specifically, we combined PRS models from European summary source (N=100K) and South 
Asian summary source (N=10K). When the genetic correlation was 1, the multi-source prediction 
methods cannot improve prediction accuracy in comparison with the single-source prediction 
methods using European summary statistics, because Europeans shared the same true effect sizes 
as South Asians and had ten times sample size. In the scenario where the genetic correlation was 
less than 1, multi-source prediction methods improved prediction accuracy over single-source 
prediction methods, reflecting the increase in source sample size. Overall, while lsum-multi 
outperformed PT-multi and PRS-CSx in most cases, MTL-PRS-lsum further improved cross-
population prediction accuracy comparing lsum-multi across all simulation settings (Figure 4.3 & 
4.4). For example, when genetic correlation was 0.4, TL-PRS-lsum improved a 6.49% average 




Figure 4.4. Relative prediction accuracy of single-source and multi-source polygenic prediction 
methods using transfer learning, with respect to the base models without transfer learning across 
20 replicates in the simulation.  
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4.3.3 Prediction performance for South Asian, African, and non-British White 
samples in UK Biobank 
After excluding related individuals, the target sample size of SAS, AFR, and NBW were 10,285, 
8,168 and 35,567, respectively. We randomly split them into training dataset (for model fitting),  
validation dataset (for hyper-parameter tuning) and testing dataset (for the evaluation of predictive 
performance) (Supplementary Table S4.1). We applied single-source prediction methods to the 
UKBB or BBJ GWAS summary results, and used multi-source prediction methods to combine the 
UKBB and BBJ GWAS results. 
Table 4.1 shows the prediction accuracy of different PRS construction methods in analyses of LDL 
in the African cohort of UK Biobank. When using UKBB GWAS results, the prediction R2 of TL-
PRS-lsum (0.044) and TL-PRS-CS (0.025) was higher than lsum (0.026) and PRS-CS (0.023). In 
addition, when using BBJ GWAS results, the prediction R2 of TL-PRS-lsum (0.075) and TL-PRS-
CS (0.034) was higher than lsum (0.048) and PRS-CS (0.030), demonstrating higher prediction 
accuracy in TL-PRS models. When combining UKBB and BBJ GWAS results, both lsum-multi 
(0.049) and PRS-CSx (0.043) outperformed PT-multi (0.030), as expected. At the same time, 
MTL-PRS-lsum (0.073) and MTL-PRS-CS (0.044) reached the best prediction accuracy. These 
consistent conclusions were reached when using the criteria of beta coefficients of normalized PRS 
or the mean difference between top 10% and bottom 10% PRS. The detailed results of other traits 






Table 4.1. Prediction accuracy of different single-source and multi-source polygenic prediction 
methods in analyses of LDL in the African cohort of UK Biobank. 
 







R2 of PRS 
Mean difference 
between top 10% and 
bottom 10% PRS 
PT (UKBB) 0.095  - 0.012 0.388 
lsum (UKBB) 0.139  - 0.026 0.543 
TL-PRS-lsum (UKBB) 0.179  - 0.044 0.684 
PRS-CS (UKBB) 0.136  - 0.023 0.448 
TL-PRS-CS (UKBB)  0.345  - 0.025 0.624 
PT (BBJ)  - 0.145 0.028 0.474 
lsum (BBJ)  - 0.187 0.048 0.585 
TL-lsum (BBJ)  - 0.235 0.075 0.913 
PRS-CS (BBJ)  - 0.148 0.03 0.484 
TL-PRS-CS (BBJ)   - 0.19 0.034 0.651 
PT-multi 0.081 0.099 0.03 0.565 
lsum-multi 0.074 0.137 0.049 0.696 
MTL-PRS-lsum 0.061 0.183 0.073 0.891 
PRSCSx 0.087 0.131 0.043 0.662 
MTL-PRS-CS 0.261 0.14 0.044 0.776 
 
 
Overall, consistent with the simulation results, TL-PRS-lsum and TL-PRS-CS outperformed lsum 
and PRS-CS in most traits from SAS and AFR (Figure 4.5). When the target population was SAS, 
TL-PRS-lsum attained 17% and 5% average relative improvement in prediction accuracy using 
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BBJ and UKBB GWAS results compared to lsum; the relative improvement of TL-PRS-CS over 
PRS-CS was on average 47% and 13% respectively. When the target population was AFR, TL-
PRS-lsum attained 21% and 26% relative improvement of prediction accuracy in BBJ and UKBB 
GWAS results compared to lsum; TL-PRS-CS improved prediction accuracy by 40% and 9% 
compared to PRS-CS. When combining BBJ and UKBB GWAS results, MTL-PRS-lsum and 
MTL-PRS-CS had higher prediction performance than lsum-multi and PRS-CSx (Figure 4.5 & 
Figure S4.1). However, since non-British white samples were genetically similar to British white 
samples, TL-PRS-lsum, TL-PRS-CS, MTL-PRS-lsum, and MTL-PRS-CS all had nearly the 
identical performance to lsum, PRS-CS, lsum-multi and PRS-CSx (Figure 4.5). In general, the 
performance of TL-PRS depends on many factors, such as target populations, traits and baseline 
methods.  
Figure S4.2 shows the cumulant event plot using the samples in the top 10% PRS across three 
populations. Across all situations, TL-PRS methods were found to have a similar or higher 
cumulant event curve than the baseline method. For example, in the analysis of CAD in the AFR 
cohort, when the age was up to 80, the cumulant prevalence of the samples with the top 10% PRS 
constructed by MTL-PRS-lsum was 0.26 while the prevalence in the samples with the top 10% 
PRS using lsum-multi was 0.12, suggesting that the TL method can be useful to help current PRS 






Figure 4.5. Relative prediction accuracy of single-source and multi-source polygenic prediction 
methods using transfer learning, with respect to the base models without transfer learning across 




4.4 Discussion  
We have presented the TL-PRS method, which can transfer the existing biased PRS model from 
other populations to the target population. We have shown, through simulation studies, that TL-
PRS-lsum and TL-PRS-CS robustly improves cross-population prediction over PT, lsum and PRS-
CS across traits with varying genetic architectures, genetic correlations between target populations 
and samples used for calculating summary statistics. Using both quantitative and dichotomous 
traits from SAS, AFR, NBW populations in UK Biobank, we have demonstrated the TL-PRS can 
leverage large-scale European GWAS to boost the accuracy of polygenic prediction in non-
European populations, for which ancestry-matched GWAS results may be orders of magnitude 
smaller in sample size. 
Overall, the performance of TL-PRS depends on many factors, such as target populations, traits 
and baseline methods. When genetic correlations between target populations and samples used for 
calculating summary statistics are large, the baseline methods are less biased, thereby sufficient 
for prediction and TL-PRS might not further improve the prediction performance. When genetic 
correlations are small, TL-PRS can be applied on the target data to help transfer biased initial 
values to less biased effect sizes. TL-PRS appears to be most effective when genetic correlations 
are small. For example, the relative improvement of TL-PRS in the AFR and SAS cohorts was 
much larger than the NBW cohort, because AFR and SAS were genetically more different from 
European populations than NBW. Moreover, the approach could be further extended to admixed 
populations with simple modifications. Future work is needed to better evaluate the performance 
in admixed populations.  
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In addition, TL-PRS requires the individual-level data of the training dataset. When the individual-
level data are not available, TL-PRS can still be applied given GWAS summary results of the targe 
samples. For example, 𝐺𝑗𝑌  can be estimated by the GWAS summary results and 𝐺𝑗
𝑇𝐺  can be 
estimated by the public available genotype data, such as 1000 Genome Project. Moreover, when 
the validation dataset is not available, the pseudo-validation(Mak et al., 2017) could further be 
applied for tuning the hyperparameters.  
Despite these advantages, our work is subject to limitations and leaves several questions open for 
future exploration. First, although we have demonstrated large relative improvements in prediction 
accuracy, absolute prediction accuracies are currently not sufficiently high to achieve clinical 
utility for most traits (Chatterjee et al., 2013; Dudbridge, 2013); our simulations suggest that multi-
ethnic polygenic risk scores will continue to produce improvements when more GWAS results are 
available, and the sample sizes are larger. Second, when combing two summary sources, the 
improvement of our MTL-PRS over the existing best PRS methods (PT-multi, lsum-multi and 
PRS-CSx) is limited. More research work is needed to combine more than one summary source. 
For example, the prediction performance might be further improved if cross-validation is used to 
determine the weights of the linear combination. The heritability of the traits, which differs across 
populations due to environmental factors, such as health behaviors and socioeconomic factors, can 
also be used to tune the weights of linear combination. Additionally, we did not incorporate data 
from the X chromosome, which is likely to harbor additional heritability that could improve 
prediction in some traits(Tukiainen et al., 2014). Finally, we restricted our analyses on common 
variants, but we may wish to incorporate the effects of rare variants in the future work. While 
extending present research to acquire more diverse genomes with sample sizes equivalent to 
European samples is the optimal, in the meantime, all existing available information should be 
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efficiently used to improve prediction across ancestries. TL-PRS increases the usefulness of PRS 





UK Biobank: https://www.ukbiobank.ac.uk/ 
BBJ summary statistics: http://jenger.riken.jp/en/result 
1000 Genome Project: https://www.internationalgenome.org/ 












4.5 Supplementary Materials 
4.5.1 Supplementary Figures  
Figure S4.1 Relative prediction accuracy of single-source and multi-source polygenic prediction 
methods with respect to lsum trained using UKBB GWAS across 8 traits in the cohorts South 







Figure S4.2. Cumulant event plot in terms of the top 10% PRS constructed by transfer learning 
methods and their base methods.  
(a) South Asian, Type 2 diabetes, Case: Control=419:2211 
 





(c) African, Type 2 diabetes, Case: Control=177:1812 
 




(e) Non-British White, Type 2 diabetes, Case: Control=771:16737 
 




4.5.2 Supplementary Tables  
Table S4.1. List of data sets used in simulations and analyses of real phenotypes 












South Asian (SAS) 
Simulation and real 
phenotypes 
 10,285 5,000 2,635 2,635 
African (AFR) real phenotypes  8,168 4,000 2,169 1,999 
Non-British White 
(NBW) 





Table S4.2. Prediction accuracy of different PRS construction methods in analyses of eight traits 
in the South Asian cohort of UK Biobank 
(a) HDL 
















PT (UKBB) 0.085 - 0.07 0.301 
lsum (UKBB) 0.094 - 0.086 0.3 
TL-PRS-lsum (UKBB) 0.104 - 0.099 0.359 
PRS-CS (UKBB) 0.102 - 0.101 0.336 
TL-PRS-CS (UKBB)  0.111 - 0.114 0.365 
PT (BBJ) - 0.067 0.044 0.225 
lsum (BBJ) - 0.08 0.062 0.304 
TL-lsum (BBJ) - 0.083 0.069 0.293 
PRS-CS (BBJ) - 0.071 0.049 0.237 
TL-PRS-CS (BBJ)  - 0.082 0.062 0.271 
PT-multi 0.074 0.032 0.082 0.336 
lsum-multi 0.076 0.041 0.102 0.364 
MTL-PRS-lsum 0.087 0.037 0.113 0.39 
PRSCSx 0.081 0.035 0.103 0.354 






















PT (UKBB) 0.12 - 0.019 0.503 
lsum (UKBB) 0.108 - 0.016 0.415 
TL-PRS-lsum (UKBB) 0.12 - 0.019 0.447 
PRS-CS (UKBB) 0.125 - 0.021 0.486 
TL-PRS-CS (UKBB)  0.153 - 0.026 0.432 
PT (BBJ) - 0.077 0.008 0.206 
lsum (BBJ) - 0.114 0.018 0.445 
TL-lsum (BBJ) - 0.122 0.02 0.449 
PRS-CS (BBJ) - 0.074 0.007 0.252 
TL-PRS-CS (BBJ)  - 0.115 0.016 0.414 
PT-multi 0.094 0.062 0.022 0.459 
lsum-multi 0.07 0.085 0.023 0.487 
MTL-PRS-lsum 0.076 0.093 0.027 0.524 
PRSCSx 0.107 0.046 0.022 0.505 






















PT (UKBB) 0.953 - 0.044 2.939 
lsum (UKBB) 1.175 - 0.067 3.598 
TL-PRS-lsum (UKBB) 1.213 - 0.069 3.429 
PRS-CS (UKBB) 1.142 - 0.064 3.763 
TL-PRS-CS (UKBB)  1.208 - 0.067 3.591 
PT (BBJ) - 0.589 0.017 1.951 
lsum (BBJ) - 0.664 0.022 2.657 
TL-lsum (BBJ) - 0.785 0.031 2.955 
PRS-CS (BBJ) - 0.686 0.024 2.165 
TL-PRS-CS (BBJ)  - 0.804 0.032 2.255 
PT-multi 0.661 0.661 0.05 3.629 
lsum-multi 0.945 0.509 0.071 4.117 
MTL-PRS-lsum 0.987 0.531 0.077 4.198 
PRSCSx 0.962 0.412 0.072 4.142 






















PT (UKBB) 0.256 - 0.053 0.787 
lsum (UKBB) 0.301 - 0.074 1.058 
TL-PRS-lsum (UKBB) 0.306 - 0.076 1.022 
PRS-CS (UKBB) 0.317 - 0.082 1.032 
TL-PRS-CS (UKBB)  0.326 - 0.082 1.022 
PT (BBJ) - 0.244 0.049 0.785 
lsum (BBJ) - 0.281 0.065 0.91 
TL-lsum (BBJ) - 0.298 0.072 0.929 
PRS-CS (BBJ) - 0.256 0.054 0.943 
TL-PRS-CS (BBJ)  - 0.253 0.051 0.872 
PT-multi 0.218 0.094 0.064 0.958 
lsum-multi 0.268 0.067 0.082 1.124 
MTL-PRS-lsum 0.272 0.068 0.084 1.084 
PRSCSx 0.263 0.113 0.094 1.144 






















PT (UKBB) 3.101 - 0.023 10.094 
lsum (UKBB) 3.867 - 0.036 14.675 
TL-PRS-lsum (UKBB) 3.782 - 0.034 15.388 
PRS-CS (UKBB) 3.908 - 0.037 13.831 
TL-PRS-CS (UKBB)  3.976 - 0.036 13.714 
PT (BBJ) - 1.479 0.005 5.576 
lsum (BBJ) - 2.328 0.013 8.706 
TL-lsum (BBJ) - 2.539 0.014 8.008 
PRS-CS (BBJ) - 1.778 0.008 8.38 
TL-PRS-CS (BBJ)  - 2.461 0.01 8.176 
PT-multi 2.926 1.254 0.026 12.106 
lsum-multi 3.836 0.677 0.04 15.125 
MTL-PRS-lsum 3.744 0.416 0.036 14.725 
PRSCSx 3.643 0.911 0.04 14.612 























PT (UKBB) 1.309 - 0.014 5.153 
lsum (UKBB) 2 - 0.033 7.435 
TL-PRS-lsum (UKBB) 2.1 - 0.034 7.42 
PRS-CS (UKBB) 2.063 - 0.035 6.973 
TL-PRS-CS (UKBB)  2.285 - 0.037 7.753 
PT (BBJ) - 0.4 0.001 1.102 
lsum (BBJ) - 0.575 0.003 2.216 
TL-lsum (BBJ) - 0.735 0.004 2.706 
PRS-CS (BBJ) - 0.529 0.002 2.643 
TL-PRS-CS (BBJ)  - 0.872 0.005 2.949 
PT-multi 1.108 0.596 0.014 4.467 
lsum-multi 1.801 0.6 0.033 7.2 
MTL-PRS-lsum 1.872 0.624 0.034 6.663 
PRSCSx 1.706 0.569 0.032 5.451 






















PT (UKBB) 0.21 - 0.009 0.005 1.741 
lsum (UKBB) 0.33 - 0.022 0.013 2.611 
TL-PRS-lsum (UKBB) 0.319 - 0.02 0.012 2.136 
PRS-CS (UKBB) 0.339 - 0.023 0.013 3.462 
TL-PRS-CS (UKBB)  0.48 - 0.031 0.018 2.75 
PT (BBJ) - 0.163 0.005 0.002 1.273 
lsum (BBJ) - 0.321 0.02 0.01 2 
TL-lsum (BBJ) - 0.293 0.017 0.011 2.238 
PRS-CS (BBJ) - 0.34 0.023 0.012 4 
TL-PRS-CS (BBJ)  - 0.407 0.028 0.016 2.286 
PT-multi 0.033 0.189 0.008 0.003 1.171 
lsum-multi 0.232 0.283 0.033 0.017 2.882 
MTL-PRS-lsum 0.157 0.292 0.027 0.016 2.938 
PRSCSx 0.347 0.187 0.039 0.022 4.077 





(h) Type II diabetes 
















PT (UKBB) 0.294 - 0.012 0.009 2.44 
lsum (UKBB) 0.392 - 0.031 0.025 2.37 
TL-PRS-lsum (UKBB) 0.46 - 0.035 0.026 3.65 
PRS-CS (UKBB) 0.402 - 0.034 0.027 2.52 
TL-PRS-CS (UKBB)  0.564 - 0.04 0.033 3.095 
PT (BBJ) - 0.249 0.014 0.01 1.867 
lsum (BBJ) - 0.352 0.027 0.023 2.739 
TL-lsum (BBJ) - 0.468 0.031 0.025 6.4 
PRS-CS (BBJ) - 0.421 0.038 0.027 2.8 
TL-PRS-CS (BBJ)  - 0.514 0.045 0.031 3.789 
PT-multi 0.244 0.244 0.023 0.018 2.583 
lsum-multi 0.337 0.276 0.047 0.038 5.214 
MTL-PRS-lsum 0.348 0.348 0.048 0.037 5.917 
PRSCSx 0.319 0.261 0.053 0.039 3.714 




Table S4.3. Prediction accuracy of different PRS construction methods in analyses of eight traits 
in the African cohort of UK Biobank 
(a) HDL 
















PT (UKBB) 0.075 - 0.039 0.219 
lsum (UKBB) 0.075 - 0.039 0.23 
TL-PRS-lsum (UKBB) 0.085 - 0.044 0.204 
PRS-CS (UKBB) 0.086 - 0.051 0.236 
TL-PRS-CS (UKBB)  0.094 - 0.056 0.288 
PT (BBJ) - 0.07 0.035 0.259 
lsum (BBJ) - 0.083 0.05 0.316 
TL-lsum (BBJ) - 0.094 0.065 0.344 
PRS-CS (BBJ) - 0.082 0.048 0.328 
TL-PRS-CS (BBJ)  - 0.089 0.053 0.311 
PT-multi 0.057 0.038 0.049 0.268 
lsum-multi 0.069 0.037 0.058 0.308 
MTL-PRS-lsum 0.075 0.05 0.073 0.325 
PRSCSx 0.071 0.047 0.07 0.312 






















PT (UKBB) 0.095 - 0.012 0.388 
lsum (UKBB) 0.139 - 0.026 0.543 
TL-PRS-lsum (UKBB) 0.179 - 0.044 0.684 
PRS-CS (UKBB) 0.136 - 0.023 0.448 
TL-PRS-CS (UKBB)  0.345 - 0.025 0.624 
PT (BBJ) - 0.145 0.028 0.474 
lsum (BBJ) - 0.187 0.048 0.585 
TL-lsum (BBJ) - 0.235 0.075 0.913 
PRS-CS (BBJ) - 0.148 0.03 0.484 
TL-PRS-CS (BBJ)  - 0.19 0.034 0.651 
PT-multi 0.081 0.099 0.03 0.565 
lsum-multi 0.074 0.137 0.049 0.696 
MTL-PRS-lsum 0.061 0.183 0.073 0.891 
PRSCSx 0.087 0.131 0.043 0.662 






















PT (UKBB) 0.813 - 0.023 2.583 
lsum (UKBB) 1.035 - 0.037 3.646 
TL-PRS-lsum (UKBB) 1.179 - 0.038 3.477 
PRS-CS (UKBB) 1.036 - 0.036 3.481 
TL-PRS-CS (UKBB)  1.126 - 0.038 3.656 
PT (BBJ) - 0.476 0.008 1.242 
lsum (BBJ) - 0.581 0.012 2.375 
TL-lsum (BBJ) - 0.581 0.012 2.23 
PRS-CS (BBJ) - 0.748 0.019 2.631 
TL-PRS-CS (BBJ)  - 0.786 0.021 2.732 
PT-multi 0.653 0.435 0.025 2.682 
lsum-multi 0.857 0.462 0.04 4.249 
MTL-PRS-lsum 1.002 0.43 0.041 3.439 
PRSCSx 0.927 0.232 0.037 3.158 






















PT (UKBB) 0.053 - 0.006 0.172 
lsum (UKBB) 0.076 - 0.013 0.27 
TL-PRS-lsum (UKBB) 0.085 - 0.015 0.377 
PRS-CS (UKBB) 0.079 - 0.014 0.295 
TL-PRS-CS (UKBB)  0.083 - 0.015 0.411 
PT (BBJ) - 0.051 0.006 0.207 
lsum (BBJ) - 0.065 0.01 0.182 
TL-lsum (BBJ) - 0.067 0.01 0.219 
PRS-CS (BBJ) - 0.049 0.006 0.172 
TL-PRS-CS (BBJ)  - 0.05 0.005 0.096 
PT-multi 0.049 0.026 0.009 0.228 
lsum-multi 0.073 0.024 0.016 0.328 
MTL-PRS-lsum 0.078 0.026 0.018 0.323 
PRSCSx 0.076 0.025 0.019 0.323 






















PT (UKBB) 1.163 - 0.003 4.451 
lsum (UKBB) 2.062 - 0.011 6.287 
TL-PRS-lsum (UKBB) 2.079 - 0.011 5.99 
PRS-CS (UKBB) 2.052 - 0.01 9.282 
TL-PRS-CS (UKBB)  2.226 - 0.011 9.174 
PT (BBJ) - 0.459 0.001 3.39 
lsum (BBJ) - 0.569 0.001 1.969 
TL-lsum (BBJ) - 0.729 0.001 3.508 
PRS-CS (BBJ) - 0.951 0.002 2.79 
TL-PRS-CS (BBJ)  - 1.541 0.004 4.328 
PT-multi 1.117 0.372 0.004 5.744 
lsum-multi 1.907 0.477 0.01 5.379 
MTL-PRS-lsum 1.951 0.488 0.011 5.446 
PRSCSx 1.88 0.627 0.012 7.641 























PT (UKBB) 0.338 - 0.001 2.246 
lsum (UKBB) 0.749 - 0.004 2.103 
TL-PRS-lsum (UKBB) 0.844 - 0.005 1.959 
PRS-CS (UKBB) 0.839 - 0.005 2.328 
TL-PRS-CS (UKBB)  0.896 - 0.006 3.359 
PT (BBJ) - 0.268 0.001 0.877 
lsum (BBJ) - 0.535 0.002 1.821 
TL-lsum (BBJ) - 0.585 0.003 2.108 
PRS-CS (BBJ) - 0.431 0.001 1.641 
TL-PRS-CS (BBJ)  - 0.642 0.003 3.621 
PT-multi 0.376 0.094 0.001 1.503 
lsum-multi 0.744 0.401 0.006 2.564 
MTL-PRS-lsum 0.829 0.446 0.007 2.236 
PRSCSx 0.942 0.314 0.009 3.59 






















PT (UKBB) 0.448 - 0.028 0.03 3.167 
lsum (UKBB) 0.154 - 0.003 0.004 3.667 
TL-PRS-lsum (UKBB) 0.155 - 0.003 0.002 1.5 
PRS-CS (UKBB) 0.3 - 0.013 0.019 2.571 
TL-PRS-CS (UKBB)  0.332 - 0.014 0.017 2.286 
PT (BBJ) - 0.112 0.002 0.003 1.556 
lsum (BBJ) - 0.078 0.001 0.002 1.25 
TL-lsum (BBJ) - 0.078 0.001 0.002 1.25 
PRS-CS (BBJ) - 0.13 0.002 0.004 1.625 
TL-PRS-CS (BBJ)  - 0.159 0.004 0.004 2.6 
PT-multi 0.456 0.051 0.029 0.031 3 
lsum-multi 0.071 0.106 0.003 0.004 1.5 
MTL-PRS-lsum 0.141 0.076 0.003 0.003 1.571 
PRSCSx 0.099 0.23 0.011 0.013 4.75 





(h) Type II diabetes 
















PT (UKBB) 0.278 - 0.012 0.005 1.118 
lsum (UKBB) 0.172 - 0.005 0.005 1.235 
TL-PRS-lsum (UKBB) 0.284 - 0.01 0.009 1.176 
PRS-CS (UKBB) 0.4 - 0.026 0.018 2.5 
TL-PRS-CS (UKBB)  0.781 - 0.031 0.022 1.389 
PT (BBJ) - 0.161 0.005 0.003 1.643 
lsum (BBJ) - 0.11 0.002 0.001 1.643 
TL-lsum (BBJ) - 0.11 0.002 0.001 1.643 
PRS-CS (BBJ) - 0.244 0.01 0.003 2.083 
TL-PRS-CS (BBJ)  - 0.337 0.017 0.006 2.5 
PT-multi 0.139 0.209 0.012 0.006 1.412 
lsum-multi 0.075 0.14 0.005 0.002 1.2 
MTL-PRS-lsum 0.138 0.169 0.008 0.004 1.556 
PRSCSx 0.251 0.205 0.025 0.014 1.786 





Table S4.4. Prediction accuracy of different PRS construction methods in analyses of eight traits 
in the Non-British White cohort of UK Biobank 
(a) HDL 
















PT (UKBB) 0.154 - 0.153 0.537 
lsum (UKBB) 0.157 - 0.16 0.559 
TL-PRS-lsum (UKBB) 0.16 - 0.162 0.541 
PRS-CS (UKBB) 0.154 - 0.153 0.54 
TL-PRS-CS (UKBB)  0.156 - 0.154 0.521 
PT (BBJ) - 0.073 0.035 0.246 
lsum (BBJ) - 0.093 0.056 0.322 
TL-lsum (BBJ) - 0.093 0.057 0.322 
PRS-CS (BBJ) - 0.086 0.048 0.303 
TL-PRS-CS (BBJ)  - 0.088 0.049 0.291 
PT-multi 0.146 0.026 0.157 0.539 
lsum-multi 0.14 0.047 0.172 0.57 
MTL-PRS-lsum 0.143 0.048 0.173 0.564 
PRSCSx 0.145 0.016 0.154 0.541 






















PT (UKBB) 0.275 - 0.101 0.991 
lsum (UKBB) 0.282 - 0.106 1.013 
TL-PRS-lsum (UKBB) 0.285 - 0.107 1.003 
PRS-CS (UKBB) 0.279 - 0.104 0.977 
TL-PRS-CS (UKBB)  0.28 - 0.104 0.981 
PT (BBJ) - 0.118 0.019 0.426 
lsum (BBJ) - 0.151 0.03 0.538 
TL-lsum (BBJ) - 0.149 0.03 0.538 
PRS-CS (BBJ) - 0.118 0.019 0.42 
TL-PRS-CS (BBJ)  - 0.12 0.019 0.423 
PT-multi 0.259 0.065 0.105 1.009 
lsum-multi 0.251 0.107 0.116 1.081 
MTL-PRS-lsum 0.255 0.109 0.118 1.072 
PRSCSx 0.259 0.046 0.105 0.988 






















PT (UKBB) 1.897 - 0.149 6.795 
lsum (UKBB) 2.058 - 0.174 7.467 
TL-PRS-lsum (UKBB) 2.071 - 0.175 7.373 
PRS-CS (UKBB) 1.893 - 0.147 6.653 
TL-PRS-CS (UKBB)  1.927 - 0.149 6.584 
PT (BBJ) - 0.704 0.02 2.573 
lsum (BBJ) - 0.857 0.03 3.201 
TL-lsum (BBJ) - 0.878 0.032 3.171 
PRS-CS (BBJ) - 0.878 0.032 3.188 
TL-PRS-CS (BBJ)  - 0.944 0.035 2.992 
PT-multi 1.833 0.323 0.153 6.905 
lsum-multi 1.992 0.221 0.176 7.4 
MTL-PRS-lsum 2.003 0.223 0.178 7.336 
PRSCSx 1.871 0.098 0.151 6.66 






















PT (UKBB) 0.325 - 0.102 1.16 
lsum (UKBB) 0.359 - 0.125 1.259 
TL-PRS-lsum (UKBB) 0.36 - 0.125 1.278 
PRS-CS (UKBB) 0.346 - 0.114 1.2 
TL-PRS-CS (UKBB)  0.346 - 0.115 1.193 
PT (BBJ) - 0.165 0.026 0.58 
lsum (BBJ) - 0.191 0.035 0.685 
TL-lsum (BBJ) - 0.192 0.035 0.707 
PRS-CS (BBJ) - 0.172 0.028 0.623 
TL-PRS-CS (BBJ)  - 0.171 0.028 0.617 
PT-multi 0.308 0.077 0.109 1.219 
lsum-multi 0.329 0.082 0.129 1.301 
MTL-PRS-lsum 0.33 0.083 0.13 1.287 
PRSCSx 0.325 0.036 0.114 1.209 






















PT (UKBB) 6.041 - 0.091 20.95 
lsum (UKBB) 6.281 - 0.1 22.002 
TL-PRS-lsum (UKBB) 6.292 - 0.101 22.208 
PRS-CS (UKBB) 5.629 - 0.081 19.795 
TL-PRS-CS (UKBB)  5.631 - 0.081 20.112 
PT (BBJ) - 1.569 0.006 5.6 
lsum (BBJ) - 1.645 0.007 5.746 
TL-lsum (BBJ) - 1.639 0.007 4.93 
PRS-CS (BBJ) - 1.879 0.009 6.204 
TL-PRS-CS (BBJ)  - 1.893 0.009 6.217 
PT-multi 5.97 0.663 0.093 21.456 
lsum-multi 6.281 0 0.1 22.002 
MTL-PRS-lsum 6.292 0 0.101 22.208 
PRSCSx 5.54 0.292 0.081 19.4 























PT (UKBB) 3.53 - 0.106 12.916 
lsum (UKBB) 3.75 - 0.12 13.761 
TL-PRS-lsum (UKBB) 3.786 - 0.12 13.821 
PRS-CS (UKBB) 3.315 - 0.094 11.892 
TL-PRS-CS (UKBB)  3.375 - 0.094 12.107 
PT (BBJ) - 0.781 0.005 2.892 
lsum (BBJ) - 0.854 0.006 2.836 
TL-lsum (BBJ) - 0.85 0.006 3.02 
PRS-CS (BBJ) - 0.882 0.007 2.89 
TL-PRS-CS (BBJ)  - 0.928 0.007 3.373 
PT-multi 3.525 0.186 0.107 12.811 
lsum-multi 3.75 0 0.12 13.761 
MTL-PRS-lsum 3.786 0 0.12 13.821 
PRSCSx 3.31 0 0.093 11.588 






















PT (UKBB) 0.293 - 0.015 0.009 2.377 
lsum (UKBB) 0.415 - 0.028 0.018 3.246 
TL-PRS-lsum (UKBB) 0.415 - 0.028 0.018 3.246 
PRS-CS (UKBB) 0.426 - 0.03 0.02 3.672 
TL-PRS-CS (UKBB)  0.426 - 0.03 0.02 3.672 
PT (BBJ) - 0.114 0.002 0.001 1.516 
lsum (BBJ) - 0.158 0.004 0.002 1.722 
TL-lsum (BBJ) - 0.155 0.004 0.002 1.831 
PRS-CS (BBJ) - 0.197 0.006 0.003 1.772 
TL-PRS-CS (BBJ)  - 0.196 0.006 0.003 1.813 
PT-multi 0.278 0.119 0.016 0.01 2.247 
lsum-multi 0.385 0.128 0.029 0.018 3.169 
MTL-PRS-lsum 0.368 0.158 0.029 0.018 3.103 
PRSCSx 0.356 0.152 0.03 0.02 3.338 





(h) Type II diabetes 
















PT (UKBB) 0.264 - 0.012 0.018 3.848 
lsum (UKBB) 0.5 - 0.034 0.043 6.417 
TL-PRS-lsum (UKBB) 0.5 - 0.034 0.043 6.417 
PRS-CS (UKBB) 0.579 - 0.045 0.052 6.538 
TL-PRS-CS (UKBB)  0.579 - 0.045 0.052 6.538 
PT (BBJ) - 0.31 0.013 0.017 3.053 
lsum (BBJ) - 0.457 0.029 0.033 5.1 
TL-lsum (BBJ) - 0.457 0.029 0.033 5.1 
PRS-CS (BBJ) - 0.522 0.037 0.041 5.862 
TL-PRS-CS (BBJ)  - 0.522 0.037 0.041 5.862 
PT-multi 0.303 0.202 0.022 0.031 5.909 
lsum-multi 0.484 0.261 0.049 0.058 8.6 
MTL-PRS-lsum 0.484 0.261 0.049 0.058 8.6 
PRSCSx 0.523 0.224 0.059 0.065 10.111 





Summary and Discussion 
5.1 Summary 
The growth of biobank datasets has presented us with enormous opportunities to gain insights into 
genetic architecture of complex traits and diseases. However, there are also a number of obstacles, 
both in terms of statistical technique and interpretation. In this dissertation, we addressed some of 
the most challenging problems of analyzing large-scale biobank datasets. To address the inflation 
of type I error rates caused by the unbalanced case-control ratios, we developed the robust region-
based tests within independent samples. The robust methods were further extended to GLMM to 
adjust for relatedness among samples. Finally, we proposed the multi-ethnic PRS models using 
transfer learning to improve disease risk prediction in minor ancestries. 
In Chapter II, we proposed the robust SKAT/SKAT-O type region-based tests to account for 
unbalanced case-control ratios, where the single-variant score statistic was calibrated based on 
SPA and ER. Through simulation studies, the proposed method was shown to provide well-
calibrated p-values. The proposed method had similar computation time as the unadjusted 
approaches and was scalable for large sample data. In our application, the UK Biobank whole 
exome sequence data analysis of 45,596 unrelated European samples and 791 PheCode 
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phenotypes identified 10 rare variant associations with p-value < 10-7, including the reported 
association between JAK2 and myeloproliferative disease.  
In Chapter III, we extended the robust method to related samples.  A scalable generalized mixed-
model region-based association test, SAIGE-GENE, was proposed that could handle large sample 
sizes and account for unbalanced case-control ratios for binary traits. This method utilized state-
of-the-art optimization strategies to reduce computational and memory cost, and hence was 
applicable to exome-wide and genome-wide region-based analysis for hundreds of thousands of 
samples. Through the analysis of the HUNT study of 69,716 Norwegian samples and the UK 
Biobank data of 408,910 White British samples, SAIGE-GENE efficiently analyzed large sample 
data (N > 400,000) with type I error rates well controlled.  
In Chapter IV, using summary statistics calculated by SAIGE-GENE, we proposed a novel multi-
ethnic PRS motivated by transfer learning from machine learning literature. Our approach, TL-
PRS, fine-tuned the potentially biased model trained with GWAS summary statistics from the 
majority ancestry to the target dataset of the minority ancestry. Through simulation studies, TL-
PRS improved the performance of PRS with a wide range of genetic architectures and cross-
population genetic correlations compared to the existing best PRS methods. In the application of 
8,168 Africans and 10,285 South Asians of UK Biobank data, TL-PRS substantially improved the 
prediction accuracy of the six quantitative and two dichotomous traits.  
In summary, these three chapters help us have a deep understanding of the associations between 
genotypes and phenotypes. Specifically, Chapter II and III aim to identify the true causal genes of 




5.2 Extension and future work 
The difficulties of high-dimensionality and computing scalability are extremely critical in this era 
of data explosion, and more efforts should be put on these issues in the future generations of 
methodological research. We addressed some of these problems in this dissertation, but the scope 
for future research is vast in this domain. 
In all three chapters, we didn’t consider potential selection bias when using UK biobank data. UK 
Biobank samples were recruited with response rate (5.5%) and it might be inaccurate to estimate 
the comorbidity of diseases (Swanson, 2012). But the disease prevalence is incorporated using the 
intercept in logistic regression and thus does not affect the detection of genetic effects or 
construction of PRS. 
In Chapter III, when applying SAIGE-GENE on the latest 200K UKBB WES data, the inflation 
was observed in QQ plots when the case control ratio was extremely unbalanced, such as 1:500. 
When the sample size of UKBB WES data increased from 50K to 200K, more rare variants were 
identified in a single gene, which could cause the inflation of type I error rates. We are currently 
working on the new version of SAIGE-GENE by collapsing ultra-rare variants to control the 
inflation issue. In unbalanced case-control GWASs, scalable gene-based tests, and adjusting for 
within-study sample relatedness in meta-analysis methods, are also important and immediate 
future research directions. The similar robust adjustment could also be applied to other types of 
traits, such as time-to-event and categorical data. 
In addition, interpreting GWAS results is a challenging process since the majority of phenotype-
associated variants are non-coding and hence have no clear identifiable effect on protein functions 
as well as the phenotype. In the near future, integrating multi-omics data, such as proteome, 
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transcriptome, epigenome, metabolome, and microbiome, can further improve our understanding 
of the functional and mechanistic roles of different variants. The extension of GWAS, as well as 
its integration with other efforts, to understand the molecular function of the human genome, will 
be critically important in the study of gene coding and their contribution to complex traits. Further 
understanding on the genetic mechanism might help identify more disease biomarkers and drug 
targets. 
In Chapter IV, although TL-PRS was shown to have large relative improvements in prediction 
accuracy using one summary source, the relative improvements of TL-PRS were limited compared 
to the best existing PRS method when combining more than one summary source. More 
investigations are needed to further improve the prediction accuracy of multi-ethnic PRS. For 
example, the performance might be improved if the cross-validation is used to determine the 
weights of the linear combination. Another possible approach is to incorporate multiple summary 
sources at the beginning of TL-PRS rather than linearly combining TL-PRS results. Additionally, 
the absolute prediction accuracies are currently not sufficiently high to achieve clinical utility for 
most traits (Chatterjee et al., 2013; Dudbridge, 2013). When more diverse genomes with sample 
sizes equivalent to European samples are available in the future, the multi-ethnic PRS will continue 
to improve the prediction performance. 
Another future direction may include the exploration of the admixed populations. The gene-based 
models, such as robust methods and SAIGE-GENE, can be directly applied on admixed 
populations when the genotype sample sizes of admixed population were equivalent to European 
samples. In the intervening time, meta-analysis can help improve the detection power. In addition, 
TL-PRS is designed for the genetic risk prediction of minor populations and thus can be further 
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extended to admixed populations with simple modifications. Future work is needed to better 
evaluate the performance in admixed populations.  
The problems and opportunities are not only confined to the ones described above. As we continue 
to generate ever huge volumes of data, new types of issues will emerge, necessitating new types 
of solutions. As a biostatistician, our objective is to keep working and avoid becoming 
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